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Abstract 
Melanoma progression occurs despite evidence of melanoma-specific T cell 
activation. Chronic or repeated antigen stimulation can cause dysregulated T 
cell differentiation through upregulation of inhibitory receptors (immune 
exhaustion) or end-stage differentiation (immune senescence). This thesis 
therefore investigated the hypothesis that blood and skin derived T cells of 
melanoma patients are driven towards immune exhaustion and senescence. An 
increase in senescent CD8+ TEMRA cells was detected in the blood of old 
melanoma patients. These cells had high cytotoxic but low proliferative 
potential. Whilst it could not be determined whether they were melanoma 
specific, the TEMRA expansions occurred independently from persistent viral 
infections such as CMV, and their function could be boosted through p38 
signalling blockade. Skin resident T cells of melanoma patients showed no 
increase in T cell differentiation but instead upregulation of exhaustion markers 
PD-1 and CTLA-4. Granzyme B and perforin, essential for granule mediated cell 
killing, remained low in these cells, suggesting insufficient cytotoxic function. 
Skin derived T cells from healthy individuals also expressed high levels of PD-1 
and low levels of cytotoxic granule components. Exposure to IL-2, IL-15 and 
CD3/CD28 boosted perforin and granzyme expression in healthy skin cells. 
Conversely, PD-1 signalling blockade during CD3 stimulation increased 
granzyme B expression. In summary, melanoma associated immune 
dysfunctions were of a different nature in blood and skin T cells. 
Immunotherapies designed to boost immune function in patients might therefore 
have different efficacies in both organs. 
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1 Introduction 
Melanoma is a cancer that arises from melanocytes. Although it can be easily 
cured in the early stages of disease through surgical removal, advanced 
disseminated melanoma often resists conventional therapies such as 
chemotherapy, resulting in high mortality. Despite being derived from self, 
melanoma can be recognized by the adaptive arm of the immune system and 
may lead to spontaneous regression (Quaglino et al. 2010). Unfortunately, in 
most melanoma patients tumour specific immune responses occur in the 
absence of disease amelioration, raising interest in identifying and 
understanding the role of T cell differentiation in the blood and skin of the 
patients affected.  
 T cell activation and effector functions 1.1
T cells constitute the cellular arm of the adaptive immune system that allows 
identification and killing of infected or malignant cells. The T cell receptor (TCR) 
recognizes antigen in form of a peptide presented on a major histocompability 
complex (MHC) molecule. The majority of cells in the body express MHC class 
I. MHC class II is expressed only by a few cell types which can act as antigen 
presenting cells that have specific immunological functions. CD4+ T cells 
recognize antigen presented on MHC class II, and can differentiate into helper 
cells (TH1, Th2, Th17, Th22, follicular helper T cells) that can mediate 
downstream activation of an array of immune cells or regulatory T cells (Tregs) 
that suppress immune processes (Nakayamada et al. 2012). CD8+ T cells 
recognize antigen presented on the MHC class I molecules and are able to 
differentiate into cytotoxic effector cells that can recognize and kill infected or 
malignant target cells. 
 T cell development 1.1.1
T cells arise from multipotent hematopoietic stem cells in the bone marrow, 
which migrate from the blood into the thymus where they proliferate, generating 
a large population of immature thymocytes. Thymocytes undergo gene 
rearrangement of the TCR, generating T cells of potentially any reactivity. 
Therefore, cells that cannot recognize the MHC molecule or are auto-reactive 
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must be removed: During positive selection, cells that are able to bind to 
MHC:self peptide presented by thymic stromal cells receive a signal to survive 
whilst cells that are not die by neglect. Depending on whether a cell recognizes 
MHC class I or class II, it will commit to the CD8 or CD4 lineage at this point. 
Thymocytes that survive positive selection migrate to the thymic medulla where 
they interact with the local MHC molecules. If they bind too strongly (i.e. are 
reactive to self), they will undergo apoptosis and die. This process is known as 
negative selection. Whilst the majority of thymocytes die during these selection 
processes, the cells that do survive emigrate from the thymus and mature into 
naïve cells once entering the blood stream. Thymic T cell selection and 
maturation therefore enable production of cells with intermediate reactivity, that 
are able to recognize MHC molecules and are potentially reactive against any 
pathogen or tumour antigen, without being reactive to self (Zippelius et al. 
2002). 
 T cell activation 1.1.2
Naïve T cells circulate between peripheral lymphoid organs and sample 
MHC:peptide complexes presented on the surface of dendritic cells until finding 
their cognate antigen. Activation of naive CD4+ and CD8+ T cells is similar and 
can be divided into four phases: 1) activation 2) clonal expansion 3) contraction 
and 4) memory. However, activation of the innate arm of the immune system is 
a pre-requisite to trigger T cell activation. This includes professional antigen 
presenting cells, in particular dendritic cells. 
 Activation of dendritic cells 1.1.2.1
Dendritic cells are a diverse population of cells that can differ in lineage, 
phenotype, function and anatomical location. Dendritic cells sample antigen in 
peripheral tissues, which they then carry back to lymphoid organs to present to 
the T cells (Banchereau and Steinman 1998). In order to successfully activate T 
cells, immature dendritic cells themselves must become activated. This occurs 
through sensing of danger signals during antigen uptake, such as recognition of 
pathogen-associated molecular patterns (PAMPs) through conserved pattern 
recognition receptors (PRRs), including toll-like receptors (TLRs) and NOD-like 
receptors (NLRs). Inflammatory cytokines such as Interleukin (IL)-1, GM-CSF 
and tumour necrosis factor (TNF)-α may also promote dendritic cell maturation
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(Banchereau and Steinman 1998). These signals lead to dendritic cell migration 
by upregulation of lymph node homing receptors as well as maturation. 
Maturation involves increased antigen processing and upregulation of surface 
molecules involved in antigen presentation, including MHC, and of costimulatory 
molecules CD80 (B7.1) and CD86 (B7.2). Inhibitory signals such as IL-10 can 
block dendritic cell maturation (Buelens et al. 1997). Once migrated to the T cell 
areas of a lymphoid organ such as the lymph node, dendritic cells further 
release chemokines to attract T cells to sample their antigen. Only mature 
dendritic cells can mediate T cell activation, whilst immature dendritic cells 
promote immune tolerance. 
 Migration of naïve T cells into the lymph nodes 1.1.2.2
Naïve T cells circulate between the blood and the T cell areas of the secondary 
lymphoid organs in order to sample antigen presented by the local dendritic 
cells and maximize the possibility of meeting their respective antigen. Migration 
of the naïve T cells in this manner is facilitated by their expression of lymph 
node homing receptors. This includes CD62L, which binds GlyCAM-1 
expressed on high endothelial venules and CCR7, a chemokine receptor that 
binds CCL19 and CCL21 produced by fibroblastic reticular cells and antigen 
presenting cells in the lymph node (Denton et al. 2014). 
 T cell activation 1.1.2.3
As they migrate through the cortical region of the lymph node, naïve T cells bind 
transiently to each antigen presenting cell they encounter with the help of 
adhesion molecules such as lymphocyte function-associated antigen 1 (LFA-1). 
When finally meeting its cognate antigen on the surface of a mature antigen 
presenting cell, the naïve T cells will become activated, divide and mature. It is 
essential that the naïve T cell obtains the appropriate signals for this to occur. 
These signals are commonly known as signal 1, 2 and 3.  
Signal 1 involves the initial antigen-specific ligation of the TCR with the 
peptide:MHC complex on the surface of the antigen presenting cell. This 
interaction is highly specific and has a short half-life and therefore needs to be 
stabilized by co-receptors. This includes the CD3 complex that stabilizes the 
TCR on the cell surface and contains immunoreceptor tyrosine-based activation 
motif (ITAM) motifs that participate in the signal transduction. TCR binding to 
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MHC is also strengthened by the co-receptors CD4 or CD8, which bind 
conserved regions on MHC class II and class I respectively. CD4 and CD8 also 
recruit lymphocyte-specific protein tyrosine kinase (Lck) on their cytoplasmic tail 
into proximity of the CD3 complex. There, Lck can phosphorylate the CD3 ITAM 
motifs. This allows recruitment of zeta-chain-associated protein kinase (ZAP)-70 
and further downstream signalling events, eventually leading to induction of 
transcription factors, including nuclear factor of activated T-cells (NFAT), 
activator protein 1 (AP-1) and nuclear factor κB (NFκB), that promote IL-2 gene 
expression and cell growth (Smith-Garvin et al. 2009). 
Signal 2 involves costimulatory receptors and ensures the survival of the 
activated T cell. The receptors involved generally belong either to the CD28 
receptor family or the TNF receptor families and include CD28, CD27, CD40L, 
4.1-BB and OX-40. The roles and functions of CD27 and CD28 will be 
discussed in detail in section 1.2. Costimulatory signals are important for 
proliferation, survival and differentiation. TCR activation in the absence of 
costimulation, in particular CD28, leads to low IL-2 production and to apoptosis 
or a hyporesponsive state known as clonal anergy (Powell et al. 1998). 
Signalling through inhibitory molecules such as programmed cell death 1 (PD-1) 
and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) can counterbalance 
costimulation during T cell activation. 
Signal 3 is mediated by cytokines produced by both, the antigen presenting cell 
as well as the stimulated T cell. IL-2 is the most important of these cytokines 
and IL-2 receptor signalling in the activated T cell allows cell cycle progression 
and differentiation. IL-2 is secreted by the activated T cell and acts in an 
autocrine fashion. Cells stimulated in the absence of IL-2 are therefore not able 
to proliferate and undergo cell death. Other cytokines can be produced by 
antigen presenting cells which may induce a variety of differentiation programs 
(depending on the specific combination of cytokines) in the stimulated T cells, 
determining CD4+ T cell commitment to the various T helper lineages including 
Th1, Th2, Th17, Th22 and Treg (Boyman and Sprent 2012). 
 Effector cell expansion and contraction 1.1.3
The association between an activated T cell with the antigen presenting cell can 
last several days during which the T cell proliferates and the daughter cells also 
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bind to the dendritic cell. After 4-5 days of proliferation, naïve T cells therefore 
expand and differentiate into cells with specialized helper or cytotoxic functions. 
These short-lived effector cells then leave the secondary lymphoid organs to 
migrate to the sites of infection. These cells no longer require costimulation 
upon activation and express high levels of LFA-1 and very late antigen (VLA)-4, 
allowing binding to stressed endothelial cells in order to enter inflamed tissues. 
Experiments in mice have shown that recently activated or reactivated CD8+ 
effector cells have the ability to enter most peripheral tissues, including those 
that are uninfected (Masopust et al. 2004). Following this initial expansion 
phase and disease resolution, the T cells enter the contraction phase, during 
which 90-95% of the cells die by apoptosis (Strasser and Pellegrini 2004). The 
remaining cells adopt a memory phenotype and persist in the circulation and 
tissues. 
 T cell effector functions 1.1.4
Cytotoxic T cells are antigen specific killers which can induce apoptosis in their 
target cells. T cell mediated target cell killing can be mediated in a receptor- or a 
cytotoxic granule-dependent manner. 
 Cytotoxic granules 1.1.4.1
Cytotoxic T cells readily carry pre-formed cytotoxic granule components in order 
to kill target cells quickly upon recognition through MHC-TCR ligation. Cytotoxic 
granules are formed from lysosomes and are surrounded by a lipid bilayer (de 
Saint Basile et al. 2010). They contain perforin, granzymes and granulysin, 
which are kept in an inactive state through a low pH (Ménager et al. 2007). 
Upon release, perforin polymerizes and creates pores in the target cell 
membrane, enabling entry of other cytotoxic molecules into the cytoplasm of 
target cells (Browne et al. 1999; Pipkin et al. 2010). Perforin is thought to be 
essential for granzyme mediated killing, as perforin deficient mice have a 
severe defect in immune responses against the majority of viruses and are 
susceptible to spontaneous and chemically induced tumours (Kägi et al. 1994; 
Lowin et al. 1994; Broek et al. 1996). Similarly, polymorphisms in the perforin 
gene have been associated with melanoma development at young age (Trapani 
et al. 2013).  
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Granzymes are a family of serine proteases that has five members in humans: 
Granzyme A, B, H, K and M. The various granzymes are all thought to be 
involved in inducing apoptosis in the target cells by different mechanisms, but 
have redundant functions in immunity as mice lacking individual granzymes do 
not generally show more severe disease outcomes (Cullen et al. 2010). The 
role granzymes play in tumour rejection is therefore not well defined, as mice 
lacking these molecules did not have impaired immune responses to various 
transplanted tumours compared to wild type mice (Smyth et al., 2003).  
Granzymes A and B are the most widely expressed and are also the most 
studied granzymes. Upon release into the target cell cytosol, granzyme B 
cleaves and activates caspase 3, which in turn activates a caspase proteolytic 
cascade that leads to the inactivation of ICAD (inhibitor of CAD), thereby 
releasing caspase-activated deoxyribonulcease (CAD), which finally degrades 
the target DNA. Granzyme B and caspase 3 also both cleave BID, triggering 
disruption of the outer mitochondrial membrane and the release of inner 
membrane proteins such as pro-apoptotic cytochrome c (Alimonti et al. 2001). 
Granzymes can also be released into the extracellular space and can be 
expressed in the absence of perforin in a number of cell types including B cells 
and mast cells, suggesting additional roles of these proteins to killing. Indeed, 
granzymes can directly induce inflammation, by acting as a chemoattractant to 
other immune cells and by promoting the release of inflammatory cytokines. 
Granzymes can also cleave inflammatory cytokines such as IL-1b and IL-18 into 
more inflammatory forms (Boivin et al. 2009; Hiebert and Granville 2012). 
Eomesodermin (eomes) and T-box expressed in T cells (T-bet) are known 
transcription factors involved in promoting a cytotoxic phenotype in T cells. 
Ectopic expression of eomes or Tbet were shown to induce perforin and 
granzyme B expression in Th2 cells that do not normally express these proteins 
(Pearce et al. 2003). Extracellular signals that promote de novo perforin and 
granzyme expression include TCR ligation and exposure to high levels of IL-2 
and IL-15 (Janas et al. 2005; Salcedo et al. 1993; Leger-Ravet et al. 1994; 
Gamero et al. 1995). Conversely transforming growth factor (TGF)-β was shown 
to inhibit perforin and granzyme B expression in mice in vivo and in human T 
cell in vitro (Thomas and Massagué 2005; van Houdt et al. 2009) 
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Degranulation can be induced by TCR crosslinking and subsequent release of 
effector molecules must be tightly regulated in order to avoid bystander cell 
death. Indeed, cytotoxic granule mediated killing is highly focussed and involves 
the formation of an immunological synapse that encompasses integrins to 
stabilize T cell:target cell binding. The cytotoxic granules, anchored to 
microtubules, migrate towards the synapse and are released onto the target cell 
in a highly polarized manner (de Saint Basile et al. 2010).  
 Death receptor mediated killing 1.1.4.2
Other mechanisms exist that can induce target cell death but are granule 
exocytosis independent. Fas/FasL mediated killing for example involves ligation 
of effector cell FasL (CD95L) with Fas (CD95) on the target cell, leading to 
trimerization of the latter and the induction of caspase-dependent intracellular 
cell death pathways (Villa-Morales and Fernández-Piqueras 2012). Fas/FasL 
mediated induction of cell death is thought to be primarily involved in immune 
regulation, rather than tumour cell killing, as Fas deficiency in mice and humans 
leads to lymphoproliferative disorders and immunopathology (Griffith et al. 
1995; Le Deist et al. 1996). However, FasL-mediated signalling can also induce 
T- and NK-cell induced tumour rejection in certain settings (Villa-Morales and 
Fernández-Piqueras 2012; Morales-Kastresana et al. 2013; Eberle et al. 2003; 
Liu et al. 2005). 
TNF-related apoptosis-inducing ligand (TRAIL) is an alternative pathway of 
receptor mediated cell death. TRAIL can be excreted or membrane bound and 
induces trimerization of its receptors TRAILR-1 or -2 upon ligation, initiating a 
caspase-8 dependent signalling cascade that will induce apoptosis in the target 
cell. Like FasL, TRAIL mediated killing is involved in both, regulation of immune 
cells as well as tumour cell killing (Thomas and Hersey 1998; Dimberg et al. 
2013). 
 Receptors controlling T cell behaviour 1.2
T cell activation is a complex process and its outcome depends on a balance of 
positive and negative signals. The function of each stimulatory and inhibitory 
molecule is strongly related to the timing and context of its ligation. Therefore, 
expression of each of these receptors and/or its ligand is tightly regulated and 
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dependent on the activation and differentiation status of the cell. The following 
section will examine in more detail the features of the costimulatory molecules 
CD27, CD28 and CD45 and the inhibitory receptors PD-1 and CTLA-4. 
 CD28  1.2.1
CD28 can act as costimulatory molecule upon binding its ligands CD80 (B7.1) 
and CD86 (B7.2) on the surface of antigen presenting cells. CD28 ligation 
during concomitant TCR stimulation recruits phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3K) to the TCR complex. PI3K converts the 
phosphoplid PIP2 to PIP3, allowing recruitment of phospholipase C (PLC)γ to 
the plasma membrane, which converts PIP2 into diacylglycerol (DAG) and IP3. 
DAG in turn initiates downstream NFκB signalling, whilst IP3 induces 
downstream calcium release and subsequent NFAT pathway activation. PIP3 
also allows recruitment of Akt (Rudd et al. 2009). 
CD28 signalling therefore decreases the threshold for TCR activation, induces 
entry into the G1 phase of the cells cycle and promotes survival via upregulation 
of Bcl-xL (Boise et al. 1995). Further, CD28 signalling promotes IL-2 production 
(at both protein and mRNA level) and causes upregulation of the high affinity IL-
2 receptor CD25 (Powell et al. 1998). CD28 knock-out mice showed a reduction 
in certain T cell functions such as induction of B cell class switching but were 
able to generate cytotoxic T cells (Shahinian et al. 1993). 
CD28 can be detected on naïve cells and certain memory T cells, but is lost 
with differentiation. Indeed, long term stimulation with allogeneic cells or IL-2 
causes CD28 downregulation in vitro (Effros et al. 1994; Borthwick et al. 2000). 
The frequency of CD28 expressing cells declines with age in humans (Effros et 
al. 1994; Boucher et al. 1998). 
 CD27 1.2.2
CD27 belongs to the TNFR superfamily and acts as a costimulatory molecule to 
enhance T cell function upon binding to its unique ligand CD70 during TCR 
activation. Ligation induces CD27 trimerization, engaging TNFR-associated 
factor 2 (TRAF2) and TRAF5 to its cytoplasmic tail and inducing downstream 
NFκB and c-Jun-N-terminal kinase (JNK)-signaling cascades. CD27 signalling 
therefore promotes survival and enhances proliferation, thereby leading to 
increased effector functions such as cytotoxicity and promoting memory 
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formation (Duttagupta et al., 2009). CD27 deficient mice develop similarly to 
wild-type mice, but show a reduction in cell numbers during primary and recall 
responses (Hendriks et al. 2000). Conversely, mice overexpressing CD70 show 
increased effector functions against certain pathogens but also display B cell 
depletion due to high levels of T cell derived interferon (IFN)-γ, leading to the 
animals becoming immunocompromised (Arens et al. 2004). 
CD27 is expressed by naïve and early-differentiated memory T cells and is 
further upregulated upon CD3-mediated stimulation (Hintzen et al. 1993). 
However, after prolonged activation in vitro and in vivo, CD27 expression is 
gradually reduced and eventually lost irreversibly. CD70 expression is highly 
regulated and normally only occurs transiently in T cells, B cells, NK cells and 
dendritic cells upon activation (Nolte et al. 2009). 
Constitutive signalling through CD27 during CD70 overexpression in T cells has 
also been shown to lead to an exhaustion-like phenotype in CD8+ but not CD4+ 
T cells, by causing reduced IL-2 and TNFα production and increased 
expression of PD-1, IL-10 and B lymphocyte-induced maturation protein-1 
(Blimp-1) (van Gisbergen et al. 2009). CD27 signalling in the tumour setting can 
be both beneficial and detrimental to anti-tumour immune responses, depending 
on the context. Studies involving injection of tumour cell lines into mice have 
shown that CD27 signalling can mediate anti-tumour immunity by promoting 
effector T cell function (Arens et al. 2004; Roberts et al. 2010). However, CD27 
signalling in mice with solid transplanted tumours was shown to be detrimental 
to the host by promoting Treg development and therefore immunosuppression 
(Claus et al. 2012). CD27 signalling therefore has a variety of outcomes, which 
may depend on the context and duration of CD70 ligation. 
 CD45  1.2.3
CD45 (lymphocyte common antigen) is a transmembrane receptor that is 
expressed on all haematopoietic cells and contains a protein tyrosine 
phosphatase on its cytoplasmic tail. The ligand for CD45 has not been identified 
to date. A number of CD45 isoforms exist that are generated through alternative 
splicing and differ in the length of their extracellular domain. On T cells, high 
molecular weight CD45RA was originally attributed to naïve T cells, whereas 
low molecular weight CD45RO was associated with antigen experienced cells 
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(Akbar et al. 1988). Subsequently, a population of antigen experienced and 
highly differentiated cells that do re-express CD45RA on their surface has also 
been identified (Hamann et al. 1997). However, the exact role of CD45 isotypes 
in T cell differentiation has not yet been established. 
CD45 modulates early T cell signalling during antigen stimulation by removing 
an inhibitory phosphate group from the Src-family kinase Lck. Activated Lck in 
turn may phosphorylate the ITAMs on the CD3 complex, enabling further 
recruitment of components involved in CD3 signalling (Hermiston et al. 2003). 
Being the smallest CD45 isoform, CD45RO more readily associates with the T 
cell receptor and enables signal transduction than CD45RA. T cell development 
is heavily impaired in CD45 deficient mice (Byth et al. 1996). 
 PD-1 1.2.4
Programmed death-1 (PD-1; CD279) is an inhibitory cell surface receptor 
homologous to CD28. It is comprised of an extracellular Immunoglobulin-like 
domain and two tyrosine-based signalling motifs in the intracellular tail 
(Sheppard et al. 2004). Engagement of PD-1 to its ligands inhibits T-cell 
activation and induces peripheral tolerance.  
The majority of T cells in the circulation do not express PD-1, but can be 
induced to do so upon TCR-mediated activation or exposure to cytokines such 
as IL-2, IL-7, IL-15, IL-21 and TGF-β (Agata et al. 1996; Kinter et al. 2008). 
Some T cell populations constitutively express PD-1, such as follicular helper T 
cells (Sage et al. 2013). 
PDL-1 (B7-H1; CD274) and PDL-2 (B7-DC; CD273) are the ligands to PD-1 and 
are differentially expressed on a variety of cells in the circulation: PD-L1 is 
constitutively expressed by a number of haematopoietic cells including T cells 
and antigen presenting cells and is expressed in various lymphoid and non-
lymphoid tissues (Freeman et al. 2000; Brown et al. 2003; Peña-Cruz et al. 
2010; Bankey et al. 2010).  PDL-2 expression is thought to be restricted to 
dendritic cells and macrophages (Freeman et al. 2006).  IFNγ in particular 
causes PDL-1 and PDL-2 upregulation in various cell types (Brown et al. 2003). 
The tyrosine residues in the cytoplasmic tail of PD-1 mark the presence of an 
immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoreceptor 
tyrosine-based switch motif (ITSM) motif (Chemnitz et al. 2004). Upon PD-1 
 34 
engagement with its ligands, the tyrosine residues in the cytoplasmic tail are 
phosphorylated, recruiting Src homology 2-domain-containing tyrosine 
phosphatase 2 (SHP-2) and SHP-1 (Chemnitz et al. 2004). SHP-1 and SHP-2 
in turn lead to the dephosphorylation of TCR proximal signalling components, 
thereby inhibiting certain TCR/CD28-mediated signals (Parry et al. 2005; 
Patsoukis et al. 2012). Because PD-1 transduces a signal when engaged in 
combination with T cell receptor (TCR) ligation only, the extent of PD-1 
mediated inhibition is dependent on the strength of the stimulation and will have 
the greatest impact under conditions of relatively weak stimulation (Freeman et 
al. 2000; Latchman et al. 2001; Brown et al. 2003).  
Both CD28 and IL-2 promote T cell proliferation and cell cycle progression, 
survival and cytokine expression and PD-1 exerts its effects directly by inhibiting 
early activation events induced by CD28 or indirectly through undermining 
production of IL-2 (Carter et al. 2002). Therefore, PD-1 signalling undermines 
TCR-signalling mediated upregulation of cytokines such as IL-2, IFNγ and 
TNFα, cell cycle progression, upregulation of the survival gene Bcl-xL and leads 
to a reduced expression of transcription factors involved in effector functions 
such as Tbet and Eomes (Chemnitz et al. 2004; Patsoukis et al. 2012; Nurieva 
et al. 2006).  
Originally discovered on murine T cell hybridoma and thought to be involved in 
cell death (Ishida et al. 1992), it is now  clear that the major function of PD-1 
involves inhibitory signalling and immune regulation. This is supported by direct 
and indirect evidence in mice deficient in PD-1 displaying a breakdown in 
peripheral tolerance and exacerbated features of autoimmunity (Nishimura et al. 
1999; Salama et al. 2003) and humans where genetic polymorphisms in the 
PD-1 locus have been linked to various autoimmune diseases (Nielsen et al. 
2003; Velázquez-Cruz et al. 2007).  
PD-1 mediated signalling is not only important in mediating tolerance to self, but 
also in preventing exacerbated immune responses. During acute infection PD-1 
is upregulated on activated T cells, but is not necessarily associated with 
impaired immune responses to the pathogen (Erickson et al. 2012; Phares et al. 
2010). PD-1 is also constitutively upregulated by T cells through chronic antigen 
exposure during persistent disease. This mechanism may prevent further 
immunopathology during chronic antigen stimulation, but may also cause 
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immune dysfunction, and lead the T cells to adopt a state known as exhaustion 
(Speiser et al. 2014). This may occur in chronic viral infections as well as 
cancer. T cell exhaustion will be discussed in more detail in section 1.4.4. 
PD-1 ligation may also suppress T cell responses to cancer. The inhibitory 
receptor can be upregulated on tumour infiltrating lymphocytes as well as 
tumour specific T cells in the circulation (Ahmadzadeh et al. 2009; Baitsch et al. 
2011; Chapon et al. 2011).  Expression of PD-1 in these cells was associated 
with decreased T cell function in humans and mice (Saito et al. 2013; Curran et 
al. 2010). PDL-1 can be expressed on tumour cells and correlated with poor 
prognosis in certain cancers, but not melanoma metastases (Hamanishi et al. 
2007; Inman et al. 2007; Ahmadzadeh et al. 2009; Gadiot et al. 2011).  
 CTLA-4 (CD152)  1.2.5
CTLA-4 is a B7/CD28 family member that inhibits T cell function. Like CD28, 
CTLA-4 binds CD80 and CD86, but does so with higher affinity (Rudd et al. 
2009). CTLA-4 is commonly expressed by Tregs and can be induced in other T 
cell subsets upon activation (Chan et al. 2014). In resting cells CTLA-4 is 
located in intracellular vesicles. Upon activation, it is transiently expressed in 
the immunological synapse before being rapidly endocytosed (Leung et al. 
1995). 
CTLA-4 can regulate T cells intrinsically or in a bystander-cell mediated fashion 
through a number of mechanisms (Wing et al. 2008). CTLA-4 is in direct 
competition with CD28 for their common ligands CD80 and CD86. Because 
CTLA-4 binds these with greater affinity, CD28 signalling is reduced in the 
presence of the inhibitory receptor. CTLA-4 has also been shown to oppose 
CD28 signalling by removing CD80 and CD86 (including their cytoplasmic 
domain) from the antigen presenting cell via trans-endocytosis (Qureshi et al. 
2011). The cytoplasmic tail of CTLA-4 does not contain a classic ITIM motif, but 
can recruit the phosphatases SHP-2 and PP2A (Marengère et al. 1996; Chuang 
et al. 2000), which may interfere with TCR signalling, although the exact 
mechanism for this remains to be elucidated (Parry et al. 2005).CTLA-4 
therefore works by opposing CD28 and TCR-mediated signalling during 
activation, leading to reduced expression of IL-2 and cell cycle arrest.  
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CTLA-4 signalling increases the activation threshold during T cell activation, 
thereby reducing the pathogenicity of effector T cells. CTLA-4 therefore plays a 
crucial role in immunological tolerance. This has been highlighted in mice 
lacking CTLA-4 globally or selectively in the FoxP3+ Treg compartment, which 
develop a lymphoproliferative disorder and die at young age (Waterhouse et al. 
1995; Wing et al. 2008). Similarly, polymorphisms within the CTLA-4 gene have 
been associated with autoimmune diseases in humans (Gough et al. 2005). 
CTLA-4 signalling has also been implicated with reduced immune responses 
during disease in infection and tumour settings. This was particularly noted in 
the context of immune exhaustion, discussed in more detail in section 1.4.4.. 
 T Cell Memory 1.3
The generation of immunological memory is the hallmark of the adaptive 
immune response. Memory cells are more sensitive to antigen and are 
generally found in higher frequencies than their naïve precursors, allowing more 
rapid proliferation and effector functions upon antigen re-encounter. Memory T 
cells are not a uniform population of cells but are generally thought to come in 
three distinct classes: central memory (TCM), effector memory (TEM) and effector 
memory cells that re-express CD45RA (TEMRA), which can be distinguished by 
their homing, proliferative and functional properties (See Fig Table 1-1, Sallusto 
et al. 1999; Faint et al. 2001). This is true for both, CD4+ and CD8+ T cells. 
 Markers used to identify subpopulations  1.3.1
Various markers and combinations of markers have been used in literature to 
define memory T cell subsets and there is currently no consensus on which is 
the most appropriate (Appay et al. 2008).  The markers most commonly used 
for this purpose are CD45RA in combination with CD62L, CCR7 or CD27, 
although there is generally high consistency in the expression patterns of these 
markers in the subsets, meaning differently defined populations using these 
markers are comparable (Sallusto et al. 1999; Appay et al. 2008). 
In this work, the combination of CD45RA and CD27 was used to define naïve, 
TCM, TEM and TEMRA subsets, as CD27 expression was found to generate more 
discrete populations than CCR7 or CD62L and less likely to be re-expressed. 
Using these markers is also in accordance with previous work published by our 
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group and others (Hamann et al. 1997; Di Mitri et al. 2011; Henson et al. 2014).  
It should be noted that the identification of memory differentiation 
subpopulations based on surface receptor expression applies to resting cells 
only, as markers can be altered upon T cell activation. TEM cells for example 
have been shown to upregulate the TCM marker CD62L after stimulation, 
although it should be noted that these cells did not display equal proliferative 
functions compared to cells that expressed CD62L prior to stimulation (Sallusto 
et al., 2004). 
Other marker combinations used to identify T cells of various differentiation 
stages are coexpression of CD27 and CD28 with double expressing cells being 
the least differentiated and double negative cells being the most differentiated 
(Henson et al. 2009). Alternatively, loss of CD28 or expression of CD57 or 
KLRG1 by themselves have been used to identify highly differentiated cells 
(Brenchley et al. 2003; Voehringer et al. 2002; Speiser et al. 1999). 
Research in identification and characterization of T cell subsets has largely 
been based on blood derived T cells. Whether the TCM/TEM/TEMRA dogma can be 
applied to tissue resident T cells remains to be established. 
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  Naïve TCM TEM TEMRA 
Receptors 
associated 
with homing 
CCR7 + + - - 
CD62L + + - - 
CLA - + + - 
CCR4 - + + - 
CXCR1 - - +/- + 
Stimulatory 
and Inhibitory 
coreceptors 
CD27 + + +/- - 
CD28 + + +/- - 
CD45RA + - - + 
CD45RO - + + - 
PD-1 - +/- +/- - 
KLRG1 
 
- - + + 
Cytokines 
and cytotoxic 
effector 
molecules 
IL-2 - +++ ++ + 
TNFα - + +++ +++ 
IFNγ - + +++ +++ 
Granzyme B - + ++ +++ 
Perforin - + ++ +++ 
Senescence 
and 
differentiation 
associated 
features 
Telomere 
length +++ ++ + ++ 
Proliferative 
capacity +++ +++ ++ + 
γH2AX - - +/- + 
CD57 - - +/- + 
Table 1-1: Phenotypic properties of T cell subsets 
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 Central memory T cells (TCM) 1.3.2
TCM are named after their homing pattern and express distinct surface receptors 
which cannot be found on effector memory cells (TEM). This includes CD62L (L-
selectin) and CCR7, which are necessary for migration to the T cell areas of 
secondary lymphoid organs, such as the lymph nodes or mucosal lymphoid 
organs (e.g. tonsils) (Sallusto et al. 1999). TCM express high levels of the 
costimulatory molecules CD27 and CD28, which bind ligands generally found 
on mature dendritic cells. Upon activation, TCM express high levels of CD40L, 
which can in turn stimulate dendritic cells, B cells and macrophages and provide 
CD8+ T cell help (Sallusto et al. 1999). 
Activated TCM have little or no immediate effector functions and do not produce 
many cytokines apart from IL-2. However, they are able to proliferate 
extensively and produce effector cytokines much later as they lose CCR7 and 
differentiate into effector cells that produce large amounts of IFN-γ or IL-4 (de 
Jong et al. 1992; Sallusto et al. 1999). TCM are therefore considered by some 
researchers to have memory stem-cell like attributes such as high proliferative 
capacity and high IL-2 production that can provide long term memory and 
contribute to the TEM cell pool that mediates effector functions (Lanzavecchia 
and Sallusto 2005). 
 Effector memory T cells (TEM) 1.3.3
TEM have lost the expression of lymphoid homing receptors such as CCR7 and 
may instead express homing receptors that facilitate migration to nonlymphoid 
tissues, particularly during inflammation. This includes high expression of 
integrins such as LFA-1 and inflammatory chemokine receptors including 
CCR1, CCR3, CCR5 and CXCR3, as well as the tissue homing receptors 
cutaneous leukocyte antigen (CLA) and CD103 (Sallusto et al. 1999; Willinger 
et al. 2005). 
TEM have a low activation threshold to CD3 stimulation and express low levels 
of the costimulatory receptors CD27 and CD28. At potential sites of 
inflammation, TEM can produce IFN-γ, TNFα, IL-4 and IL-5 within hours of TCR 
restimulation and readily release prestored effector molecules such as perforin 
and granzyme A, B and H (Sallusto et al. 1999; Willinger et al. 2005). TEM can 
also express high levels of TRAIL and FasL, involved in perforin independent 
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killing (Willinger et al. 2005). Consistent with expression of these molecules, 
TEM express high levels of the transcription factors involved in effector T cell 
functions, such as T-bet and eomes (McLane et al. 2013). Compared to TCM, 
TEM have decreased proliferative function but markedly increased effector 
capacities, allowing them to mediate immediate immune protection upon 
challenge (Sallusto et al. 1999). 
 Effector memory T cells re-expressing CD45RA (TEMRA) 1.3.4
A third class of memory cells have a greatly reduced proliferative potential 
compared to the other subsets and accumulates with age (Koch et al. 2008). 
Similarly to the TEM, these cells express particularly large amounts of effector 
cytokines, cytotoxic granule components and receptors that allow migration to 
inflammatory sites, whilst lacking the costimulatory molecules CD27 and CD28 
(Hamann et al. 1997; Faint et al. 2001; Willinger et al. 2005). These cells are 
known as TEMRA, as they can be distinguished from TEM through the expression 
of CD45RA, a marker normally found on naïve T cells only (Faint et al. 2001).  
TEMRA are thought to be the most differentiated of all T cell subpopulations, as 
they have the highest levels of DNA damage associated marker γH2AX and 
lowest levels of telomerase activity, although it should be noted that their 
telomeres are longer than in TEM (Di Mitri et al. 2011). TEMRA also express the 
highest levels of the senescence associated receptors CD57 and KLRG1 (Di 
Mitri et al. 2011; Libri et al. 2011). The senescent nature of TEMRA cells will be 
discussed in more detail later (section 1.4.1). TEMRA cells also express high 
levels of inhibitory receptors commonly associated with NK cells, such as CD94, 
NKG2A, CD158a and NKB-1 ( Baars et al. 2000). 
TEMRA are though to be the most differentiated of all the memory subsets and 
whilst they have very low proliferative function, their effector-like nature allows 
them to rapidly kill target cells upon challenge. 
 Lineage relationship and differentiation of T cell subsets 1.3.5
Transfer models in mice have shown that a single naïve T cell is multipotent 
and can give rise to any memory subset (Stemberger et al. 2007; Gerlach et al. 
2010). It is generally accepted that TCM are the least differentiated out of all the 
memory T cell subsets, whilst TEMRA have reached an end stage (Di Mitri et al. 
2011; Willinger et al. 2005). However, the exact generation and lineage 
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relationships between these cells are still a matter of debate. Certain models 
propose a linear differentiation from naïveà TCMà TEMàTEMRA, determined by 
repetitive stimulation or signal strength. Alternatively, asymmetric division may 
generate TCM, TEM or TEMRA independently from each other (Chang et al. 2007; 
Kaech and Cui 2012). 
 Antigen specificity of T cell subsets 1.3.6
Cells specific against various pathogens and of different clonotypes can be 
preferentially driven towards certain memory phenotypes rather than others and 
this can vary with anatomical location of the cells and period of exposure to the 
pathogen. Influenza specific T cells for example preferably adopt a TCM-like 
phenotype (CD62Lhi) (Kedzierska et al. 2006). In Epstein-Barr virus (EBV) 
positive individuals, CD8+ T cells specific against latent antigens show a TCM-
like CD45RO+CD28+ phenotype, whilst T cells against lytic epitopes were 
heterogenous but contained TEMRA-like (CD45RA+CD28-) cells (Hislop et al. 
2002). Cytomegalovirus (CMV) specific cells typically are skewed towards a TEM 
or TEMRA phenotype (Griffiths et al. 2013). Indeed, the TCR repertoires of 
circulating human CD8+ TCM and TEM are largely distinct (Baron et al. 2003). 
 Maintenance of memory 1.3.7
All T cell memory subsets are stable T cell populations that can persist in the 
absence of antigen for a lifetime. Maintenance of memory T cells in the absence 
of antigen stimulation is a dynamic process during which the cells proliferate 
and die. Radioactive isotope labelled CD4+ T cells were followed up in human 
volunteers in vivo and displayed an estimated doubling time of 1 year for naïve 
T cells, 48 days for TCM and 15 days in TEM cells (Macallan et al. 2004). 
Simultaneously, TEM also displayed the highest disappearance rates, 
suggesting that homeostasis is maintained through occasional cell death as well 
as proliferation of the surviving cells (Macallan et al. 2004).  
Long-term persistence of the memory cells is dependent on homeostatic 
proliferation driven by common γ-chain cytokines such as IL-7 and IL-15, which 
also promote survival (Sprent et al. 2008). Indeed, TEMRA are thought to be 
predominantly generated by cytokine exposure rather than by antigen-
dependent stimulation (Geginat, Lanzavecchia, and Sallusto 2003). Excess 
cells (generated during homeostatic proliferation or during expansion following 
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antigenic stimulation) undergo apoptosis due to cytokine deprivation or 
programmed cell death (Jameson 2002; Prlic and Bevan 2008). These cells 
display “eat-me” signals and are cleared by phagocytic cells such as 
macrophages or immature dendritic cells in an anti-inflammatory manner (W. 
Chen et al. 2001; Savill et al. 2002). 
 Tissue resident T cells 1.3.8
Various studies in the past have analysed cells in peripheral tissues and 
classified them into the three classic subsets described above based on the 
detection of CD45RA and CCR7 (Clark, Chong, Mirchandani, Brinster, et al. 
2006; Sathaliyawala et al. 2013). However, it has become apparent that T cells 
in the skin, blood, lung and many other peripheral organs do in fact comprise an 
additional independent memory subset, as the cells differ in phenotypes and 
functions from their circulating counterparts. These cells are therefore now 
termed tissue-resident memory cells, or TRM (Jiang et al. 2012; Purwar et al. 
2011; Zhang and Bevan 2013). 
TRM are thought to act as immune sentinels in the peripheral tissues, as they 
are able to not only kill target cells but also secrete proinflammatory cytokines 
and chemokines to attract other immune cells. Indeed, TRM have been shown to 
confer increased protection upon pathogen re-encounter and their efficacy has 
been directly linked to the numbers of pathogen-specific cells before re-infection 
(Liang et al. 1994). The nature of TRM with a focus on skin resident TRM will be 
discussed in more detail in section 1.5.3. 
 CD4+ FoxP3+ Tregs 1.3.9
Forkhead box p3 (Foxp3) positive regulatory T cells (Tregs) are a suppressive 
subpopulation of CD4+ T cells that control immune responses to self and foreign 
antigen. They can be induced in the thymus (natural Tregs) as well as in the 
periphery (induced Tregs) and are characterized by expression of the high 
affinity IL-2 receptor CD25 in absence of the IL-7 receptor CD127 (Sakaguchi et 
al. 2008). Further, circulating FoxP3 Tregs express CD27 and are heterogenous 
for CD45, placing these cells either into the naïve or the TCM compartments 
(Booth et al. 2010; Shen et al. 2011). Tregs can be detected in both, the 
circulation and peripheral organs where they ensure immune tolerance and 
control excessive immune reactions (Akbar et al. 2007; Fulton et al. 2010). 
 43 
Tregs regulate immune responses in a number of ways. This includes 
production of anti-inflammatory cytokines such as IL-10, TGF-β and IL-35, IL-2 
depletion and inhibitory receptor mediated inhibition (e.g. via CTLA-4 and PD-1) 
(Tang et al. 2004; Wang et al. 2009). Through these mechanisms, Tregs can 
inhibit T cell effector functions directly or indirectly by modulating accessory 
cells such as dendritic cells (Sakaguchi et al. 2009). 
 T cell dysfunction: Exhaustion and Senescence 1.4
Disease and disease free episodes dictate expansion and resting phases in 
memory T cells. However, under conditions of prolonged antigen stimulation, for 
example during persistent or chronic viral infections, T cell populations can be 
driven into dysfunctional states, such as T cell senescence or exhaustion. 
Whilst the terms are often being used interchangeably, senescence and 
exhaustion are in fact two distinct processes characterized by different 
phenotypic markers and different underlying molecular pathways (Akbar and 
Henson 2011). Senescence is generally associated with persistent reactivating 
infections, whilst exhaustion is associated with chronic antigen exposure as a 
result of failure of disease containment. 
 T cell senescence 1.4.1
Senescence was first described in fibroblast cultures, where, after 50 passages, 
cells underwent growth arrest but were resistant to cell death (Effros and 
Walford 1984). This state, termed replicative senescence, is characterized by 
irreversible loss of proliferative capacity and has since been described in T 
cells. Senescence in memory T cells is associated with end-stage 
differentiation, lack of proliferative capacity and evidence of DNA damage but 
preservation of certain effector functions ( Akbar and Henson 2011; Baars et al. 
2000). Senescence occurs when telomere loss due to excessive cell division 
and general DNA damage (which can be induced by reactive oxygen species, 
ionizing radiation and other mechanisms) induce DNA damage responses, 
triggering intracellular signalling cascades involving p53 and p38 that lead to 
growth arrest and loss of telomerase activity (Plunkett et al. 2005; Iwasa et al. 
2003).  
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Senescent T cells are characterized by a loss of their CD27 and CD28 
costimulatory molecules, increased expression of the DNA damage associated 
marker γH2AX and upregulation of NK-cell associated inhibitory makers KLRG1 
and CD57 (Henson et al. 2009; Di Mitri et al. 2011). The TEMRA memory subset 
bears the hallmarks of cellular senescence, by showing low proliferative 
capacity and telomerase activity upon activation but high levels of γH2AX, 
reactive oxygen species and CD57 and KLRG1 expression (Di Mitri et al. 2011; 
Henson et al. 2014). 
Cells with a senescence associated phenotype accumulate as a result of 
repeated exposure stimulation and with age (Griffiths et al. 2013; 
Derhovanessian et al. 2011; Koch et al. 2008). The accumulation of senescent 
cells is most commonly associated with cytomegalovirus (CMV) infection in 
healthy individuals (Ouyang et al. 2004; Kuijpers et al. 2003). After infections, 
this herpes virus establishes latency in a variety of cell types and persists for life 
in the immunocompetent host (Gandhi and Khanna 2004). Progressive long 
term antigen exposure during reactivation can lead to progressive T cell 
differentiation and large oligoclonal expansions of senescent and dysfunctional 
cells (Lachmann et al. 2012; Ouyang et al. 2004).  
Pathogen specific cells may also have senescent features in other viral 
diseases such as Epstein-Barr virus (EBV), human immunodeficiency virus 
(HIV), and hepatitis C (Hoare et al. 2013; Mojumdar et al. 2011). Senescent 
cells were also increased in individuals with autoimmune conditions, such as 
rheumatoid arthritis (Michel et al. 2007). Repeated T cell stimulation during 
these conditions may lead to senescent cells accumulating in large oligoclonal 
expansions (Di Mitri et al. 2011).  
Whilst they show low proliferative capacity and lack of IL-2 production, most 
senescent cells are functional and express high levels of effector cytokines such 
as IFNγ and TNFα, as well as granzyme B and perforin, indicating high 
cytotoxic potential (Akbar and Henson 2011; Lachmann et al. 2012; Henson et 
al. 2014). Indeed, the fact that CMV is generally only reactivated during 
immunosuppression suggests that these cells are able to mediate effective 
immune surveillance (Gandhi and Khanna 2004). However, early stages of 
senescence can precede eventual loss of functionality, as some studies 
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suggest reduced in vitro cytokine production of CMV specific cells derived from 
old individuals compared to young donors (Ouyang et al. 2004). 
The accumulation of large oligoclonal populations of senescent cells has been 
associated with detrimental effects in overall immune function and health in a 
number of studies. Studies in mice showed that large clonal expansions caused 
by herpes simplex virus (HSV)-1 caused reduced anti-viral function in old but 
not young mice (Messaoudi et al. 2004). Similarly, old rhesus monkeys showed 
reduced responsiveness to vaccinia virus in vivo and this was associated with a 
reduced naïve T cell pool due to persistent clonal expansions (Čičin-Šain et al. 
2010). In humans, CMV infection and large oligoclonal T cell expansions have 
been associated with reduced responsiveness to EBV and increased mortality 
in old individuals (Khan et al. 2004; Wikby et al. 2005). In a different study, 
increased mortality in old individuals was associated with low overall telomere 
length of leukocytes, but not with CMV status (Deelen et al. 2014). Conversely, 
a number of studies exist that fail to show a negative impact of high T cell 
senescence in old animals (Cicin-Sain et al. 2011). 
It has been demonstrated that T cell senescence can be manipulated, as 
inhibition of KLRG1 ligation rescued proliferation but not telomerase activity 
whilst p38 inhibition allowed the restoration of both in highly differentiated T 
cells in vitro (Henson et al. 2009; Di Mitri et al. 2011, 20)  
 Senescence associated markers 1.4.2
CD57 (beta-1,3-glucuronyltransferase 1 or NK-1) is a surface glycoprotein that 
binds L- and P-selectin and a fragment of laminin. On T cells, CD57 expression 
has been shown to inversely correlate with telomere length and physical and 
emotional stress can increase CD57+ cells in peripheral blood of humans 
(Brenchley et al. 2003). Although its expression is associated with low 
proliferative function and end stage differentiation in T cells, the exact role of 
CD57 in T cell senescence is unknown.  
Killer cell lectin-like receptor subfamily G, member 1 (KLRG1) is a 
transmembrane receptor belonging to the C-type lectin-like superfamily and 
contains an ITIM in its intracellular domain. Its ligands are E- (Epithelial), N- 
(neural) and R-(retinal) cadherin which comprise a family of transmembrane 
glycoproteins that mediate cell-to-cell adhesion. KLRG1 is upregulated on T 
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cells during infection and can be found on highly differentiated resting memory 
cells, including TEM and TEMRA. KLRG1 expression on T cells is often associated 
with low proliferative function and high levels of differentiation. However, rather 
than just being a marker, KLRG1 signalling (through recruitment of SHIP-1 and 
SHP-2 to its ITIM motif) has been shown to actively contribute to decreased 
proliferation in CD8+CD28−CD27− T cells (Henson et al. 2009). 
 Telomere length as marker of replicative history 1.4.3
Telomeres are non-coding DNA regions at the end of chromosomes that consist 
of hexanucleotide (TTAGGG) repeats. During chromosomal replication upon 
cell division, a portion (typically 50-200 bases) of the terminal DNA sequence is 
lost in each telomere. This leads to proliferation induced telomere erosion and 
ultimately results in DNA damage responses that induce cell cycle arrest or 
apoptosis (Boer and Noest 1998). Telomere length can therefore be used as an 
indicator of proliferative history and differentiation stage of a cell subset. Indeed, 
within the T cell subsets, telomeres are longest in the naïve subset, shorter in 
the TCM subset and shortest in the TEM subset, suggesting a stepwise 
differentiation along the telomere loss in these subsets (Sallusto et al. 1999). 
TEMRA have longer telomeres than TEM, suggesting that TEMRA might not 
originate from TEM direclty (Di Mitri et al. 2011; Plunkett et al. 2005). 
 T cell Exhaustion 1.4.4
Exhaustion in T cells occurs during conditions of high antigenic load, when 
upregulation of inhibitory receptors causes signalling that leads to growth arrest, 
decreased cytotoxic capacity and decreased cytokine production (Akbar and 
Henson 2011). Exhaustion occurs in a hierarchical manner with a loss in IL-2 
and proliferation preceding reduced killing capacity, TNFα production and finally 
an inability to produce IFNγ, leading to functional impairment and deletion in 
some cases (Wherry et al. 2003).  
Exhaustion is mediated by inhibitory receptors which are usually associated 
with maintenance of self-tolerance and prevention of autoimmunity such as PD-
1, CTLA-4, T-cell immunoglobulin and mucin domain 3 (TIM-3) and lymphocyte-
activation gene 3 (LAG-3) (Sharpe et al. 2007; Blackburn et al. 2009). Blocking 
experiments targeting receptors associated with exhaustion such as PD-1 and 
CTLA-4 or PD-1 and LAG-3 have been shown to increase proliferation and 
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functionality in T cells in a non-redundant manner (Blackburn et al. 2009; Parry 
et al. 2005). 
Exhaustion has been shown to occur during chronic viral infections when the 
host fails to contain the pathogen. Such infections can be caused by LCMV in 
mice (Wherry et al. 2003) and HIV and Hepatitis B virus in humans (Wherry et 
al. 2003). Cells displaying exhaustion markers are mostly found within TEM and 
TCM cells that are of intermediate stages of differentiation (Akbar and Henson 
2011; Henson et al. 2012). The chronic antigenic stimulation occurring during 
these infections drives upregulation of the exhaustion associated inhibitory 
receptors but also results in downregulation of IL-7 and IL-15 receptor 
components, making them insensitive to the homeostatic cytokines IL-7 and IL-
15. Indeed, exhausted cells cannot be maintained in the absence of antigen in 
mouse models and are thought to be arrested in an intermediate stage of 
differentiation (Wherry et al. 2004). 
The inhibitory receptors involved in immune exhaustion, such as PD-1 and 
CTLA-4, play independent roles in immune tolerance. Expression of individual 
inhibitory markers is indeed not necessarily a sign of immune exhaustion 
(Erickson et al. 2012). Exhaustion can also be seen as a physiological 
mechanism designed to limit immunopathology during persistent infection 
(Speiser et al. 2014). However, exhaustion mechanisms are also hijacked by 
viruses and tumour cells, which use exhaustion pathways to avoid immune 
recognition and clearance (Baitsch et al. 2011; Day et al. 2006).  
 The skin as an immunological organ 1.5
 
Despite being the site of melanoma induction, the skin is often neglected by 
studies assessing melanoma-associated immune responses. Indeed, the skin is 
not only the largest organ in the body but is also the home of a variety of 
immune cells, including high numbers of resident lymphocytes (Clark et al. 
2006). 
 Anatomy of the Skin 1.5.1
The skin is a highly complex organ that, exposed to the environment, fulfils a 
variety of functions such as physical sensing, temperature control, barrier 
 48 
function and immunity. The skin consists of several layers, whereby the 
epidermis is exposed to the environment and shields the underlying dermis, 
under which in turn there is a layer of subcutaneous fat. The skin is interspersed 
by a number of structures, including hair follicles, sweat glands (in humans but 
not mice), sebaceous glands, nerves, blood vessels and lymphatics. A variety of 
immune cells reside in the skin, including T cells, NK cells, mast cells, various 
dendritic cell subsets, innate lymphoid cells, αβ and γδ T cells, NKT cells and 
macrophages. Structural cells such as keratinocytes and fibroblasts may also 
actively be involved in immune responses (see Fig. 1-1; Bos et al. 1987; Nestle 
et al. 2009). 
 
Fig. 1-1: Anatomy and immune cells of the skin 
Schematic diagram showing the anatomic layers of the skin (epidermis and dermis, separated 
by the stratum basale) and the various cells involved in immune responses in the skin. DC= 
dendritic cell, pDC= plasmatycoid dendritic cell. 
Adapted from (Nestle et al. 2009) 
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 Methods of studying immune cells in skin 1.5.2
Whilst most research on immune processes heavily relies on blood derived 
immune cells, much less is known about tissue resident T cells. This is not only 
due to the fact that obtaining blood samples from a human donor is generally 
much less invasive than taking biopsies, but also to the fact that it is much more 
easy to isolate and manipulate cells from the blood than from solid organs.  
Much research on skin immunity has therefore relied on imaging techniques 
that allow visualization of markers in situ using immunhistological techniques. 
However, immunofluorescence techniques are limited by the amount of 
detectors available (generally up to 4 colours) and interest is therefore high in 
using isolation techniques that allow multicolour flow cytometry in order to study 
more markers. 
A number of techniques have been devised in order to obtain single cell 
suspensions from skin samples, which will be discussed in more detail in the 
material and methods and results sections. In general, these techniques rely on 
initial mechanical disruption followed by release of the cells from the skin matrix 
using EDTA or collagenase digestion (Clark et al. 2006). Alternatively, skin cells 
can also be recovered after emigration from skin explants in culture, although 
this entails extended periods of time between sampling and cell recovery and 
might therefore artificially select for and affect results obtained (Richters et al. 
1995; Clark et al. 2006). 
Because of the limitations of working with human skin, many studies have 
investigated skin T cells in animal models, leading to important observations. 
However, it should be noted that the mouse skin immune system is distinct from 
the human one in many respects, particularly as the dominant T cell population 
in mice are γδ T cells, whilst in humans αβ T cell prevail (Heath and Carbone 
2013).  
 Skin resident T cells 1.5.3
The adult skin contains vast numbers of T cells and an emerging number of 
studies on their functions and phenotypes have yielded fascinating insights into 
the nature of these cells in humans and mice. Indeed, whilst skin resident T 
cells were initially thought to largely resemble the TEM subset in the blood, 
recent studies in mice confirmed that skin resident T cells recognize different 
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targets and are transcriptionally distinct from their circulating counterparts 
(Mackay et al. 2013). T cells enter the skin during inflammation. After disease 
resolution, antigen specific T cells preferentially accumulate at the site of former 
infection, although they will also populate the entire skin (Jiang et al. 2012). 
However, parabiosis experiments have shown that skin resident memory T cells 
are not exchanged between animals sharing a common circulatory system 
(Jiang et al. 2012). Interestingly, skin CD4+ T cells seem to be more mobile than 
their CD8+ counterpart (Gebhardt et al. 2011). 
Skin derived T cells are largely memory cells, as conventional naïve T cells are 
not thought to migrate into the peripheral organs until after activation in the 
lymph nodes. The majority of T cells in resting skin do not express the lymphoid 
homing markers CCR7 and CD62L and are CD45RO+, which is why they were 
originally postulated to be TEM cells (Clark, Chong, Mirchandani, Brinster, et al. 
2006). In humans skin derived T cells almost exclusively express the skin 
homing markers CLA, CCR4 as well as high levels of CCR6 and CCR8 (Clark, 
Chong, Mirchandani, Brinster, et al. 2006). Skin resident CD4+ T cells produce a 
variety of cytokines and are thought to be polarized towards a Th1 rather than a 
Th2 phenotype, although Th17 and Th22 have also been detected in the skin in 
various disease settings (Clark, Chong, Mirchandani, Brinster, et al. 2006; 
Segura et al. 2013; Fujita 2013).  
Skin resident T cells can become activated, proliferate and carry out local 
immune responses. The importance of skin resident T cells in absence of T cell 
recruitment from the blood has been highlighted by an elegant study, which 
involved transfer of symptomless skin from psoriasis patients onto 
immunodeficient mice. This resulted in psoriasis-like inflammation in the skin 
transplant, which was caused by reactivation of skin resident T cells (Boyman et 
al. 2004). Cell transfer studies in mice have shown that skin derived T cells 
provided superior immune protection compared to TCM upon localized vaccinia 
virus skin infection (Jiang et al. 2012). In humans, CD8+ T cells were shown to 
infiltrate herpes simplex virus (HSV) infected genital skin and proliferate and 
display perforin expression during reactivation, confirming the role of skin 
resident CD8+ T cells in immune surveillance in humans (Zhu et al. 2007; Zhu et 
al. 2013). Final evidence of the protective role of skin resident memory T cells 
comes from leukemic cutaneous T cell lymphoma patients who remain free from 
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skin infections despite being treated with alemtuzumab, a CD52-specific 
monoclonal antibody that depletes circulating T cells (Clark et al. 2012). 
Resident T cells can therefore protect the skin in the absence of T cell 
recruitment from the blood. 
 Homing and tissue retention of skin T cells 1.5.4
Whilst conventional T cells are abundant in adult human skin, they are virtually 
absent in the skin of neonates (Watanabe et al. 2015). T cells enter the skin 
during inflammation, where they eventually disappear or convert to a memory 
phenotype (Mackay et al. 2013). This occurs not only at the site of antigenic 
challenge, as T cells that have been activated in the draining lymph nodes also 
access and colonize uninvolved skin. Upon disease resolution, T cell trafficking 
to and from the skin ceases. The majority of T cells resident in healthy skin are 
therefore non-migratory, with only a fraction of cells immigrating into and 
emigrating from the skin during steady state conditions (Clark et al. 2012; Jiang 
et al. 2012). Interestingly, CD8+ T cells are generally found to be static and 
resident in the epidermis, whilst CD4+ T cells (and CD4+ FoxP3+ Tregs in 
particular) are more likely to localize to the dermis and traffic between the skin 
and circulation (Yawalkar et al. 2000; Tomura et al. 2010; Gebhardt et al. 2011; 
Watanabe et al. 2015). 
T cells are able to home to different anatomical locations by bearing a variety of 
receptors that recognize various vascular addressins. For cells that home to the 
lymph nodes, this includes CD62L and CCR7. Conversely CLA, CCR4, CCR8 
and CCR10 are thought to enable T cell homing into the skin. Expression of 
these receptors is thought to be imprinted during activation and can be 
influenced by the microenvironment of the local draining lymph node through 
local dendritic and stromal cells (Masopust and Schenkel 2013). T cell migration 
into healthy skin is low but enhanced during inflammation, thanks to 
upregulation of adhesion molecules such as VCAM-1 on the vascular 
endothelium and local expression of chemokines, such as CCL17 and CCL22 
(both binding CCR4) and CCL27 (binding CCR10) (Mackay et al. 1992; McCully 
and Moser 2011). 
CD69 and CD103 have been identified as markers for T cells resident in the 
skin and other peripheral tissues (Sathaliyawala et al. 2013). CD103 allows 
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binding to E-cadherin on epithelial cells and can be induced in skin infiltrating T 
cells through exposure with TGFβ (Mackay et al. 2013). The ligand for CD69 
has not been identified, but CD69 is thought to mediate tissue retention by 
preventing surface expression of sphingosine 1-phosphate (S1P) receptor, 
which signals migration towards S1P in the blood (Lamana et al. 2011). Local 
cells, including keratinocytes and Langerhans cells, provide IL-15 to support 
TRM development and survival (Mackay et al. 2013). 
 Regulatory FoxP3+ Tregs in the skin 1.5.5
FoxP3+ CD4+ Tregs limit immune responses against self and foreign antigen. 
The majority Tregs in human blood express the skin homing receptors CLA and 
CCR4 and mice in which the Treg compartment is selectively deficient in either 
receptor develop severe autoimmune skin inflammation, testifying of the 
important role Tregs play in cutaneous immune regulation (Hirahara et al. 2006; 
Sather et al. 2007; Dudda et al. 2008). Indeed, Tregs are more abundant in the 
skin compared to the blood in both mice and humans and are recruited and 
proliferate further in the tissue during inflammation caused by antigenic 
challenge, autoimmune reactions or UVB-exposure (Vukmanovic-Stejic et al. 
2013; Sanchez Rodriguez et al. 2014; Yamazaki et al. 2014). Interestingly, skin 
derived Tregs are highly mobile and show increased trafficking into the draining 
lymph nodes during inflammation (Tomura et al. 2010).  FoxP3 Tregs are 
therefore abundant in healthy and diseased skin and crucial in preventing local 
immunopathology (Dudda et al. 2008). 
 Innate immune cells in the skin 1.5.6
Other cells present in the skin might modulate local immune responses. A 
variety of dendritic cell types occupy the healthy skin, including Langerhans 
cells and various dermal dendritic cells. These cells may have both, 
proinflammatory and immunomodulatory functions depending on the context in 
which they encounter antigen and may promote Treg formation or T cell 
activation (Seneschal et al. 2012; Bennett and Chakraverty 2012). Stromal cells 
such as keratinocytes or fibroblasts may also contribute to local immune 
responses (Barker et al. 1991; Rappl et al. 2001).  
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 Melanoma  1.6
 Melanoma: biology and epidemiology 1.6.1
 Melanoma development 1.6.1.1
Healthy melanocytes normally reside in the basal layer of the epidermis with 
their main function being protection against UV radiation by increasing 
production of the melanin pigments. In healthy tissue, melanocytes are evenly 
distributed within the basal layer of the epidermis. Melanocytes may undergo 
mutations in genes regulating growth and cell adhesion, leading them to escape 
the control from surrounding keratinocytes. Subsequent proliferation can lead to 
a benign naevus (i.e. a common mole), and some melanocytes become 
morphologically atypical. When uncontrolled proliferation continues, radial 
growth phase and vertical growth phase melanoma might occur. Dissemination 
into other organs is the hallmark of the metastatic stage. 
Melanoma incidence is associated with specific risk groups correlating with 
genetic background (i.e. in fair skinned populations, family history), behaviour 
(i.e. sun exposure and sunbed use), immunosuppression (e.g. treatment with 
methotrexate) and age and has been increasing worldwide more than any other 
cancer (Cancer Research UK 2010). Melanoma is especially prevalent among 
the elderly, who also suffer the greatest morbidity and mortality from this 
condition. However, this is thought to be at least in part due to diagnosis and 
treatment being delayed in the older age groups (Tsai et al. 2010). 
Melanoma disease can be divided into four stages, with stage I and II patients 
having localized tumour, whilst stage III and IV patients display metastases in 
the draining lymph nodes and beyond (see Table 1-2). The fatal outcome of 
melanoma is generally caused by metastases in distant organs, such as the 
brain or the lung. 
 
 
 
 
 54 
Stage I II III IV 
Disease Local to 
epidermis 
Invasion of 
dermis 
Lymph node 
metastases 
present 
Metastases in 
peripheral 
tissues 
5-year  
Survival 
88-95% 43-79% 20-73% 5-22% 
Table 1-2: Staging in cutaneous melanoma 
Adapted from Cancer Research UK, 2012 
 
Several features are independently linked with disease outcome. These include 
tumour stage as mentioned above, as well as sentinel lymph node status, 
Breslow thickness, melanoma mitotic rate, presence of ulceration and the 
location of the primary tumour (Teixeira et al. 2013). Positive prognostic factors 
include presence of infiltrating lymphocytes (van Houdt et al. 2008). Poor 
prognosis has been associated with lack of MHC class I expression on tumour 
cells and presence of infiltrating neutrophils and plasmatycoid dendritic cells 
(Jensen et al. 2012; van Houdt et al. 2009) 
 Melanoma immunogenicity 1.6.2
Melanoma is a highly immunogenic tumour and direct and indirect evidence 
exist highlighting the importance of naturally occurring immune responses 
against the malignant cells. Despite the pessimistic outlook of advanced 
disease, spontaneous complete and partial tumour regressions do occur. This is 
often associated with vitiligo, where autoimmune destruction of healthy 
melanocytes is indicative of active tumour-specific immune responses 
(Quaglino et al. 2010). Melanoma can develop during immunosuppression, 
which has been reported in rheumatoid arthritis patients receiving methotrexate 
(Buchbinder et al. 2008) and in transplant patients receiving organs donated by 
melanoma survivors thought to be disease free (Laing et al. 2006). Further 
evidence for the importance of immune responses in controlling melanoma 
disease includes the widely accepted correlation between the presence of 
tumour infiltrating lymphocytes and improved disease outcome, the detectable 
presence of tumour specific T cells and antibodies, and finally the vast array of 
active and passive immune evasion strategies displayed by the cancer, 
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including downregulation of genes coding for immunodominant proteins in the 
tumour (Aisner et al. 2005; McGovern 1975; Kaur et al. 2008; Jäger et al. 1996). 
Although being derived from self, tumour cells often display antigens that are 
either distinct or overexpressed compared to the surrounding tissue and can 
therefore be targeted by the adaptive immune system. In many melanoma 
patients, a number of these tumour associated antigens (TAA) have been 
identified. These include proteins such as Melan-A (also known as MART-1), 
tyrosinase and gp100 which are also expressed in healthy melanocytes (Jäger 
et al. 1996). A different class of antigens overexpressed in melanoma cells are 
proteins which are not commonly found in healthy tissue but restricted to 
immunoprivileged germline cells. These antigens include NY-ESO-1, normally 
found in the testis (Velazquez et al. 2007). Melanoma cells may also acquire 
unique cancer antigens through genetic mutation (Robbins et al. 2013). 
The discovery of immunodominant TAA epitopes has highly facilitated the 
identification and characterization of melanoma-specific T cells via the 
generation of fluorochrome-conjugated peptide containing MHC multimers 
(Maeurer et al. 2002). Whist the underlying genetic mechanisms of melanoma 
progression are different among patients, the same is true for anti-melanoma 
immune responses, which translates into a vast array of contradicting 
publications on T cell phenotypes in melanoma patients. It is generally agreed 
upon that detectable melanoma specific T cell populations are more likely to 
arise in patients with advanced disease only, as the disruptive nature of the 
cancer in the later disease stages is required to break tolerance and trigger an 
adaptive immune response (Dunbar et al. 2000; van Oijen et al. 2004).  
It should be noted that Melan-A specific CD8+ T cells, which are probably the 
most widely studied tumour specific T cells, can also be found at low but 
detectable frequencies of around 0.1-0.01% in healthy individuals where they 
are generally found to have a naïve-like (CD45RA+CD27+) phenotype (Pittet et 
al. 1999). Melanoma-specific CD4+ T cells identified via fluorochrome 
conjugated MHC class II multimers have also been described but are not 
commonly used due to their low avidity nature that poses technical difficulties in 
using them in experiments reliably (Bioley et al. 2006).  
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 Melanoma Immune evasion 1.6.3
Like any tumour, melanomas are the result of accumulated mutations in 
autologous cells leading to uncontrolled growth and proliferation, which do not 
only entail withdrawal of intra- and intercellular regulation mechanisms but also 
escape from immune regulation. Much research has been devoted to identifying 
tumour escape mechanisms such as secretion of immunosuppressive cytokines 
(e.g. IL-10 and TGFβ), increased frequencies of suppressive cells (e.g. Tregs, 
M2 macrophages or myeloid suppressor cells) upregulation of inhibitory 
receptors (e.g. PDL-1) or downregulation of HLA, target antigen, integrins and 
costimulatory molecule expression (Zitvogel, Tesniere, and Kroemer 2006).  
Tregs are also known to play an important role in tumour immune responses. 
CD4+ Tregs are increased in the circulation of some melanoma patients 
compared to healthy controls and enriched in primary melanoma and 
melanoma-infiltrated lymph nodes and metastases (Ascierto et al. 2010; Viguier 
et al. 2004). Tregs may contribute to a lack in T cell functionality in the tumour 
microenvironment (Read et al. 2000; Jacobs et al. 2012). Depletion of Tregs 
during treatment of melanoma has shown better outcome in mouse models as 
well as human trials (Sutmuller et al. 2001; Mahnke et al. 2007). 
 The melanoma microenvironment 1.6.4
The melanoma microenvironment is both, inflammatory and immunuppressive. 
Inflammatory mediators such as CCL-2, CCL-3, TNFα, IL-1β, IL-4 and IL-6 were 
shown to be increased in the tumour environment and can support tumour 
development by providing growth signals and angiogenesis (Umansky and 
Sevko 2012). This inflammatory environment leads to the accumulation of 
suppressive cell types such as myeloid derived suppressor cells, CD4+ FoxP3 
Tregs and M2 macrophages (Meyer et al. 2011). These, or the melanoma cells, 
secrete immunosuppressive factors such as VEGF, IL-10 and TGFβ leading to 
local immunosuppression. Dendritic cells in the tumour environment may have 
also regulatory/tolerogenic phenotypes or may be depleted locally (Molenkamp 
et al. 2005).  
Cytotoxic T cells attracted to the tumour may not only be impaired by these 
local inhibitory factors but may also be simply denied access to the tumour 
microenvironment through lack of adhesion molecules, therefore accumulating 
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in the areas surrounding the tumour (Mempel and Bauer 2009). However, 
ectopic lymphoid structures may also form in melanoma lesions, attracting and 
potentially activating effector T cells on site (Messina et al. 2012; van Baren and 
Coulie 2013; Ladányi et al. 2014). 
 T cell senescence and exhaustion in melanoma 1.6.5
Since melanoma is highly immunogenic this malignancy, like persistent viral 
infections, may cause decreased T cell proliferation and functionality associated 
with chronic antigen exposure. This phenomenon is debated, as melanoma-
specific T cells were found to be dysfunctional in some studies but not others 
(Mortarini et al. 2003). Some evidence further suggests that within the same 
person different clonotypes of melanoma specific CD8+ T cells may be 
differentiated to different degrees. Similarly, melanoma specific T cells may 
adopt different phenotypic and functional properties in the melanoma lesion 
compared to the blood (Zippelius et al. 2004). 
Evidence for T cell senescence in melanoma patients includes published data 
by two different groups who found that tyrosinase but not Melan-A specific CD8+ 
T cells had a TEMRA-like phenotype and low responsiveness to peptide pulsed 
target cells or PMA/ionomycin stimulation in vitro (Lee et al. 1999; Maczek et al. 
2005). Increased frequencies of CD8+ TEMRA-like cells bearing NK cell markers 
have also been reported in melanoma patients compared to healthy age 
matched controls (Casado et al. 2005).  
Evidence for inhibitory receptor upregulation and immune exhaustion in the 
context of melanoma has been shown in both mice and humans. Tumour 
infiltrating lymphocytes expressed high levels of PD-1 and TIM-3 and failed to 
proliferate and produce cytokines upon stimulation (Sakuishi et al. 2010). 
Similarly, melanoma specific NY-ESO-1 (but not Melan-A) specific cells 
coexpressed TIM-3 and PD-1 in humans and blocking both receptors showed 
increased function (Fourcade et al. 2010). In a different study, dual blockade of 
PD-1 and CLTA-4 was shown to increase melanoma rejection in murine models 
(Curran et al. 2010). 
Encouraging clinical trials involving Ipilimumab, an anti-CTLA-4 blocking 
antibody, in advanced stage patients (Hodi et al. 2010; Cranmer and Hersh 
2007; Gyorki et al. 2013) and anti-PD-1 trials (Brahmer et al. 2012; Brahmer et 
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al. 2010; Mkrtichyan et al. 2011) indicate the role of exhaustion-associated 
receptors in melanoma. However, whilst some patients do respond to anti-PD-1 
and anti-CTLA-4 treatments, the effect is not always permanent and mortalities 
remain high, as highlighted in the survival curve of patients treated with anti-
CTLA-4 shown in Fig. 1-2 (Prieto et al. 2012; Robert et al. 2011).  
The need for improved immunotherapies for advanced stage patients therefore 
remains as important as ever and whilst most focus is concentrated on PD-1, 
CTLA-4 and other exhaustion-associated inhibitory receptor blockades to 
improve immune function, melanoma patients may also benefit from alternative 
interventions (Fourcade et al. 2010). Inhibition of p38 MAP kinase signalling for 
example has been shown to rescue proliferation and telomerase activity in 
highly differentiated and senescent T cells which are known to accumulate with 
age (Koch et al. 2008; Di Mitri et al. 2011; Akbar and Henson 2011). Such a 
treatment might therefore be especially beneficial to old patients, who 
additionally suffer from age-related immune defects but are generally 
underrepresented in melanoma related investigations and trials (Castle 2000; 
Hegde et al. 2010).  
Another consideration in studying melanoma related immune defects and 
treatment efficacy is that there seems to be an imbalance between the function 
and phenotypes of melanoma associated T cells in the circulation and those 
infiltrating the tumour (Appay et al. 2006). When studying T cells in melanoma 
patients, one must therefore also consider T cells resident in the skin, as this is 
the site of tumour induction. 
 
Fig. 1-2: Survival in patients with metastatic melanoma treated with dacarbazine alone or 
in conjunction with the anti-CTLA-4 blocking antibody Ipilimumab.  
Adapted from (Robert et al. 2011) 
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 Aims 1.7
The aim of this project was to characterize and define global and melanoma-
specific T cell differentiation in patients with melanoma with the ultimate goal to 
identify means to reverse potential defects and to improve current melanoma 
therapies. 
The objectives were as follows: 
• Assess global and melanoma specific T cell differentiation in melanoma 
patients as compared to healthy controls 
• Place particular emphasis on the older age groups which are the most 
affected by the disease 
• Investigate T cell differentiation in uninvolved skin and sites of tumour 
invasion in the melanoma patients and compare it when possible to 
healthy controls 
• Investigate the potential benefits of targeting receptors and intracellular 
pathways associated with senescence and exhaustion in T cells derived 
from melanoma patients   
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2 Material & Methods 
 Recruitment, Ethics and Exclusion Criteria 2.1
 Healthy donors 2.1.1
Blood and blister samples were collected from consented healthy individuals 
from within UCL and the local community in accordance with the ethical 
committee of the Royal Free Hospital and University College London. Skin from 
healthy individuals was obtained from previously consented donors undergoing 
plastic surgery at the Guy’s and St. Thomas’ or Royal Free hospitals and 
approved by the Institutional Review Board of Guy’s Hospital or the ethical 
committee of the Royal Free Hospital and University College London 
respectively. Skin samples from healthy donors were typically derived from 
breast or abdomen of individuals that underwent cosmetic or risk reducing (due 
to genetic predisposition to breast cancer) surgery. Individuals suffering from 
acute or chronic illness, with a history of cancer or on medication were excluded 
from this study. 
 Melanoma Patients 2.1.2
Consented cutaneous melanoma patients from Guys’ and St Thomas Hospital 
provided fresh blood and skin samples. Blood was obtained from patients 
during their follow up visits. Skin was obtained in the form of several punch 
biopsies taken from local wide excisions extracted after positive melanoma 
diagnosis. Lymph node and primary tumour samples were obtained when there 
was excess tissue not needed for histological grading. Patients suffering from 
co-morbidities or on medication (including drugs for melanoma treatment) were 
excluded from this study. Frozen primary melanoma specimens were obtained 
from Professor Jim Kruger at the Rockefeller University, New York. 
 Sample preparation 2.2
 PBMC isolation 2.2.1
Whole blood from melanoma patients and healthy controls was collected in 9ml 
EDTA or heparin tubes. Blood was mixed with an equal volume of Hanks 
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Balanced Salt Solution (HBSS) (Sigma-Aldrich, Gillingham, UK) and layered 
carefully onto 15ml Ficoll-Paque PLUS (GE Healthcare, Little Chalfont, UK) in a 
50ml Falcon tube to a total maximum volume of 50ml. The tubes were 
centrifuged at 2000 rpm for 20 minutes with the lowest brake setting. The 
resulting peripheral blood mononuclear cell (PBMC) layer between diluted 
serum and Ficoll was aspirated manually using a pasteurette and transferred 
into a new 50ml tube, in which it was washed twice in HBSS for 10 minutes, first 
at 1800rpm and subsequently at 1200rpm. Finally, the cells were resuspended 
in complete medium (RPMI 1640 complemented with 10% fetal bovine serum 
(FBS), 1% penicillin/streptomycin and 1% L-Glutamine; all purchased from 
Sigma-Aldrich) and either frozen, kept in the fridge overnight or used 
immediately for further experiments. 
 Isolation of cells from whole skin specimen 2.2.2
 Enzymatic extraction of skin lymphocytes 2.2.2.1
T cell extraction from the skin was performed using an enzymatic digestion 
protocol adapted from a method described by Haniffa and colleagues (Haniffa 
et al. 2009): Skin biopsies underwent removal of subcutaneous fat, followed by 
several washes in phosphate buffered saline (PBS). Skin was then cut into ~1-
2mm2 pieces in order to facilitate digestion. Pieces of skin were incubated in a 
48-well plate overnight in complete medium with 0.8mg/ml of Collagenase IV 
(Life Technologies, Paisley, UK) with varying percentages of FBS (see results 
section). The following day, skin and supernatant were transferred to a 100µm 
cell strainer. Mechanical action with a syringe plunger and washes with PBS 
allowed transfer of cells through the mesh. The flow through was centrifuged 
and cells were resuspended in complete medium.  Further experiments were 
performed on the same day.  
 Devices for semi-automatic mechanical skin dissociation 2.2.2.2
Two benchtop devices for mechanical disaggregation of skin were tested. The 
Medimachine (BD Biosciences, Oxford, UK) and GentleMACS (Miltenyi Biotec, 
Bisley, UK) both rely on disposable sterile plastic tubes, which contain either a 
stainless steel or plastic blades respectively.  Tissue sample and PBS are 
added into the tubes and inserted into the machines that power the rotation of 
the blades at high speed. This process only lasts minutes but was found to be 
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inadequate for full skin disaggregation for obtaining tissue resident cells into 
suspension (see results section 4.3.1.1). 
 Isolation of cells from suction blisters 2.2.3
Applying negative pressure on a section of live skin over time leads to the 
physical separation of the epidermis from the dermis, creating a fluid-filled 
blister (Kiistala 1968). Immune cells accumulate in this fluid over time, making 
suction blisters an ideal tool to generate viable skin derived cells for research 
purposes. During this study, suction blisters were induced as previously 
described (See Fig. 2-1)(Akbar et al. 2013): A suction chamber with a round 
opening of 12.5mm in diameter (Medical Engineering, Royal Free Hospital, UK) 
was applied to the normal skin on the forearm of healthy volunteers, and kept 
under constant negative pressure of 25-40 kPa. Negative pressure in the 
chamber was provided from a clinical suction pump (VP25, Eschmann, Lancing, 
UK) connected via sterile disposable tubing and was maintained until a fully 
formed blister had been raised in the induration area of the chamber. This took 
typically 2-4 hours. The blister was then protected overnight through the 
assembly of a rigid adhesive dressing composed of a universal tube lid (Sterilin, 
Fisher Scientific UK Ltd, Loughborough, UK), Comfeel plus ulcer dressing 
(Coloplast, Peterborough, UK), Micropore tape (3M healthcare, Loughborough, 
UK) and Tubigrip bandaging (Seton Healthcare Group plc, Oldham, UK). The 
following day, blister fluid was aspirated using a 2ml syringe, collected in a 
1.5ml Eppendorf tube and centrifuged at 650g (3000rpm) for 4 minutes. Blister 
fluid was removed gently and the cell pellet resuspended in 500µl complete 
medium for cell counting. 
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Fig. 2-1: Outline of the method for suction blister induction and collection of blister fluid 
(1) A blister was induced by negative pressure through a suction chamber placed onto healthy 
skin. 
(2) Representation of a fully formed suction blister 
(3) Protective dressing was applied to the area of the suction blister 
(4) The following day, blister fluid was aspirated using a syringe 
Pictures were adapted from (Akbar et al. 2013) 
 
(1)$Raising$of$suc/on$blister$$$ (2)$A$suc/on$blister$$$
(3)$The$blister$is$
dressed$for$protec/on$
from$physical$damage$
(4)$Blister$is$aspirated$
using$a$syringe$
2"4$h$
24$h$
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 Freezing and thawing of cells 2.2.4
When experiments could not be performed on the same or following day after 
extraction, cells were carefully resuspended in FBS with 10% DMSO at a 
concentration of 4-12 million cells/ml and aliquoted in 1ml volumes into cryovials 
(Nunc, Cramlington, UK). They were immediately placed into a “Mr Frosty” 
container (Nalgene/Thermo Fisher, Rochester, NY, USA) for gradual freezing at 
-80°C before being transferred into liquid nitrogen the following day for long-
term storage. In order to recover frozen PBMCs, the cryovials were incubated at 
37°C until most of the sample was thawed. Contents were swiftly transferred 
into pre-warmed complete medium and centrifuged, then resuspended in 
complete medium and finally counted using a haemocytometer before being 
used for further experiments. Freezing or storage in the fridge overnight of the 
PBMCs is routinely used in our lab and has not been found to significantly 
impair T cell cytokine production. 
 Viable cell counts 2.2.5
Cells were resuspended in a known volume of which 10µl were transferred to 
an equal volume of 0.4% trypan blue (Sigma-Aldrich). The cell:trypan blue 
suspension was applied to a Neubauer chamber (Weber Scientific International, 
Sussex, UK) mounted with a coverslip. Cells in the central chamber of both 
sides were counted, not including the dead cells that stained blue. The average 
of both counts were multiplied by the dilution factor of 2 and by 10 000, resulting 
in the estimated amount of cells per ml. If the counts of the two chambers 
differed considerably, this process was repeated to ensure an accurate 
enumeration. 
 Isolation of CD8+ T cell subsets from PBMCs 2.2.6
In order to obtain purified CD8+ T cell subset populations, CD8+ T cells were 
isolated from total PBMCs using magnetic bead isolation, followed by FACS-
based cells sorting: 
 Magnetic cell isolation 2.2.6.1
Magnetic cell isolation was performed using MACS columns (Miltenyi Biotec). 
The technique involves cell populations binding antibody-coated super-
paramagnetic beads that are biodegradable and do not influence cell function. 
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Cells are applied to a separation column placed into a magnetic field in which 
labelled cells are retained, whilst unlabelled cells pass through. Labelled cells 
can be collected after removal of the column from the magnetic field. CD8+ T 
cells were isolated by positive selection using CD8 microbeads, following the 
manufacturer’s instructions: PBMCs were washed in cold MACS buffer (PBS, 
0.5% Bovine Serum Albumin [BSA], 2mM EDTA) at 1200 rpm and labelled with 
anti-CD8 microbeads. The cells were incubated for 15 minutes at 4°C, before 
being washed again and resuspended in MACS buffer. The cells were then 
transferred to a pre-rinsed MACS column inserted into a magnetic holder. 
Columns were rinsed three times with cold MACS buffer in order to remove the 
CD8 negative fraction. Then, the column was removed from the magnetic field 
and MACS buffer was applied in order to remove the CD8 positive cells. 
 FACS based sorting 2.2.6.2
Some experiments required further sorting of CD27/CD45RA subsets. 
Magnetically purified CD8+ T cells were stained with antibodies against CD8, 
CD27 and CD45RA for 30 minutes at 4°C in PBS with 1%BSA. Cells were 
subsequently washed in MACS buffer to avoid cell clumping, resuspended in 
MACS buffer and passed through a 35 µm nylon mesh into a new FACS tube 
(BD Biosciences). Cells were sorted into the four CD27/CD45RA subsets using 
a FACS Aria device (BD Biosciences) and collected in sterile tubes containing 
50% FBS in RPMI. As soon as possible, cells were then centrifuged and 
resuspended at 2x106 cells/ml in complete medium. 
 Purification of immune cells from digested skin 2.2.7
Purification using FACS sorting of immune cells from the skin was necessary for 
certain functional assays. For this purpose, skin cells extracted through the 
collagenase digestion method were stained with live/dead UV, CD3-FITC and a 
cocktail of APC-conjugated antibodies against CD11c, CD209, HLA-DR and 
CD34 for 30 minutes at 4°C, washed and resuspended in MACS buffer and 
filtered through a 35 µm nylon mesh. Samples were sorted into FITC positive T 
cells and APC positive antigen presenting cells that were used in a 1:1 ratio in 
subsequent functional assays. 
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 Functional assays 2.3
 Cell culture conditions 2.3.1
Cells were cultured in complete medium at 37°C in a humidified 5% CO2 
incubator unless otherwise stated.  
 Screening for CMV, EBV and VZV responders 2.3.2
Viral lysate stimulation as mean to identify carriers of the persistent virus CMV 
is routinely used in our laboratory as it has been found to reliably identify 
seropositive individuals (Fletcher et al. 2005). Fresh or thawed cells were 
incubated overnight in complete medium with CMV lysate (1:10). The CMV 
lysate was prepared in house as described by Fletcher and colleagues (Fletcher 
et al. 2005): Human embryonic lung fibroblasts were infected with Towne strain 
CMV for 5 days, after which cells were lysed by repeated freeze-thawing. For 
each batch prepared, titration was performed to determine the optimal 
concentration for cytokine production in PBMCs of CMV positive donors. 
Screening for Epstein-Barr Virus (EBV; 1:200) and Varicella-Zoster virus (VZV; 
1:25) was performed using commercially available viral antigen (both from 
Virusys, Taneytown, USA). The superantigen Staphylococcal Enterotoxin B 
(SEB; 1ng/ml; Sigma-Aldrich) was used as a positive control and no stimulant 
was added as a negative control in separate wells.  
Stimulated cells were incubated overnight at 37°C. Brefeldin A (5µg/ml, Sigma-
Aldrich) was added 2 hours after the start of incubation. Brefeldin A is a fungal 
metabolite that inhibits transport of vesicles from the Golgi apparatus to the 
endoplasmic reticulum, thereby inhibiting secretion and leading to intracellular 
accumulation of cytokines, facilitating their detection using flow cytometry. 
The following day, cells were harvested and IL-2 and IFNγ levels were 
measured via intracellular flow cytometry as detailed below. Participants were 
considered to be CMV, EBV or VZV positive if above background production of 
cytokines was at least 0.01% of the total CD4+ T cells. 
 Polyclonal T cell activation 2.3.3
Certain proteins of interest, such as markers of cytotoxicity, are only 
upregulated upon T cell activation. In order to detect their presence, or measure 
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proliferation, cells were stimulated polyclonally via incubation with immobilized 
anti-CD3 antibodies (0.5 µg/ml, clone: OKT3). If sorted cell subsets were 
stimulated with anti-CD3, 40Gy irradiated autologous APCs were added in 
equal numbers as a source of costimulation. 
 IL-15 stimulation assay 2.3.4
FACS sorted T cell subsets were incubated with 10ng/ml of rhIL-15 (R&D 
systems, Abingdon, UK) for up to 14 days. The complete medium used included 
HyClone (GE Healthcare) instead of RPMI. Half of the medium was replaced 
with fresh medium complemented with IL-15 every 3 to 4 days. Surface marker 
expression was measured by flow cytometry before incubation and at day 14. 
 P38 signalling blockade 2.3.5
Cells were incubated for one hour prior to stimulation with 500nM of the p38 
inhibitor BIRB 796 (Selleck chemicals) or 0.1% DMSO as control. For cytokine 
detection following p38 blockade, cells were stimulated overnight in the 
presence of brefeldin A, added after 2 hours of stimulation, and harvested the 
following day for intracellular flow cytometry. For measurement of proliferation, 
cells were harvested 3 days after stimulation and stained intracellularly for Ki67. 
 PD-1 ligand blockade 2.3.6
In order to block PD-1 signalling, cells were incubated with functional grade 
purified anti-PDL-1 and anti-PDL-2 antibodies (specified in Table 2-1) or the 
isotype control antibody, for two hours before being stimulated with 0.05µg/ml 
immobilized anti-CD3. Cells were stimulated for 3 days before being harvested 
and analysed for intracellular granzyme B, perforin and Ki67 levels. 
Target Clone isotype Stock Working 
concentration 
Manufacturer 
PDL-1 MIH1 Mouse IgG1, kappa 1mg/ml 10µg/ml eBioscience 
PDL-2 MIH18 Mouse IgG1, kappa 1mg/ml 10µg/ml eBioscience 
irrelevant P3.6.2.8.1 Mouse IgG1, kappa 1mg/ml 20µg/ml eBioscience 
 Table 2-1: Antibodies and isotype controls used for PD-1 signalling blockade 
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 Measurement of cytotoxic degranulation via detection of surface 2.3.7
CD107a 
Pre-formed cytotoxic granules can be found in the cytoplasm of cytotoxic T 
cells. The granules are surrounded by a lipid bilayer and contain the cytotoxic 
effector molecules as well as lysosomal membrane proteins such CD107a 
(LAMP-1). Upon stimulation, degranulation occurs, releasing not only effector 
molecules but also exposing CD107a to the cell surface, thus making 
extracellular CD107a detection an ideal method for detection of cytotoxic 
degranulation. 
CD107a based detection of degranulation required pre-incubation of PBMCs 
with the CD107a antibody (1:10, CD107a-APC, H4A3, BD Biosciences) before 
adding the cells to anti-CD3-coated plates. After 2 hours at 37°C, brefeldin A 
was added to allow simultaneous cytokine detection and monensin was added 
to prevent anti-CD107a antibody degradation. Cells were further incubated 
overnight and harvested the following day to be stained for flow cytometry. 
Anti-CD107a antibody uptake was measured in all samples and flow cytometry 
gates were set according to unstimulated cells, allowing quantification and 
characterization of cells having undergone degranulation. 
 Perforin and granzyme expression in response to cytokine 2.3.8
exposure 
PBMCs or cells derived from collagenase digested skin were incubated for four 
days in the presence of no stimulant, 10ng/ml TNFα (PeproTech, London, UK), 
5ng/ml IL-2 (PeproTech, London, UK), 10ng/ml IL-15 (R&D systems) or anti-
CD3/CD28 coated beads (Dynabeads; Life Technologies). After this period, 
cells were harvested and stained for granzyme B, perforin and the appropriate 
extracellular antibodies as described below. 
 Flow Cytometry 2.4
Flow cytometry allows measurement of various properties of individual cells in 
suspension as they pass a laser. Size, granularity and fluorescence of the cells 
can be measured through various filters and detectors. Cells can be stained 
extracellularly and intracellularly with fluorescent dyes or fluorochrome-
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conjugated antibodies, allowing measurements of various phenotypic and 
functional properties of cell populations. 
 Surface staining  2.4.1
Cells were centrifuged and washed in PBS. Fluorochrome-conjugated 
extracellular antibodies were added together with a UV live/dead stain 
(Invitrogen, Life technologies) at the appropriate concentration (see Table 2-2) 
and allowed to bind for 15 minutes at room temperature or 30 minutes at 4 ̊C. 
After staining, cells were resuspended in PBSA (PBS, 1% bovine serum 
albumin, 0.01% sodium azide), spun down at 1800 rpm and fixed in 2% 
paraformaldehyde, unless further intracellular staining was needed.  
If a biotin-labelled antibody was used, cells were incubated with streptavidin-
Cy3 for 15 minutes at room temperature and washed again in PBSA before 
fixation. 
 Cytoplasmic staining 2.4.2
For detection of cytoplasmic proteins such as cytokines, perforin and granzyme 
B, cells first underwent surface staining as described above. However, before 
fixation, cells were treated using Fix & Perm Cell Permeabilization Kit reagents 
(An Der Grub, Buckingham, UK): cells were initially incubated for 20 minutes at 
room temperature with the fixation reagent A, followed by a wash with PBSA 
and 20 minutes incubation with the permeabilization reagent B together with the 
intracellular antibodies. After that, cells were washed in PBSA and resuspended 
in 2% paraformaldehyde until acquisition. 
 Nuclear staining 2.4.3
Nuclear antigens such as ki67 and FoxP3 were detected using the appropriate 
antibodies (listed in Table 2-2) using the intranulcear Miltenyi FoxP3 Staining 
Buffer Set according to the manufactures instructions (Miltenyi): First, cells 
underwent surface staining as described above. Then, cells were resuspended 
in the fix/perm solution (reagents A and B, diluted 1 to 3) for 30 minutes at 4°C, 
washed in cold perm buffer (stock diluted 1:10 in distilled water) twice, before 
being resuspended with the antibodies specific to Ki67 or FoxP3 for 30 minutes 
at 4°C.  Finally, cells were washed in the perm buffer and resuspended in 2% 
paraformaldehyde. 
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 Phosphoflow staining 2.4.4
Cells were stained extracellularly at room temperature as described above, 
washed in 1%FBS in PBS and fixed with pre-warmed cytofix buffer (BD 
Biosciences) for 30 minutes at 37°C. Cells were centrifuged and permeabilized 
with ice-cold Perm Buffer III (BD Biosciences) for 30 minutes on ice. Cells were 
subsequently washed twice with BD stain buffer and resuspended with the anti-
phophorypated p38 (pp38) antibody and incubated for 30 minutes at room 
temperature. Finally, cells were washed in stain buffer and resuspended in stain 
buffer in order to be acquired on the flow cytometer.  
 Target Clone Fluorochrome Working 
Dilution 
Manu-
facturer 
E
xt
ra
ce
llu
la
r t
ar
ge
ts
 
CD4  RPA-T4 APC-H7,  
BrilliantViolet421 
1:20 BD 
SK3 PE-Cy7 1:10 BD 
CD8  SK1 PerCP  1:5 BD 
RPA-T8 Biotin 1:20 BD 
CD27  0323 APC  1:10 eBioscience 
M-T271 FITC ,PE, V500 1:10 BD 
L128 AlexaFluor786 1:20 BD 
CD25  M-A251 PE-Cy7 1:20 BD 
CD28  CD28.2 PE  BD 
CD45RA HI100 PE-Cy7 1:20 BD 
MEM-56 APC 1:10 Invitrogen 
HI100 BV605 1:50 BD 
CD127  HIL-7R-M21 AlexaFluor647 1:10 BD 
CD69 FN50 FITC 1:10 BD 
PD-1  EH12.2H7 PE-Cy7 1:20 Bioloegend 
CD3 UCHT1 ECD 1:50 Beckman 
Coulter 
SK7 FITC 1:10 FITC 
KLRG1 13F12 PE 1:100 (A kind gift 
from H.P. 
Pircher). 
C
yt
op
la
sm
ic
 
ta
rg
et
s 
IL-2  MQ1-17H12 FITC 1:10 BD 
IFNγ  B27 V450 1:100 BD 
TNFα MAb11 APC 1:10 BD 
CTLA-4  BNI3 APC 1:10 BD 
Perforin  δG9 FITC 1:10 BD 
Granzyme B  GB11 AlexaFluor700 1:25 BD 
N
uc
le
ar
 
Ta
rg
et
s 
Ki67 MOPC-21 FITC or PE 1:10 BD 
FoxP3 PCH101 PE 1:10 BD 
P
ho
sp
ho
-
Ta
rg
et
s 
p-p38 
(pT180/pY182) 
36 PE 1:20 BD 
Table 2-2: Antibodies used for flow cytometry 
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 CFSE staining 2.4.5
5- (and 6-) carboxyfluorescein succinimidyl ester (CFSE) stably incorporates 
into cells by covalently binding to intracellular molecules. It is used as a 
florescent dye to stain whole cell preparations and monitor proliferation through 
halving of florescence intensity with each cell division. For this purpose, cells 
were washed in PBS to remove any free protein in the solution. Cells were then 
resuspended in warm PBS with 0.5µM CFSE (Molecular Probes, Paisley, UK) 
and incubated at 37°C for 10 minutes. FBS was added to a final concentration 
of 10% and cells were placed on ice to stop the reaction. Cells were washed 
twice in complete medium and stimulated for 4 days before being harvested, 
stained and analysed via flow cytometry. CFSE labelled cells were protected 
from light at all times in order to prevent photo bleaching. 
 Detection of Melanoma specific T cells 2.4.6
Only HLA-A2 positive donors were used for MHC multimer screens. They were 
identified by extracellular staining using an anti-HLA-A2.1 antibody (clone 
BB7.2, AbD Serotec, Kidlington, UK).  Initial experiments involved using an 
unconjugated Melan-A pentamer (loaded with ELAGIGILTV, Proimmune, 
Oxford, UK), but due to low rates of staining, the higher avidity dextramer 
system (Immudex, Sheffield, UK) was used. After optimisation, the following 
protocol was adopted: cells were stained in complete medium with peptide 
loaded MHC dextramers for 12 minutes at 37°C, followed by two washes with 
PBS with 10% FBS.  Subsequent extra- and intracellular stains were performed 
on ice. Dextramers were loaded with a peptide derived from Melan-A 
(ELAGIGILTV) or NY-ESO-1 (SLLMWITQV) conjugated with PE or APC 
respectively.  A PE or APC conjugated HLA-A2 Dextramer loaded with an 
irrelevant peptide was used as negative control.  
 Measuring telomere length using Flow-FISH 2.4.7
Flow cytometric detection of fluorescence in situ hybridization (flow-FISH) 
allows quantification of telomeric repeats using flow cytometry. The technique 
involves annealing fluorescently labeled nucleic acid probes with the 
complimentary telomeric DNA within fixed cells. The fluorescent signal can be 
measured via flow cytometry and signal strength correlates with telomere 
length. The technique can be used together with other flow cytometric staining 
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procedures in order to link telomere length with phenotypic and functional 
properties at a single cell level. 
2x106 PBMCs were stained in FACS tubes with antibodies conjugated to 
fluorochromes that can withstand the heat and chemical treatment used during 
this protocol (CD3- FITC, CD4- BV421, CD8-Biotin+Strept-Cy3, CD27-AF786 
and CD45RA-BV605), as well as a live/dead stain, using the extracellular FACS 
staining method described in section 2.4.1. 
Cells were then fixed in 1mM BS3 (Thermo Scientific) for 30 minutes at 4°C, 
which was then quenched using 50mM Tris pH7.2 for 20 minutes, before being 
washed in PBS. 
Fixed cells were washed using hybridization buffer (70% formamide, 20mM Tris 
HCl, 1%BSA, 150mM NaCl) and resuspended in exactly 300µl hybridization 
solution to be spit into three separate tubes. An equal volume of 1.5ug/ml Cy5 
conjugated telomeric (CCCTAA) peptide nucleic acid probe (PNA Bio, Daejon, 
South Korea) was added to each tube and cells were transferred to a 82°C 
water bath for 10 minutes before being snap cooled in an ice water bath. 
Samples were then left to rest in the dark at room temperature for 60 minutes, 
washed twice in post-hybridization buffer (70% Formamide, 10mM Tris HCl, 
0.25% Tween20, 1.5mM NaCl and 22.5% H2O) and finally washed twice in 
PBSA before being acquired on the flow cytometer. 
During acquisition, voltages for the Cy5 detection channel were adjusted to the 
fluorescence of QuantumCy5 Molecules of Equivalent Soluble Fluorochrome 
beads (Bangs Laboratories, Fishers, Indianapolis, USA): The standard curve 
which allows the conversion of fluorescence intensity of the samples into the 
telomere length in kilo base pairs (kbp) was previously generated by members 
of our group using telomere lengths from PBMC samples of varying telomere 
length that were measured by both Flow-FISH and telomeric restriction 
fragment analysis (Riddell et al. 2014). 
 Flow Cytometers 2.4.8
Samples were acquired on LSRII or Fortessa (both from BD Biosciences, San 
Jose, CA, USA) flow cytometry machines. Both machines were equipped with 
blue (488nm), red (640nm) and yellow/green (561nm) and violet (405nm) 
lasers. The LSRII had an additional ultraviolet (355nm) laser. Up to 11 different 
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fluorochromes were detected simultaneously. Data was acquired using Diva 
software (BD Biosciences). Control samples stained with a single colour were 
used for compensation to account for emission overlap between different 
fluorochromes. 
 Analysis of flow cytometry data 2.4.9
Flow cytometry data were analysed using FlowJo (Tree Star Inc., Asland, USA). 
Lymphocytes were identified by forward/side scatter profiles and dead cells 
staining positive for the live/dead stain marker were excluded. Fluorescence 
minus one (FMO) control samples, containing all but one colour, were used to 
define positive populations and confirm the quality of the stain. Antibodies were 
titrated for optimal concentrations before routine use. 
 Histology 2.5
 Sample preparation and cutting 2.5.1
5mm punch biopsies from young and old healthy donors were embedded with 
the epidermis facing up in OCT compound (VWR, Lutterworth, UK) on a cork 
disk and snap frozen in isopentane (Sigma-Aldrich) precooled in liquid nitrogen. 
Frozen skin samples were stored at -80°C until being cut into 6µm sections and 
mounted on poly-L-lysine coated glass slides (Sigma-Aldrich). Poly-L-lysine 
provides increased adhesion of biomaterial compared to uncoated glass. 
Cutting was performed using a Leica Biosystems CM1950 cryostat. Two sections 
were mounted on each slide and left overnight at room temperature overnight to 
air dry, before being fixed in acetone for 10 minutes, and then for 10 minutes in 
99% Ethanol. Sections were then air-dried for 10 minutes, wrapped in cling-film 
and stored at -80°C. 
Primary melanoma sections from old patients were prepared by Professor 
James Krueger’s laboratory at Rockefeller University. After cutting, these 
samples were dried but not fixed before being frozen. Instead, sections needed 
to be fixed in acetone for 5 minutes after thawing and before staining. 
 Immunohistochemistry 2.5.2
An indirect streptavidin-biotin immunoenzymatic antigen detection system was 
used to detect and quantify PDL-1 and PDL-2 expressing cells in frozen skin 
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sections. The technique involves using a primary antibody specific to the 
antigen of interest followed by a secondary detection antibody specific to the 
conserved FC portion of the primary antibody. The secondary antibody is 
biotinylated and will in turn bind an avidin-biotinylated peroxidase H complex 
that will catalyse 3-amino-9-ethylcarbazole (AEC) into a brown coloured product, 
thus staining the area that bound the primary antibody. Detection was performed 
using Mouse Vectastain Elite ABC kit: PK-602 (Vector laboratories, Burlingame, 
USA). 
Skin sections from healthy individuals and primary melanoma patients were 
brought to room temperature and fixed if necessary, before being circled using 
a water repellent Dakopen (Dako, Stockport, UK) in order to contain any liquid 
applied to the sections. Samples were then washed twice for 5 minutes in a 
PBS water bath. Excess PBS was removed by gentle tapping and 10% horse 
serum in PBS was applied for 20 minutes to prevent unspecific antibody 
binding. Excess blocking solution was removed and the primary antibody was 
added in 1% horse serum in PBS in the optimised dilution as listed for each 
antibody in Table 2-3 and incubated overnight at 4°C in a humidified chamber. 
The following day, slides were washed twice in PBS and incubated for 30 
minutes with the biotinylated horse anti-mouse secondary antibody in 1% horse 
serum, followed by two washes in PBS. Slides were then incubated for 10 
minutes in 0.3% H2O2 in ddH2O in order to block endogenous peroxidase 
activity, followed by 2 washes in PBS. Excess PBS was removed and freshly 
prepared Vectastain ABC solution (1:100 of both solution A, containing the 
avidin, and solution B, containing the biotinylated peroxidase, in PBS) was 
applied for 30 minutes onto the sections, before being washed twice in PBS. 
The Vectastain AEC solution (0.25ml of 40mM AEC in N,N-dimethyl formamide 
was diluted in 4.75 0.1M Acetic acid and then activated with 2.5µl H2O2) was 
applied to each section. Resulting colour change was monitored and slides 
were washed when the desired intensity developed. Sections were left to dry at 
room temperature and mounted with a coverslip.  
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Target Clone (Animal) Dilution Company Secondary antibody 
[dilution] 
PDL-1 MIH1 (mouse) 1:50 eBioscience Horse anti-mouse [1:200] 
PDL-2 MIH18 (mouse) 1:200 eBioscience 
Table 2-3: Antibodies used for immunohistochemistry 
 Double Immunofluorescence  2.5.3
Double labelled indirect immunofluorescence involves several primary 
unconjugated antibodies being used for the simultaneous detection of several 
antigenic targets in frozen skin sections. Fluorochrome conjugated secondary 
antibodies raised against the FC portions of the primary antibodies are then 
used to amplify the signal and emit light of various colours that can be 
individually detected by fluorescent microscopy. This technique generally 
requires the primary antibodies to be raised in different animals to ensure 
differently coloured secondary antibodies bind their respective target only. As 
this was not possible for the simultaneous detection of CD8 with perforin, an 
additional step needed to be added to the protocol. This was possible because 
the anti-CD8 antibody was directly conjugated to FITC, which could be detected 
by a separate secondary antibody to the one previously used to detect perforin. 
Frozen skin sections mounted on glass slides were brought to room 
temperature before being circled using a water repellent Dakopen (Dako). 
Slides were washed twice for 5 minutes in a container with PBS. PBS was 
removed by gentle tapping and 10% goat serum in PBS was applied for 30 
minutes at room temperature in order to minimize unspecific antibody binding. 
Slides were again washed twice in PBS, which was removed before applying 
the primary antibodies (see Table 2-4) in 1% serum. Slides were incubated 
overnight at 4°C in a humidified chamber. The following day, unbound antibody 
was tapped off, followed by two washes with PBS in the dark. Then, the 
fluorochrome-conjugated secondary antibodies (see Table 2-4) was applied and 
incubated in the dark for 30 minutes at room temperature, before being washed 
off by two washes with PBS. Finally, sections were dried at room temperature in 
the dark before being mounted with coverslips and mounting reagent ProLong 
Antifade Gold (Invitrogen), which contains the nuclei staining DAPI. 
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As mentioned, staining for perforin and CD8 required an additional step during 
the staining procedure as the two antibodies were raised in the same species of 
animal. For this, only perforin but not CD8 was incubated during the first day. 
Instead, staining on day 1 used anti-perforin antibody only. The appropriate 
secondary antibody was applied on the second day, followed by two washes 
and 30 minutes blocking with 10% mouse serum in PBS. After blocking, the 
anti-CD8-FITC antibody was applied overnight, followed by two washes and 
addition of anti-FITC antibody for 30 minutes on the third day. Unbound 
antibody was washed off in two washes and slides were washed and mounted 
as described above.   
Control slides were incubated with secondary antibodies only to ensure no 
unspecific staining occurred. Collagen fibres gave green autofluorescence, 
which could not be removed. 
Table 2-4: Antibodies used in immunofluorescence 
 Microscopy and image processing 2.5.4
 Immmunofluorescence 2.5.4.1
Immunofluorescent images were acquired for each antibody combination on the 
same day, using the appropriate filters of a Zeiss Axioplan 2I microscope. 
Images were taken with an emphasis on areas showing staining for CD8+ T 
cells (in green). Images were overlaid and analysed using ImageJ software and 
colour threshold were adjusted for the whole image in order to reduce 
unspecific background fluorescence equally in all samples from the same batch. 
Target Conjugate Clone  
(Animal) 
Dilution Company Detection antibody 
(all from Invitrogen) 
CD8 FITC SK1 
(mouse) 
1:50 BD Goat-anti-FITC 
[1:250], 
AlexaFluor488 
Perforin none  δG9   
(mouse) 
1:50 BD Goat-anti mouse 
[1:250], 
AlexaFluor468 
Granzyme 
B 
none polyclonal 
(rabbit) 
1:200 Abcam Goat-anti-rabbit 
[1:25], AlexaFluor546 
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 Immunohisotchemistry 2.5.4.2
Skin sections stained by immunohistochemistry were acquired using a light 
microscope (Nikon Eclipse E600). Images generated were analysed using 
ImageJ software, allowing manual counting of positive staining cells per surface 
area. 
 Statistical Analysis 2.6
Graphs were drawn and statistical analysis was performed using GraphPad 
Prism version 5 (GraphPad Software, San Diego, USA).  Non-parametric data 
were identified using the D'Agostino and Pearson omnibus normality test. 
Statistical tests used included the Student’s T-test or paired T-test when data 
followed a Gaussian distribution and the Whitney-Mann test or Wilcoxon test for 
non-parametric data. Correlations were calculated using Pearson correlation 
coefficient or Spearman correlation for non-parametric data. Lines of best fit 
were generated using linear regression. Fisher’s exact test was used to 
compare prevalence of CMV between melanoma patients and healthy controls. 
If more than two groups were compared simultaneously, one-way ANOVA (for 
parametric data) or the Friedman test (for non-parametric data) were applied, 
followed by Holm-Sidak or Dunn’s multiple comparison tests respectively for 
paired comparisons. 
Differences were considered significant when p<0.05. 
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3 Investigating global and specific T cell 
differentiation in the circulation of patients with 
melanoma 
 Chapter Introduction 3.1
Melanoma is a highly immunogenic tumour, but despite the reported presence 
of melanoma specific T cells in patients with advanced stage, disease 
progression occurs (Jäger et al. 1996). Some persistent diseases are known to 
cause increased T cell differentiation and drive T cell dysfunction via chronic 
antigen exposure, especially with age (Ouyang et al. 2004). By virtue of its 
antigenicity and simultaneous lack of disease resolution, melanoma may 
therefore drive T cell differentiation in the patients affected. 
T cell differentiation or senescence can be measured in a number of ways. The 
cell surface markers CD45RA and CD27 are often used to distinguish the less 
differentiated naïve (CD45RA+CD27+) and central memory (TCM; CD45RA-
CD27+) from the more differentiated effector memory (TEM; CD45RA-CD27-) and 
the end-stage differentiated and senescent effector memory T cells re-
expressing CD45RA (TEMRA; CD45RA+CD27-) (Hamann et al. 1997; Sallusto et 
al. 1999). Surface CD57 and KLRG1 expression are also associated with highly 
differentiated cells (Brenchley et al. 2003; Henson and Akbar 2009). Expression 
of inhibitory markers such as PD-1 and CTLA-4 on the other hand is not usually 
associated with senescence, but instead with exhaustion which affects less 
differentiated cells (Libri et al. 2011; Akbar and Henson 2011). Despite showing 
low proliferative capacity, highly differentiated T cells often display high effector 
potential such as inflammatory cytokine production upon challenge or 
expression of cytotoxic granule components (Akbar and Henson 2011). 
Known pathogens that drive T cell differentiation include Epstein-Barr virus 
(EBV) and human immunodeficiency virus (HIV) and most prominently 
Cytomegalovirus (CMV), which has been associated with a global increase in T 
cell differentiation in healthy appearing individuals (Ouyang et al. 2004; Fletcher 
et al. 2005; Lachmann et al. 2012). CMV induced global CD4+ and CD8+ T cell 
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differentiation is particularly apparent among the old, which is most likely due to 
the lifelong exposure to the virus (Koch et al. 2008). 
Previous studies have reported an increase in highly differentiated T cells in a 
number of non-melanoma tumours such as myeloma and renal cell carcinoma 
(Sze et al. 2001; Characiejus et al. 2002). In the context of melanoma, no highly 
differentiated cells could be detected amongst T cells infiltrating the primary 
melanoma or tumour invaded lymph nodes (Mortarini et al. 2003; Anichini et al. 
2010). Conversely, reports do exist confirming the presence of melanoma-
specific T cells with a TEMRA phenotype in the blood of patients with metastatic 
disease (Maczek et al. 2005). It should be noted that most studies have 
focussed on patients of intermediate age groups with the old cohorts (which 
present with the highest mortality) generally being underrepresented.  
This first results chapter therefore investigates whether increased T cell 
differentiation occurs in old melanoma patients compared to healthy controls by 
measuring the differentiation patterns in circulating CD4+ and CD8+ T cells 
using relative expression of CD45RA/CD27 and other differentiation associated 
markers. 
 Aims and objectives 3.2
The aim of this chapter was to characterize and define global and melanoma-
specific differentiation patterns in the blood T cells of patients with melanoma. 
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 Results 3.3
 Global CD4+ T cell differentiation in the circulation of melanoma 3.3.1
patients compared to healthy controls  
Melanoma patients and healthy volunteers were assessed for their CD4+ and 
CD8+ T cell differentiation patterns based on the cells surface expression of  
CD45RA and CD27 using flow cytometry (Representative gating strategy shown 
in Fig. 3-1). Cells that are CD45RA+CD27+ are considered to be naïve, 
CD45RA-CD27+ cells are central memory cells (TCM), CD45RA-CD27- cells are 
effector memory cells (TEM) and finally cells which are CD45RA+CD27- are 
termed effector memory cells re-expressing CD45RA (TEMRA). TEMRA cells are 
considered to be the most differentiated (Di Mitri et al. 2011; Henson et al. 
2014). 
 
Fig. 3-1: Representative FACS plots showing gating of live CD4+ and CD8+ T cell subsets 
based on their CD27 and CD45RA surface expression in PBMCs derived from a healthy 
individual. 
The T cell differentiation compartments are: CD45RA+CD27+ = naïve cells, CD45RA-CD27+ = 
central memory cells (TCM), CD45RA-CD27- = effector memory cells (TEM), CD45RA+CD27- = 
CD45RA re-expressing effector memory cells (TEMRA). 
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 Differentiation patterns of circulating CD4+ T cells are altered in 3.3.1.1
melanoma patients 
The distribution of the CD45RA/CD27 subsets within the CD4+ T cell 
compartment was stratified by age in both healthy individuals and melanoma 
patients (representative staining and cumulative data are shown in Fig. 3-2A,B).  
In both healthy and melanoma groups, the percentage of naïve cells decreased 
with age (p=0.0193 and p<0.0001 respectively) and the amount of TEM 
increased (p=0.0115 and p=0.0050), although these trends were more 
pronounced among the melanoma patients. Further, the melanoma patients 
(but not the healthy controls) displayed a significant increase of TCM with age 
(p=0.029). Direct comparison of CD4+ T cell subset distributions between 
melanoma patients and healthy controls showed no difference in the younger 
age group (aged 35 or less), whilst a significant increase in TCM could be 
confirmed among old (aged 60 and above) melanoma patients compared to the 
age matched healthy controls (p=0.0393; Fig. 3-2C). No increase of highly 
differentiated cells was therefore found in the CD4+ T cell compartment of 
patients with melanoma. 
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Fig. 3-2: Blood CD4+ T cell subset distribution with age in melanoma patients and healthy 
controls 
A: Representative FACS plots showing CD4+ T cell CD45RA/CD27 expression patterns in 
young and old melanoma patients and healthy controls. The schematic diagram on the right 
shows the names given to the subpopulations in each gate. 
B: Frequencies of each of the CD45RA/CD27 subsets within total CD4+ T cells are correlated 
against age in melanoma patients (n=113) and healthy controls (n=59). Lines of best fit were 
generated by linear regression and the correlation (r-value) and significance were assessed by 
Pearson and Spearman rank. 
C: Direct comparison of percentages of the CD4+ T cell subsets between young melanoma 
patients (n=11) and young healthy controls (18) and between old melanoma patients (n=67) and 
old healthy controls (n=33).  Populations were compared using the unpaired T-test or the Mann-
Whitney test. Horizontal lines depict mean values with standard deviation for all graphs. 
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0 102 103 104 105
0
103
104
105 0.48 52.9
43.72.94
0 102 103 104 105
0
103
104
105 3.76 35.1
49.711.5
0 102 103 104 105
0
103
104
105 0.27 61.7
36.12
0 102 103 104 105
0
103
104
105 0.52 58.3
365.19
0 20 40 60 80 100
0
25
50
75
100
TEMRA
0.08304 ns
-0.01628 ns
r=
r=
Healthy
Melanoma
0 20 40 60 80 100
0
25
50
75
100
TCM
0.1324 ns
0.2776 **
r=
r=
Healthy
Melanoma
0 20 40 60 80 100
0
25
50
75
100
TEM
0.3271 *
0.2625 **
r=
r=
Healthy
Melanoma
B"
age"
%
"o
f"C
D4
+ "T
"c
el
ls"
A"
TEMRA" Naive"
TEM" TCM"CD
45
RA
'
CD27'
CD4+'T'cells'
C"
Naive TCM TEM TEMRA
0
20
40
60
80
100
%
 o
f C
D
8+
 T
 c
el
ls
Healthy
Melanoma
Old donors (60+)
C
D
45
R
A 
CD27 
Healthy Melanoma 
Young 
Old 
0 20 40 60 80 100
0
25
50
75
100
Naive
r=
r=
-0.3038
-0.3596****
*
Healthy
Melanoma
Naive TCM TEM TEMRA
0
25
50
75
100
%
 o
f C
D
4+
 T
 c
el
ls
Young participants (35-)
Naive TCM TEM TEMRA
0
25
50
75
100
%
 o
f C
D
4+
 T
 c
el
ls HealthyMelanoma
Old participants (60+)
*
 83 
 CMV infection is associated with altered CD4+ T cell differentiation 3.3.1.2
in old melanoma patients  
CMV infection is known to heavily influence global T cell differentiation patterns 
of carriers, especially with advanced age (Chidrawar et al. 2009; 
Derhovanessian et al. 2011). It was therefore of interest to determine whether 
CMV played a role in the T cell differentiation patterns observed among the 
melanoma patients and healthy controls. Analyses were made in the old (60 
years and above) age group only, as no differences were found in global CD4+ 
T cell differentiation between young patients and controls. Old participants were 
identified as CMV responders and non-responders via CD4+ T cell cytokine 
production (measured by intracellular flow cytometry, Fig. 3-3A) following 
overnight incubation with viral lysate. Results obtained by this method have 
been shown to correlate with screening through serological testing by our group 
previously (Fletcher et al. 2005). The frequency of CMV responders and the 
magnitude of the in vitro response to the lysate (Fig. 3-3B) were not found to 
differ significantly between old patients and controls (64% and 58% CMV 
responders respectively; p= 0.5040).  
Melanoma patients were further subdivided according to their disease stage 
with stages I-II being local disease and III-IV disseminated. No stage IV patients 
were available for this analysis. Amongst the melanoma patients, only 26% 
stage I melanoma patients were found to be CMV+, whilst 72% and 62% of 
stage II and III were positive respectively. It should be noted that although we 
attempted to compare age matched groups in this work, old melanoma patients 
belonging to different disease stages were not age matched: Stage I 
participants were on average younger that stage II and stage III patients (mean 
ages= 69.7, 74.0 and 72.6 respectively). Any differences detected between 
patients of different stages might therefore be solely due to discrepancies in 
age. 
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Fig. 3-3: Identification of CMV infected individuals among old (aged 60 or above) patients 
and controls 
A: Representative FACS plot showing identification of CMV positive individuals through 
detection of IFNγ+ or IL-2+ CD4+ T cells following overnight stimulation of PBMCs with CMV 
lysate.  
B: Percentages of CMV positive and negative donors amongst old melanoma patients (n=64) 
and healthy controls (n=29) 
C: Frequency of CD4+ T cells producing cytokines in response to CMV lysate among old CMV 
positive melanoma patients (n=37) and healthy controls (n=19). Horizontal lines depict mean 
values with standard deviation. 
C:  Percentages of CMV positive and negative donors amongst stage I (n=15), II (n=22) and III 
(n=26) melanoma patients. 
D: Frequency of CD4+ T cells producing cytokines in response to CMV lysate among CMV 
positive stage I, II and III melanoma patients (n=4, 16 and 17 respectively). Populations were 
compared using the Kruskal Wallis test. Horizontal lines depict mean values with standard 
deviation for all graphs. 
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Among the melanoma patients, a CMV+ status was associated with a significant 
decrease in naïve cell frequencies and increase in TEM and TEMRA, compared to 
patients that were CMV- (p=0.0221, p>0.001 and p=0.0053 respectively; Fig. 
3-4A). Similarly, healthy old CMV+ individuals had increased frequencies of TEM 
and TEMRA compared to healthy old CMV- donors (p=0.006 and p= 0.0204, 
respectively). The increase of TCM detected in the old melanoma patients 
compared to healthy controls did not persist after excluding all the participants 
that were CMV+. Instead, CD4+ TCM was increased compared to the controls in 
the CMV carrier group only (p= 0.0448). 
In order to investigate whether the increase in TCM among CMV+ melanoma 
patients varied with tumour stage, participants were separated into their 
respective disease stages and analysed for subset frequencies (Fig. 3-4C). 
However, as mentioned above, the groups were not age matched and no 
significant differences in naïve, TCM, TEM and TEMRA CD4+ subset distributions 
were detected among patients of different stages.  
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Fig. 3-4: The role of CMV status and disease stage in the subset distribution of 
circulating CD4+ T cells in old melanoma patients and healthy controls 
A: Percentages of CD4+ T cell subpopulations in old (>60 years) CMV positive and CMV 
negative melanoma patients (n=37 and 27, respectively) and healthy controls (n=19 and 10, 
respectively). 
B: Frequency of CD4+ T cell subsets in old (>60 years) CMV negative melanoma patients 
according to their disease stage (n=11 for stage I, n=6 for stage II and n=9 for stage III).  
C: Frequency of CD4+ T cell subsets in old (>60 years) CMV positive melanoma patients 
according to their disease stage (n=4 for stage I, n=15 for stage II and n=17 for stage III).  
Horizontal lines depict mean values with standard deviation for all graphs and populations were 
compared using the Student t-test in A and one-way ANOVA in B and C. Note that the old 
patients of different stages are not age matched. 
*=p<0.05; **=p<0.01; ***=p<0.001; ****p>0.0001 
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 CD4+FoxP3+ Tregs are not increased in old melanoma patients 3.3.1.3
CD4+ FoxP3+ Tregs have suppressive activity and are often associated with 
malignancies (Viguier et al. 2004; Chen et al. 2005). In both, old melanoma 
patients and healthy controls, the majority of FoxP3+ Tregs were confined to the 
TCM compartment within the CD4+ T cells (Fig. 3-5A,C). It was therefore 
investigated if the increase in TCM detected amongst the old CMV positive 
patients could be linked to an increase in FoxP3+ Tregs in the patients. This 
was not found to be the case as FoxP3+ Treg frequencies remained similar 
between circulating CD4+ T cells of old melanoma patients and healthy aged 
matched controls (Fig. 3-5B). 
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Fig. 3-5: Quantification and phenotyping of circulating CD4+ FoxP3+ Tregs in old 
melanoma patients and healthy controls 
A: Representative gating strategy showing identification of CD4+FoxP3+CD127-CD25+ cells, 
also known as Tregs, and showing the CD45RA/CD27 phenotype of total CD4+ T cells and 
Tregs. 
B: Percentages of Tregs amongst the CD4+ T cells of old melanoma patients and healthy age 
matched controls (n=6 each). 
C: CD45RA/CD27 subset distribution of Tregs derived from melanoma patients and healthy 
controls (n=6 each). 
Horizontal lines depict mean values with standard deviation for all graphs. 
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 Global circulating CD8+ T cell differentiation in melanoma patients 3.3.2
compared to healthy controls  
 
 Old melanoma patients display an increase in CD8+ TEMRA 3.3.2.1
compared to healthy age matched controls 
Each CD45RA/CD27 subset was measured as percentage of the total CD8+ T 
cell population and plotted against age in healthy individuals and melanoma 
patients (representative staining and cumulative data are shown in Fig. 3-6A,B). 
In both healthy and melanoma groups, naïve CD8+ T cells decreased 
significantly with age (both p<0.0001), whilst TEM and TEMRA increased 
(p=0.0025 and p<0.0001 for TEM and p=0.0084 and p<0.0001 for TEMRA 
respectively). The fraction of TCM also increased with age amongst healthy 
individuals (p=0.0057), but was not found to change with age in the melanoma 
patients. Young melanoma patients did not show a significant difference in the 
CD8+ T cell subset distribution compared to age matched healthy controls. Old 
melanoma patients however showed a significant increase in TEMRA (p=0.0382; 
Fig. 3-6C). 
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Fig. 3-6: Frequency of CD8+ T cell subsets by age in the blood of melanoma patients and 
healthy controls 
A: Representative FACS plots showing CD45RA/CD27 defined CD8+ T cell subset distribution 
in young and old melanoma patients and healthy controls. The schematic diagram on the right 
shows the names given to the subpopulations in each gate. 
B: Frequencies of each of the CD45RA/CD27 populations within total CD8+ T cells are 
correlated against age in melanoma patients (n=113) and healthy controls (n=59). Lines of best 
fit were generated by linear regression and the correlation assessed by Pearson and Spearman 
rank. 
C: comparison of percentages of the CD8+ T cell subsets between young melanoma patients 
(n=11) and young healthy controls (18) and between old melanoma patients (n=67) and old 
healthy controls (n=33). Populations were compared using the unpaired T-test or the Mann-
Whitney test. Horizontal lines depict mean values with standard deviation for all graphs. 
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 TEMRA CD8+ T cells are increased in melanoma patients in the 3.3.2.2
absence of CMV  
The effect of CMV infection history on CD8+ T cell differentiation in older 
melanoma patients and healthy controls was also assessed (Fig. 3-7A). Positive 
CMV status was linked to a decrease in naïve CD8+ T cell frequencies in 
patients (p<0.0001) and controls (p=0.0156) and in TCM (p=0.0088 in melanoma 
and p<0.0001 in healthy subjects). TEM levels were increased among CMV 
positive melanoma patients (p<0.0001) and controls (p=0.0024) compared to 
individuals from the same groups that were unaffected by the virus and so were 
TEMRA levels (p=0.0009 in melanoma and p=0.0018 in healthy subjects). 
Intriguingly, old melanoma patients who did not have CMV still displayed 
decreased levels of TCM and increased levels of TEM and TEMRA compared to 
healthy age matched individuals who were also CMV negative (p=0.0044 for 
differences in TCM, p=0.0275 in TEM and p=0.0470 in TEMRA; Fig. 3-7A).  
In order to determine whether the accumulation of these highly differentiated 
CD8+ TEMRA cells in melanoma patients was related to disease severity, the 
CMV negative melanoma patients aged 60 or more were further subdivided into 
their respective disease stage for comparison of CD8+ T cell subset frequencies 
(Fig. 3-7B,C). However, no association could be found between increased 
disease stage and CD8+ TEMRA cell frequency, although it should be noted that 
the old participants of different stages were not age matched. 
A non-CMV associated increase in highly differentiated CD8+ TEMRA cells was 
therefore detected in old melanoma patients. However, since high TEMRA levels 
could not be linked to disease stage, no links could be drawn between TEMRA 
levels and disease severity. 
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Fig. 3-7: The role of CMV status and disease stage in the CD8+ T cell subset distribution 
in the circulation of old melanoma patients and healthy controls 
A: Percentages of CD8+ T cell subpopulations in old (>60 years) CMV positive and CMV 
negative melanoma patients (n=37 and 27, respectively) and positive and negative healthy 
controls (n=19 and 10, respectively). 
B: Frequency of CD8+ T cell subsets in old CMV negative melanoma patients according to their 
disease stage (n=11 for stage I, n=6 for stage II and n=9 for stage III).  
C: Frequency of CD8+ T cell subsets in old (>60 years) CMV positive melanoma patients 
according to their disease stage (n=4 for stage I, n=15 for stage II and n=17 for stage III).  
Horizontal lines depict mean values with standard deviation for all graphs and populations were 
compared using the student t-test or Mann-Whitney test (in A) or one-way ANOVA or Kruskal 
Wallis test (in B and C). Note that the old patients of different stages are not age matched. 
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 EBV infection is not responsible for increased TEMRA levels in CMV 3.3.2.3
negative patients. 
EBV is another common persistent herpes virus that potentially generates 
CD45RA+ memory cells (Dunne et al. 2002) and might therefore explain the 
high levels of TEMRA found in some CMV negative melanoma patients. However, 
cytokine production in response to EBV lysate was only found in one out of six 
melanoma patients who had previously been shown to display high frequencies 
of TEMRA in the absence of CMV (Fig. 3-8).  
In order to rule out the possibility that the PBMCs from the patients of interest 
had a defect in their ability to respond to stimuli in vitro and might therefore be 
mis-interpreted as CMV or EBV negative, cells were further treated with 
Varicella zoster virus (VZV) lysate or the superantigen Staphylococcus 
Enterotoxin B (SEB). Four out of six melanoma patients responded to VZV 
lysate and all responded to unspecific stimulation with SEB, confirming that the 
cells were able to respond to other stimuli (Fig. 3-8).  
Additionally to CMV, EBV could therefore be ruled out as potential cause for 
increased TEMRA in the melanoma patients. 
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Fig. 3-8: EBV and VZV prevalence in the six old melanoma patients who displayed high 
frequencies of CD8+ TEMRA in the absence of CMV. 
PBMCs were stimulated overnight with Staphylococcus enterotoxin B (SEB), Epstein–Barr virus 
(EBV) or Varicella zoster virus (VZV) lysate or left unstimulated. IL-2 and IFNγ production were 
measured intracellularily in the CD4+ T cell subset by flow cytometry and compared to the 
unstimulated control to determine presence of anti-viral responses. SEB was used as positive 
control. The donors selected were 6 melanoma patients who had previously been shown to 
have high CD8+ TEMRA frequencies despite appearing to be CMV negative. 
A: representative flow cytometric gating showing cytokine responses of CD4+ T cells under the 
various stimulation conditions. 
B: Stacked histograms showing the prevalence of individuals responding to EBV, VZV and SEB 
in vitro. 
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 Characteristics of CD8+ T cell subsets of old melanoma patients 3.3.3
As an increase in CD8+ TEM and TEMRA was observed in the circulation of 
patients with melanoma, it was of interest to investigate whether these cells 
displayed the same functional and phenotypic properties as in healthy 
individuals. Features of senescence and exhaustion, cytotoxic potential, 
proinflammatory cytokine production and expression of skin homing markers 
were therefore assessed in the CD8+ T cell subpopulations of melanoma 
patients aged 60 and above.  
 CD8+ TEMRA of old melanoma patients display features of 3.3.3.1
senescence  
TEMRA are thought to be the most differentiated T cell subset based on their low 
proliferative capacity and telomere length compared to the other subsets (Di 
Mitri et al. 2011; Libri et al. 2011; S. M. Henson et al. 2014). Indeed TEMRA of old 
melanoma patients were confirmed to have the lowest levels of proliferative 
capacity amongst all the subsets, as shown by ki67 expression following three 
days of stimulation with plate bound anti-CD3 and irradiated autologous antigen 
presenting cells (difference between TEMRA and naïve: p=0.0008 and between 
TEMRA and TCM: p=0.0011; Fig. 3-9). Similarly and as has been described in 
healthy subsets, TEMRA of melanoma patients showed significantly reduced 
telomere lengths compared to Naive (p=0.0098) and TCM p=0.0342) subsets 
(Fig. 3-10) and reduced capacity to produce IL-2 compared to TCM and TEM 
(p>0.0005; Fig. 3-11). 
CD57 and KLRG1 have previously been described as senescence-associated 
markers. Indeed, the co-expression of these receptors was found to be highest 
in TEMRA of melanoma patients and healthy controls alike (Fig. 3-12). 
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Fig. 3-9: Proliferative capacity of blood-derived CD8+ T cell subpopulations in old 
melanoma patients measured by Ki67 expression. 
CD8+ T cells were FACS sorted according to their CD27 and CD45RA expression and 
incubated for 3 days in the presence of 0.5µg/ml plate bound anti-CD3 antibody and irradiated 
autologous antigen presenting cells.  
A: Representative flow cytometry dor plots showing Ki67 in the various subsets 
B: Cumulative data showing mean Ki67 levels and standard error amongst the various subsets 
obtained from 5 participants. 
Populations were compared using one-way ANOVA.  
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Fig. 3-10: Telomere length of blood-derived CD8+ T cell subsets of old melanoma 
patients. 
Telomere length was measured using the Flow-FISH method (described in detail in the 
materials and methods chapter).  
A: Representative histograms showing mean fluorescence (MFI) of telomere probe stained 
CD8+ T cells subsets. 
B: Bars show mean telomere lengths in kilo base pairs (kbp) in the subsets with standard error 
in 3 participants. Populations were compared using one-way ANOVA. *=p<0.05; **=p<0.01 
 
 
 
 
Fig. 3-11 IL-2 production in the blood-derived CD8+ T cell subsets of old melanoma 
patients and healthy controls 
PBMCs from old (60+ years) melanoma (n=17) patients and healthy controls (n=17) were 
stimulated overnight with the superantigen SEB before being measuring IL-2 production per cell 
intracellularily via flow cytometry. Horizontal bars and stars highlight significant differences 
between the melanoma patient subsets, calculated with the Friedman test. Vertical bars indicate 
standard deviation. 
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Fig. 3-12: Senescence associated marker expression in blood-derived CD8+ T cell 
subsets of old melanoma patients compared to healthy controls. 
CD57 and KLRG1 expression were measured ex vivo in CD8+ T cell subsets using flow 
cytometry. 
A: Representative flow cytometric dot plots showing CD57 and KLRG1 coexpression in the 
subsets of melanoma patients and healthy controls. 
B: Frequency of CD57 and KLRG1 double expressing cells in the CD8+ T cell subsets of old 
melanoma patients (n=15) and healthy controls (n=19). Vertical bars indicate standard 
deviations. Stars and horizontal bars highlight significant differences between the melanoma 
patients’ subsets (calculated using the Friedman test). Vertical bars indicate standard deviation. 
*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 
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 Cytotoxic potential in the subsets of old melanoma patients 3.3.3.2
Despite showing decreased ability to proliferate and an increase in senescent 
features, TEMRA of healthy individuals display an array of effector functions 
(Henson et al. 2014). In old melanoma patients and old healthy individuals alike, 
TEMRA were found to bear the highest levels of perforin and granzyme B 
coexpression out of all the CD8+ T cell subsets, as 57±23% of TEMRA in healthy 
and 59±31% of TEMRA in old melanoma patients expressed both granzyme B 
and perforin (Fig. 3-13). 
CD107a, a marker of cytotoxic granule release, was measured after overnight 
stimulation with anti-CD3 antibody  (Fig. 3-14). In old healthy individuals, the 
highest levels of CD107a were measured in the TEM (14±4%) and TEMRA 
(15±4%) CD8+ T cell subsets. Melanoma patients were found to have 
significantly increased levels of CD107a in their TEM compartment (20±6%; 
p=0.0355), but similar levels the TEMRA compartment (14±6%) compared to 
healthy controls.  
TEMRA of melanoma patients therefore resembled those of healthy individuals in 
terms of cytotoxic potential.  
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Fig. 3-13: Cytotoxic granule components located in blood-derived CD8+ T cell subsets of 
old melanoma patients and healthy controls. 
A: Representative flow cytometry dot plots showing Granzyme B and Perforin expression 
patters in the CD8+ T cell subsets of old melanoma patients and healthy controls. 
B: Cumulative data showing standard deviations and means of granzyme B and perforin 
coexpression in the CD8+ T cell subsets of old melanoma patients (n=11) and healthy controls 
(n=14). Grey horizontal bars and stars mark statistical differences in the frequency of Granzyme 
B and Perforin coexpressing cells amongst the subsets of the melanoma patients. These were 
calculated using one-way ANOVA.  
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Fig. 3-14: Cytotoxic degranulation in the blood-derived CD8+ T cell subsets of old 
melanoma patients and healthy controls. 
PBMCs were stimulated overnight in the presence of plate-bound anti-CD3 antibody and 
fluorochrome-conjugated anti-CD107a antibody. Cells were labelled with the appropriate 
antibodies the following day before being analysed via flow cytometry.  
A: Representative flow cytometric histograms showing CD107a expression in the CD8+ T cell 
subsets of old melanoma patients and healthy controls. 
B: Cumulative data showing average percentages and standard deviations of CD107a+ cells in 
the CD8+ T cell subsets of old melanoma patients (n=8) and healthy controls (n=6). Stars in 
black denote significant differences in CD107a expression between patient and control subsets 
(calculated by the unpaired T-test). Stars in grey highlight significant differences between the 
subsets within the melanoma patients (calculated using one-way ANOVA). Vertical bars indicate 
standard deviation. 
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 TEMRA of old melanoma patients produce less TNFα than those of 3.3.3.3
healthy controls 
Known effector functions associated with TEMRA are not only restricted to 
cytotoxic granule components but also include increased ability to produce high 
levels of effector cytokines such as TNFα and IFNγ (Hamann et al. 1997). 
In order to test whether TEMRA cells of the old melanoma patients were also able 
to produce these cytokines, IFNγ and TNFα production were measured in 
response to overnight stimulation with anti-CD3 antibody via intracellular flow 
cytometry in the CD8+ T cell subsets of old participants (Fig. 3-15). Whilst TEMRA 
and TEM were the highest producers of both cytokines among the healthy, TEMRA 
of old melanoma patients produced significantly less TNFα than their healthy 
counterparts (p=0.0111). 
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Fig. 3-15: Cytokine production in blood-derived CD8+ T cell subsets in old healthy 
individuals and melanoma patients (aged 60+) 
IFNγ and TNFα cytokine production were measured by intracellular flow cytometry staining in 
the CD8+ T cell subsets of old melanoma patients (n=13) and healthy controls (n=9) following 
overnight incubation in the presence of immobilized anti-CD3 antibody.  
A: Representative flow cytometric dot plots and  
B: Cumulative data showing IFNγ production in the CD8+ T cell subsets. 
C: Representative flow cytometric dot plots and  
D: Cumulative data showing TNFα production in the CD8+ T cell subsets.  
Histograms show mean values with standard deviation. Stars in black denote significant 
differences in cytokine production between the patients’ and control subsets (calculated by the 
unpaired T-test). Stars in grey highlight significant differences between the subsets within the 
melanoma patients (calculated using one-way ANOVA). 
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 Exhaustion markers PD-1 and CTLA-4 are not increased in the 3.3.3.4
circulating CD8+ T cell subsets of old melanoma patients 
compared to healthy controls 
Exhaustion in T cells is characterized by the simultaneous expression of an 
array of inhibitory markers on the surface of these cells (Blackburn et al. 2009). 
Since CTLA-4 and PD-1 expression are associated with immune exhaustion, 
the expression of these molecules was measured in the T cell subsets of old 
healthy individuals and melanoma patients. Both PD-1 and CTLA-4 were 
highest in the TCM and TEM subsets compared to the Naïve and TEMRA cells in 
both participant groups and not different between patients and controls (Fig. 
3-16). Therefore, TEMRA in melanoma patients did not display features of 
immune exhaustion. 
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Fig. 3-16: Expression of exhaustion the associated markers PD-1 and CLTLA-4 in the 
blood-derived CD8+ subsets of old melanoma patients and healthy controls. 
PD-1 surface expression was detected ex vivo via flow cytometry on unstimulated cells, whilst 
intracellular detection of CTLA-4 necessitated stimulation of the PBMCs with immobilized anti-
CD3 antibody overnight before intracellular staining. 
A: Histograms show representative gating for PD-1 and CTLA-4 in the various CD8+ T cell 
subsets.  
B: Frequencies of PD-1+ cells in the CD8+ T cell subsets of old melanoma patients (n=15) and 
healthy individuals (n=17).  
C: Frequencies of CTLA-4+ cells amongst the CD8+ T cell subsets of old melanoma patients 
(n=10 ) and healthy controls (n=10) 
Bar graphs depict mean values with standard deviation. Grey horizontal lines and stars highlight 
statistical differences in PD-1 or CTLA-4 percentage expression between the individual subsets 
of the melanoma patients and were calculated using one-way ANOVA. 
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 The skin homing marker CLA is reduced among the TCM and TEM of 3.3.3.5
old melanoma patients 
CLA and CCR4 are surface receptors involved in the migration of circulating T 
cells into the skin. CLA and CCR4 expression were measured on the surface of 
the CD8+ T cell subsets in old melanoma patients and healthy controls (Fig. 
3-17).  
In the CD8+ T cells of old melanoma patients, the highest levels of CLA and 
CCR4 were found on cells of intermediate differentiation stages. CLA was 
expressed by 11±5% of TCM and 6±6% of TEM. CCR4 was detected on 6±2% of 
TCM and on 5±3% of TEM. Only 2±1% of naïve or TEMRA subsets of melanoma 
patients expressed CLA or CCR4. The relative distribution of the homing 
markers was similar for healthy individuals. Interestingly melanoma patients 
were found to display significantly decreased levels of CLA on their TCM and TEM 
subsets (p=0.0428 and 0.0077 respectively) compared to healthy controls (Fig. 
3-17). Therefore, CLA was reduced in the old melanoma patients compared to 
healthy controls, particularly in the TCM and TEM subsets. 
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Fig. 3-17: Expression of the skin homing markers CLA and CCR4 in the blood-derived 
CD8+ T cell subsets of old melanoma patients and healthy controls. 
CLA and CCR4 expression were measured ex vivo by flow cytometry in circulating the subsets 
of CD8+ T cells of old melanoma patients and healthy age matched controls. 
A: Representative FACS histograms showing the expression patterns of the skin homing 
surface receptor CLA in the CD8+ T cell subsets of old melanoma patients and healthy controls  
B: Cumulative data showing the percentage CLA surface expression in the CD8+ T cell subsets 
of old melanoma patients (n=15) and healthy controls (n=11) 
C:  Representative FACS histograms showing the expression patterns of the skin homing 
surface receptor CCR4 in the CD8+ T cell subsets of old melanoma patients and healthy 
controls  
D: Cumulative data showing the percentage CCR4 surface expression in the CD8+ T cell 
subsets of old melanoma patients (n=6) and healthy controls (n=6)  
Mean and standard deviation are shown; Participants were compared using the unpaired T-test 
or Mann-Whitney test, subsets from melanoma patients by one-way ANOVA. 
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 Differentiation status of tumour specific CD8+ T cells in old 3.3.4
melanoma patients 
 Optimization and gating for the detection of melanoma-specific T 3.3.4.1
cells 
We next investigated whether the highly differentiated TEMRA cells found to be 
expanded in old melanoma patients were specific to melanoma antigens. 
Fluorochrome labelled peptide loaded MHC class I multimers are routinely used 
to identify peptide specific CD8+ T cells in patients with the appropriate matched 
HLA haplotype. A Melan-A peptide loaded HLA-A2 pentamer was initially used, 
but produced unreliable and non-specific staining. When a Melan-A specific 
MHC class I Dextramer was used, it generated reproducible data that allowed 
labelling of CD8+ T cell populations without staining positively in any HLA-A2 
negative participants. Every experiment included a negative control dextramer 
stain by using a MHC dextramer loaded with an irrelevant peptide (see Fig. 
3-18). 
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Fig. 3-18: Detection of Melan-A and NY-ESO-1 specific cells among blood-derived CD8+ T 
cells using fluorochrome conjugated MHC class I dextramers. 
Representative flow cytometry gating strategy used to identify melanoma specific CD8+ T cells 
in a melanoma patient. 
A:  Gating of true live CD8+ T cells, excluding doublets. 
B: Gates for Melan-A and NY-ESO-1 peptide containing Dextramer stains were drawn 
according to a control sample stained with a dextramer containing an irrelevant peptide as 
shown in the flow cytometry plots. 
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 Melan-A specific CD8+ T cells in old melanoma patients belong to 3.3.4.2
naïve or TCM subsets. 
Melan-A peptide loaded dextramers were used to detect Melan-A specific cells 
among the PBMCs of HLA-A2 positive participants. Four out of seven stage I, 
seven out of eight stage II and ten out of 12 stage III old melanoma patients 
displayed detectable levels of Melan-A specific CD8+ T cells (Fig. 3-19A). The 
frequency of these cells ranged between 0.01 to 0.09% of the total CD8+ T cells 
and was not found to be significantly altered among the old melanoma patients 
of different stages (p>0.05). 
Based on their CD27/CD45RA expression profiles, Melan-A cells detected 
among the patients were found to belong either to the naïve or the TCM subset 
(Fig. 3-19C). None of the old melanoma patients screened displayed Melan-A 
specific cells with a TEM or TEMRA phenotype. In order to see if the phenotype of 
Melan-A specific cells changed with disease stage, we compared the frequency 
of naïve-like cells among the Melan-A specific cells between patients of stages 
I, II and III (Fig. 3-19D). The fraction of Melan-A specific cells averaged 84±18% 
in stage I, 73±33% in stage II and 75±27% in stage III patients. Therefore, 
frequency and differentiation state of Melan-A specific cells were unchanged 
between patients of different disease stages.  
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Fig. 3-19: Frequency and differentiation profiles of Melan-A specific CD8+ T cells in the 
circulation of old melanoma patients. 
Melan-A specific CD8+ T cells were detected by flow cytometry using fluorochrome conjugated 
Melan-A peptide loaded MHC class I HLA-A2 Dextramers. 
A: Frequency of stage I, II and III donors presenting with detectable levels of Melan-A specific 
cells amongst their CD8+ T cell compartment. 
B: Percentages of Melan-A specific cells amongst CD8+ T cells of stage I (n=7), II (n=8) and III 
(n=12) melanoma patients. Means and standard deviation are shown. 
C: Representative flow cytometry dot plots showing CD45RA and CD27 expression patterns in 
total CD8+ T cells and Melan-A specific cells detected in old melanoma patients.  
D: Percentages of Melan-A specific cells that display a naïve-like phenotype in stage I (n=4), II 
(n=6) and III (n=10) melanoma patients. Means and standard deviation are shown. 
Populations were compared using the one-way ANOVA. 
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 Low frequency of NY-ESO-1 specific CD8+ T cells amongst 3.3.4.3
melanoma patients 
A second HLA-A2 dextramer containing a peptide of NY-ESO-1, another widely 
described melanoma antigen, was used to detect and characterize melanoma 
specific CD8+ T cells amongst the old melanoma patients (Fig. 3-20). Amongst 
22 HLA-A2 positive donors tested, only two were found to have detectable 
levels of NY-ESO-1 specific CD8+ T cells and both were confined to stage III 
disease. Further, in both donors, the NY-ESO-1 specific CD8+ T cells were 
confined to the TCM subset. 
 
Fig. 3-20 Frequency and differentiation profiles of NY-ESO-1 specific CD8+ T cells in the 
circulation of old melanoma patients 
Melan-A specific CD8+ T cells were detected by flow cytometry using fluorochrome conjugated 
Melan-A peptide loaded MHC class I HLA-A2 Dextramers. 
A: Frequency of patients with detectable levels of NY-ESO-1-specific CD8+ T cells amongst 
stage I (n=6), II (n=5) and III  (n=11) melanoma patients. Mean and standard deviation are 
shown. 
B: Frequency of NY-ESO-1 specific cells detected amongst old stage III melanoma patients. 
C: CD45RA/CD27 profile of total and NY-ESO-1 specific CD8+ T cells. NY-ESO-1 specific cells 
in both donors were >60% TCM. 
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 The role of IL-15 in CD45RA expression 3.3.5
 IL-15 causes upregulation of CD45RA on CD8+ T cells of old 3.3.5.1
melanoma patients 
CD45RA, which is used as a marker to identify naïve and TEMRA cells, can be 
upregulated in response to IL-15 (Griffiths et al. 2013). By inducing CD45RA 
expression, IL-15 may therefore generate TEMRA- or naïve-appearing memory 
cells. This may occur in melanoma patients and cause the increased 
occurrence of TEMRA cells and occurrence of naïve-like Melan-A specific cells in 
an antigen independent manner. To address this, melanoma patients’ CD8+ 
naïve, TCM, TEM and TEMRA were therefore FACS sorted and individually cultured 
in the presence of IL-15. CD45RA and CD27 surface expression were 
measured on the subsets by flow cytometry directly after sorting and after 14 
days in culture. Indeed, CD45RA was significantly increased on TCM and TEM 
cells after 14 days in culture with IL-15 compared to pre-culture levels at day 0 
(p= 0.0021 for TCM and p= 0.0373 for TEM; see Fig. 3-21A,B). Whilst TCM and 
TEM cells upregulated CD45RA in response to IL-15, they also retained 
expression of CD45RO (Fig. 3-21C). 
Therefore, IL-15 might explain the high levels of TEMRA cells in some CMV 
negative old melanoma patients. IL-15 might also lead to the development of 
naïve-appearing (CD45RA+CD27+) memory cells and could explain the high 
frequencies of naïve-like Melan-A specific cells.  
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Fig. 3-21: Change in CD45RA surface expression in blood-derived CD8+ T cells from 
melanoma patients after in vitro incubation with IL-15. 
CD8+ T cells subsets (based on CD27/CD45RA expression) taken from melanoma patients 
were FACS sorted and subsequently incubated with IL-15 for 14 days. Surface marker 
expression was measured via flow cytometry at day 0 (pre-incubation) and day 14 following 
incubation with IL-15. 
A: Representative flow cytometry dot plots showing CD45RA and CD27 surface marker 
expression at day 0 and day 14 following incubation with IL-15 in T cell subsets derived from an 
old melanoma patient. 
B: Change in percentages of cells expressing CD45RA in sorted CD8+ T cells subsets of 7 
melanoma patients after incubation with 10ng/ml IL-15 for 14 days (note: one patient did not 
yield enough naïve and TEMRA cells for measurement at d=12). 
C: Representative flow cytometry dot plots showing CD45RA and CD45RO surface marker 
expression at day 14 following incubation with IL-15 in T cell subsets derived from an old 
melanoma patient. 
*=p<0.05; **=p<0.01 
d=0 d=14
0
25
50
75
100
d=0 d=14
0
25
50
75
100
*
d=0 d=14
0
25
50
75
100
**
Naive& TCM& TEM& TEMRA&
0 102 103 104 105
0
102
103
104
105 95.3 0
0.0354.68
0 102 103 104 105
0
102
103
104
105 91.3 0.96
0.0577.65
0 102 103 104 105
0
102
103
104
105 5.17 0
0.2194.6
0 102 103 104 105
0
102
103
104
105 18.3 .
3.0777.1
0 102 103 104 105
0
102
103
104
105 0.013 3.82
96.10.081
0 102 103 104 105
0
102
103
104
105 0.44 26.7
70.22.62
A&
B&
d=0 d=14
0
25
50
75
100
0 102 103 104 105
0
102
103
104
105 0.44 98.4
0.870.25
0 102 103 104 105
0
102
103
104
105 1.11 96.4
1.820.68
d=0&
d=14&
CD27%
CD
45
RA
%
%%
%C
D4
5R
A+
%
Naive& TCM& TEM& TEMRA& d=0 
d=14 
CD
45
RA
%
CD45RO%
0 102 103 104 105
0
102
103
104
105 81.9 17.2
0.210.61
0 102 103 104 105
0
102
103
104
105 12.8 55.7
30.50.88
0 102 103 104 105
0
102
103
104
105 6.69 43.7
47.91.67
0 102 103 104 105
0
102
103
104
105 90 7. 7
2.20.61
Naive& TCM& TEM& TEMRA&
C& d=14&
 115 
 Discussion 3.4
This chapter explored whether differentiation of circulating T cells is increased 
in the context of melanoma. Differentiation was measured by assessing 
CD45RA/CD27 subset frequencies in both CD4+ and CD8+ T cells of 
participants across all ages. Differences in patients compared to healthy 
controls were restricted to the old age group and only the changes in the CD8+ 
T cell compartment were found to be CMV independent. This discussion 
therefore focuses on results generated in the old cohort and on the CD8+ T cells 
in particular. 
Global T cell differentiation patterns were strongly affected by CMV positivity in 
both old melanoma patients and healthy controls. However, CMV+ melanoma 
patients showed particularly high levels of CD4+ TCM levels compared to age 
matched CMV+ controls, suggesting that the melanoma patients were affected 
more profoundly by their CMV burden than healthy controls. Literature 
discussing the role of CMV infections in the context of melanoma is scarce, with 
only one report suggesting an increase in CMV viral loads in patients with 
malignancies (Dolgikh and Bychkova 2004). CMV is known to reactivate under 
conditions of psychological stress and immunosuppression (Prosch et al. 1999; 
Mehta et al. 2000; Torres et al. 2006). The increase in the CD4+ TCM in old 
CMV+ melanoma patients compared to old CMV+ healthy individuals might 
therefore be due to increased CD4+ T cell stimulation after increased CMV 
reactivation. This could be caused directly by the immunosuppressive effects of 
the tumour or indirectly by the psychological stress patients might undergo after 
becoming aware of their disease. Published follow up studies in healthy elderly 
participants have linked large expansions of CMV specific T cells to increased 
mortality (Wikby et al. 2005). In the present study, no correlation between CMV 
burden and the melanoma patients’ health status could be made due to a lack 
of follow up data.  
Within the CD8+ T cell compartment, a significant increase in TEMRA cell 
percentages could be detected in old melanoma patients compared to healthy 
age matched controls. High frequencies of CD8+ TEMRA in the melanoma 
patients were partly CMV independent, as a significant number of the patients 
with high TEMRA tested negative for the virus. Further analyses confirmed that 
 116 
these cells matched the functional and phenotypic properties of TEMRA cells in 
healthy individuals in terms of decreased proliferative capacity, IL-2 production 
and telomere length and increased cytotoxic capacity and senescence 
associated marker expression. Increased T cell exhaustion (as measured by 
PD-1 and CTLA-4 expression) was not detected among circulating CD8+ T cells 
of old melanoma patients compared to healthy controls. 
The question that arose next was whether the CD8+ TEMRA found among the 
melanoma patients were melanoma specific. Using peptide loaded Dextramers, 
CD8+ T cells specific to the tumour antigens Melan-A and NY-ESO-1 were 
detected in a number of the old melanoma patients. However, specific cells in 
these patients did not have a TEMRA phenotype. It should be noted that MHC 
multimer technology is restricted to detecting T cell populations specific to a 
single peptide:MHC combination and might therefore not pick up on other 
possible melanoma-specific clones. It is consequently still possible that the 
global T cell changes observed are related to T cells of specificity to other 
melanoma associated antigens or different epitopes presented on alternative 
HLA molecules. For example, another widely described tumour-specific T cell 
population can recognize tyrosinase epitopes. Cells of this specificity were not 
investigated in this study but have been reported by others to show a 
senescent-like, unresponsive phenotype in patients with advanced stage 
disease (Lee et al. 1999; Maczek et al. 2005).  
Recent evidence involving CMV specific TEMRA indicates that these cells have 
lower avidity compared to CMV-specific CD45RO+ cells (Griffiths et al. 2013). 
Since most anti-tumour specific T cells are thought to be of low affinity (due to 
deletion of highly self-reactive clones in the thymus) (Zhong et al. 2013), the 
TEMRA compartment might indeed contain weakly melanoma reactive T cells, 
which would be difficult to detect in vitro. In the absence of evidence for a link 
between tumour specific immunity and increased global T cell differentiation, 
non-antigen specific T cell stimuli such as cytokines might also play a role in the 
generation of TEMRA in melanoma.  IL-15 can contribute directly to TEMRA 
generation and maintenance in an antigen independent manner (Griffiths et al. 
2013) and was shown to induce CD45RA in this work in TEM and TCM of 
melanoma patients. IL-15 improved in vivo CD8+ T cell reactivity to murine 
melanoma and, at high concentrations, T cell responses to human melanoma in 
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vitro (Gamero et al. 1995). Although there are currently no reports suggesting 
increased IL-15 levels in the circulation of patients, TEMRA in melanoma patients 
might therefore have been expanded in an antigen-independent manner 
through cytokines. 
Accumulation of highly differentiated CMV-associated T cells in old healthy 
individuals has been linked to decreased survival (Wikby et al. 2005). Although 
high TEMRA levels in melanoma patients might similarly be associated with 
poorer disease outcome, no link was found between the frequency of these 
cells and disease stage. Current literature suggests no clinical benefit for 
melanoma patients in having expanded populations of highly differentiated 
CD8+ cells. Indeed, high levels of CD8+CD57+ cells were linked to worse 
prognosis amongst melanoma patients treated with IFN-α (Characiejus et al. 
2008). Further, in melanoma treatments involving adoptive transfer of 
autologous T cells expanded in vitro from tumour infiltrating lymphocytes, 
clinical responses were associated with the level of persistence of the 
reintroduced T cells. Increased persistence and proliferative capacity were 
enhanced in cells that had longer telomeres and higher expression of CD28 
compared to cells with shorter telomeres, indicating a beneficial role of cells 
having undergone less differentiation in vitro and in vivo in mice and humans 
(Zhou et al. 2005; Huang et al. 2005; Klebanoff et al. 2005; Li et al. 2010).   
Interestingly, a decrease in CLA positive CD8+ TCM and TEM could be found in 
the melanoma patients compared to healthy controls. TEMRA generally only 
express low levels of this skin homing receptor and expressed similar levels of 
CLA in the patients compared to controls. The reduction in skin homing cells in 
the melanoma patients could be due to the cells being recruited to the skin. 
Indeed, it is published that vitiligo patients, who suffer from autoimmune 
destruction of cutaneous melanocytes, have reduced frequencies of CD8+CLA+ 
cells in the circulation compared to healthy controls, whilst showing increased T 
cell infiltration in the skin (Antelo et al. 2011).   
Using Melan-A and NY-ESO-1 peptide loaded Dextramers, melanoma specific 
cells were detected in the blood of old melanoma patients. Large expansions of 
circulating melanoma specific T cells of over 1% of the total CD8+ T cells were 
not observed, which was surprising given the abundance of literature describing 
the phenotypes of such cells in the patients. However these are often found in 
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stage IV melanoma patients that were not available to us (Lee et al. 1999; 
Fourcade et al. 2009).  
The Melan-A specific cells detected among the melanoma specific cells were 
found to have either a naïve-like phenotype or a TCM-like phenotype. Healthy 
HLA-A2 positive individuals often present with naïve like Melan-A CD8+ T cells 
of frequencies around 0.1% of the total CD8+T cells (Pittet et al. 1999). Such an 
abundance of naïve appearing cells specific for one antigen is unusual as 
frequencies of naïve precursor T cells against other known epitopes are in 
average 100 fold lower (Alanio et al. 2010). Data have been published on 
Melan-A specific T cells being generated at high frequencies in the thymus and 
having a low proliferative history (Zippelius et al. 2002), supporting the notion 
that these cells are indeed naïve. However, recent publications have described 
memory populations expressing markers usually associated with naïve T cells 
and the upregulation of naïve cell markers in memory cells in response to 
cytokines (Gattinoni et al. 2011; Griffiths et al. 2013), indicating that naïve 
appearing cells such as Melan-A cells might not necessarily be truly naïve. 
It is thought that the shift in the melanoma-specific T cells from naïve to an 
activated or memory phenotype requires tumour metastasizing into of the lymph 
node and beyond in order to activate the cells sufficiently (Dunbar et al. 2000; 
van Oijen et al. 2004). However, Melan-A specific T cells that had a TCM 
phenotype could also be detected in the circulation of patients who had 
localized melanoma only (stages I and II), indicating that melanoma-specific T 
cells can become activated before melanoma has spread beyond the skin. NY-
ESO-1 specific CD8+ T cells, which were detected in two out of 22 HLA-A2 
positive patients tested, also showed a TCM-like phenotype. TCM express low 
levels of effector molecules such as perforin and granzyme B and high levels of 
costimulatory molecules CD27 and CD28, suggesting that they have a low 
proliferative history and are not very differentiated. This implies that the memory 
T cells specific to Melan-A and NY-ESO-1 have only encountered low levels of 
antigen but have the capacity to differentiate to effector cells if the antigen is re-
encountered.  
In summary, the results presented in this chapter revealed a CMV-independent 
expansion of highly differentiated TEMRA cells in a number of old melanoma 
patients. However, we were not able to show whether these TEMRA comprise 
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melanoma specific cells. Instead, the Melan-A and NY-ESO-1 specific cells 
detected in the old melanoma patients displayed less differentiated naïve or 
TCM-like phenotypes. 
It should be noted that T cell subset frequencies were measured in melanoma 
patients and healthy controls as percentage within the CD4+ or CD8+ T cell 
compartments and not as absolute cell numbers per volume of blood. Although 
lymphocyte counts were reportedly unchanged in melanoma patients compared 
to healthy controls in previous studies (Andres et al. 2006), this might not have 
been true for the participants of this study. Increased levels of TEMRA cells 
observed in some melanoma patients might therefore be due to an overall 
increase in distribution of these cells, or alternatively to the depletion of all other 
subsets because of an overall decrease in CD8+ T cells. To conclusively 
determine which scenario is true, absolute cell numbers should have been 
measured in whole blood via TruCount or similar techniques. 
Recent advances in melanoma therapies have focussed on antibody therapies 
against inhibitory receptors such as PD-1 to boost anti-tumour T cell function. 
However, these treatments only work on a fraction of patients and beneficial 
effects are often found to be only transient (Brahmer et al. 2012). Assuming that 
the increased TEMRA cells detected in the old melanoma patients are melanoma-
reactive but hindered in tumour killing by their senescent nature, these patients 
might benefit from additional treatment by targeting pathways or receptors 
intrinsic to these senescent T cells, such as p38 signalling which is thought to 
actively maintain highly differentiated T cells in their senescent-like state (Di 
Mitri et al. 2011; Henson et al. 2014). This has been attempted during this 
project and is discussed in the final results chapter (chapter 6). 
A point of consideration in this work is the use of CD45RA in conjunction with 
costimulatory receptor CD27, rather than the lymph node homing receptors 
CCR7 or CD62L to define T cell memory subsets. The latter were originally 
used to distinguish the lymph node homing subset TCM from TEM and TEMRA 
which by definition do not home to the lymph nodes (Sallusto et al. 1999). 
Despite a broad correlation between CD27 and CCR7/CD62L expression, co-
expression of these receptors is not absolute, as T cells can be highly 
heterogeneous and populations displaying intermediate CCR7-CD27+ and 
CCR7+CD27- profiles have been described (Appay et al. 2002; Appay et al. 
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2008). Since T cells irreversibly lose CD27 during differentiation (Hintzen et al. 
1993), the use of this marker allows distinction of cells at different stages of 
differentiation, rather than lymph node homing capability. Although the terms 
TCM, TEM and TEMRA are used here, CCR7 or CD62L were not measured and the 
ability of these cells to home to lymphoid organs was therefore not addressed. 
The use of the TCM/TEM/TEMRA terminology is therefore restricted in the context 
of this work and comparisons with other studies using these terms should be 
made with care as different subset markers might have been used. 
The frequency and differentiation status of melanoma-specific T cells in the 
circulation is often thought to be a late event and to have no predictive value to 
disease outcome (van Oijen et al. 2004). Conversely, the presence of tumour 
infiltrating lymphocytes has been shown to be a positive prognostic factor by a 
number of studies (Ladányi et al. 2004; Haanen et al. 2005).  The following 
results chapters will therefore investigate differentiation patterns of T cells in the 
skin of melanoma patients. 
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4 Establishing patterns of T cell differentiation in 
healthy skin 
 
  Introduction 4.1
In order to assess T cell differentiation in the skin of patients with melanoma, it 
is important to understand T cell phenotypes and functions in healthy skin first. 
The characteristics of T cells in the skin have only been poorly studied 
compared to the circulation, as blood samples are easier to obtain and 
technically less challenging to process. However, the last decade has seen a 
surge in research on tissue resident T cells as their importance in tissue 
immunity is being recognized. 
As described in the previous chapters, T cells in the blood can be divided into 
subsets, namely naïve, TCM, TEM and TEMRA, with the former being the least and 
the latter being the most differentiated. These subsets can be distinguished on 
the basis of surface receptors involved in various physiological processes such 
as costimulation or migration. Whilst TCM are thought to migrate between 
secondary lymphoid organs, TEM and TEMRA have often been associated with 
migration to peripheral tissues. As it was discovered that the skin is populated 
with a vast number of resident T cells, it was originally proposed that these cells 
are of the TEM subset because they lack the lymph node homing markers CCR7 
and CD62L (Clark et al. 2006; Clark et al. 2012). Although the paradigm has 
now shifted toward the notion that these cells are not true effector memory T 
cells (TEM), but instead a separate subset of tissue resident memory T cells 
(TRM), the idea persists that skin resident T cells share many characteristics with 
blood borne TEM and are readily poised to respond to antigenic challenges 
(Schenkel and Masopust 2014; Natsuaki et al. 2014).  
The differentiation patterns of skin resident T cells under steady state remain 
poorly understood, particularly in humans. The following chapter will therefore 
try to assess the differentiation of skin resident T cells in healthy human skin 
based on the expression of surface markers commonly associated with 
differentiation in T cells derived from the blood. 
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 Aims  4.2
The aim of this chapter was to establish rules and patterns of T cell 
differentiation in the skin of healthy individuals to enable the interpretation of 
changes found in the skin of patients with melanoma (described in the following 
chapter). 
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 Results 4.3
 T cell extraction from skin specimens 4.3.1
 Optimizing a protocol to isolate T cells from the skin 4.3.1.1
A skin digestion protocol involving overnight incubation of samples with 
collagenase type IV in complete medium was adopted in order to disaggregate 
skin specimen and to obtain a single cell suspension suitable for flow cytometry 
(outlined schematically in Fig. 4-1A and in full detail in the methods section). 
This technique is a laborious and time consuming process which requires 
manual cutting of skin specimen and filtration using a syringe plunger and 
repeated additions of PBS to pass the sample through a nylon mesh. 
In order to reduce processing time and increase cell recovery, other methods of 
skin disaggregation were explored. The use of mechanical disaggregation 
methods was tested, initially by using the Medimachine tissue dissociator (by 
Becton Dickinson Biosciences). However, even small pieces of skin were found 
to not disaggregate efficiently and to obstruct the rotating blades of the device. 
This resulted in low cell yields compared to the enzymatic method (Fig. 4-1B). 
Combining overnight enzymatic digestion with the mechanical disaggregation 
allowed the blades to rotate unobstructed but did not result in increased yields 
(Fig. 4-1B). Likewise, no advantage in cell recovery was obtained by a similar 
device called GentleMACS (by Miltenyi; Fig. 4-1C). Mechanical skin 
disaggregation methods were therefore abandoned in favour of the combined 
manual/enzymatic method.  
Initial analyses of lymphocytes recovered using collagenase digestion showed 
decreased surface expression of certain markers such as CD4 but not of others, 
including CD8 (Fig. 4-2A). Using a different type of collagenase (Type Is, Fig. 
4-2A) also affected cell surface markers. Allowing the isolated cells to rest 
overnight in collagenase-free medium did also not recover the lost epitopes 
(data not shown). Finally, increasing the serum content in the digestion medium 
from 10% to 20% or above, as suggested by Mulder and colleagues, allowed 
prevention of surface marker degradation without significant reduction in 
collagenase-mediated tissue breakdown (Mulder et al. 1994) (Fig. 4-2B).  
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The skin samples available from healthy volunteers were generally obtained 
from redundant plastic surgery skin, whilst melanoma skin samples were 
obtained from wide local excisions. Cell yields were estimated from counts of 
leukocytes using a haemocytometer. Cell recovery from skin samples was 
highly variable, averaging 49,000±35,0000 cells per cm2 in healthy skin and 
116,000±180,000 cells per cm2 in melanoma patient skin samples (difference in 
recovery between patients and controls was not significant). 
Skin samples were obtained on an irregular basis, at unpredictable times and 
were subject to availability. Due to these difficulties in sample collection, data 
obtained on skin T cell differentiation is spread across participants of all ages 
and adequate age matching between participants was not always possible, 
particularly in the melanoma cohort. 
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Fig. 4-1: Comparison of cell yields using various methods of skin disaggregation. 
A: Schematic diagram outlining the method of skin disaggregation for the extraction of single 
cell suspensions. Manual disaggregation involved filtration directly after overnight digestion. 
Mechanical disaggregation using the Medimachine or GentleMACS was tested on undigested 
or overnight digested skin before filtration. 
B: Cell yields were compared using enzymatic (overnight collagenase treatment) and 
mechanical (Medimachine) skin disaggregation methods, alone or in combination on 8mm 
punch biopsies. Horizontal lines depict mean values with standard deviation between three 
biopsies. 
C: Cell yields of skin T cells from punch biopsies obtained following collagenase digestion via 
manual/enzymatic disaggregation or mechanical/enzymatic disaggregation using the 
GentleMACS tissue dissociator. Horizontal lines depict mean values with standard deviation 
between three 8mm punch biopsies. 
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Fig. 4-2 Loss of T cell surface markers after incubation of PBMCs from a healthy donor 
with collagenase and prevention of this phenomenon through increased FBS 
concentration 
A: Comparison of cell surface marker expression following collagenase digestion. CD4 and 
CD8 surface expression were assessed by flow cytometry following overnight incubation of 
PBMCs with 0.8mg of collagenase type IV and type Is and 10% FBS in RPMI medium. Flow 
cytometry gates were drawn on the dot plots according the untreated sample and applied to 
collagenase treated samples. 
B: Cell surface marker detection after digestion in the presence of varying levels of FBS. Cells 
were incubated overnight with medium containing 0.8mg of collagenase type IV and varying 
concentrations of FBS. CD4 and CD8 surface expression were measured via flow cytometry the 
following day and percentage change in MFI for both markers was calculated compared to 
untreated cells. 
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 T cell differentiation in healthy skin 4.3.2
To date little is still known about the T cell differentiation in the skin of healthy 
humans. It was therefore necessary to first investigate T cell differentiation 
patterns in the skin of healthy individuals, before being able to assess the state 
of T cell differentiation in the skin of patients with melanoma. The 
characterization of T cell differentiation in healthy skin, based on T cell 
differentiation markers commonly used in the blood, was therefore attempted. 
 Skin derived T cells in healthy individuals express high levels of 4.3.2.1
the tissue retention marker CD69 
First, expression of CD69 was measured in order to verify if cells extracted from 
the skin samples were true skin resident T cells. CD69 is not normally 
expressed on resting T cells in the circulation, but is stably expressed on tissue 
resident T cells, as it is thought to be involved in tissue retention (Ledgerwood 
et al. 2008; Sathaliyawala et al. 2013). Blood derived T cells from healthy 
individuals did not express CD69, whilst 80±8% of CD4+ T cells and 91±5% of 
CD8+ T cells expressed CD69 in the skin (Fig. 4-3A,B). 
To see which of the differentiation subsets in the skin were the most likely to 
express CD69, expression of the receptor was measured in the CD45RA/CD27 
defined differentiation subsets of skin derived CD4+ and CD8+ T cells. In the 
skin CD4+ T cells the CD27 positive subsets (Naïve and TCM) expressed 
significantly lower levels of CD69 than the CD27 negative subsets (TEM and 
TEMRA), as 88±6% of TEM and 92±5% of TEMRA expressed CD69, whilst only 
63±25% of naïve and 60±13% of TCM did so. All CD8+ T cell subsets expressed 
CD69 equally at averages of 87-92%. 
Therefore, the majority of skin CD8+ T cells extracted had characteristics of 
resident T cells, whilst 20% of CD4+ T cells appeared to be transient as they 
were CD69 negative. The majority of these transient CD4+ T cells belonged to 
the naïve and TCM subsets. 
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Fig. 4-3: Ex vivo expression of the tissue retention marker CD69 in skin and blood 
derived T cells in healthy individuals. 
CD69 expression was measured by flow cytometry in blood and skin derived CD4+ and CD8+ T 
cells derived from healthy individuals. 
A: representative flow cytometry histogram showing CD69 expression in matched blood and 
skin derived CD4+ and CD8+ T cells. 
B: Cumulative data showing CD69 expression in CD4+ and CD8+ T cells from the blood (n=26) 
and skin (n=24) of healthy individuals. Mean and standard deviation are shown. 
C: Cumulative data showing CD69 expression in the CD45/CD27 defined subsets of skin 
derived CD4+ and CD8+ T cells from 24 healthy individuals. Mean and standard error are 
shown. Subsets were compared using the Friedman test. 
*=p<0.05; ****=p<0.0001 
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 The majority of healthy skin resident CD4+ T cells have a TEM 4.3.2.2
phenotype, irrespective of age 
As described previously, CD27 and CD45RA are commonly used to identify T 
cell differentiation subsets in the blood. CD27 and CD45RA based subset 
distribution was therefore assessed by flow cytometry in T cells extracted from 
the skin and blood of healthy individuals (Fig. 4-4A).  
No significant age-related changes in subset distribution were observed among 
the skin derived CD4+ T cells, although this might be due to the low number of 
skin donors and high variation between the samples (Fig. 4-4B). The dominant 
skin subset in donors of all ages was found to be the TEM subset, which in 
average constituted 60±15% of CD4+ T cells. A smaller population of TCM cells 
was also present at 32±13%, whilst the CD45RA expressing naïve and TEMRA 
subsets were only detected at minor frequencies (2±3% and 6±5% 
respectively).  
When comparing paired samples in young and old individuals respectively, skin 
derived naïve T cells (p= 0.0023 and 0.0101 for young and old respectively) and 
TCM cells (p=0.0255 and 0.0624) were reduced and TEM (p=0.0007 and 0.0006) 
and TEMRA (p= 0.2889 and 0.0408) increased when compared to matched blood 
samples. 
Therefore, CD4+ T cell differentiation profiles are profoundly altered in the 
healthy skin compared to the blood and are dominated by TEM- like cells in both 
young and old donors. 
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Fig. 4-4: CD4+ T cell subset distribution with age in skin compared to blood in healthy 
donors. 
CD45RA and CD27 expression were measured via flow cytometry in CD4+ T cells of healthy 
blood and skin donors. 
A: Representative flow cytometry plots show CD45RA and CD27 expression in blood and skin 
derived CD4+ T cells obtained from the same healthy donor. The diagram on the right highlights 
the names given to the four subsets. 
B: Relationship with age of subset frequencies in the skin (n=29) and blood (n=35) of healthy 
individuals. Lines of best fit were generated by linear regression and the correlation (r-value) 
and significance were assessed by Pearson and Spearman rank. 
C: Comparison of paired blood and skin T cell subset frequencies in young (n=4; aged 40 and 
younger) and old (n=5; aged 60 and older) healthy individuals. Percentages were compared 
using the paired T test or the Wilcoxon test. 
*=p<0.05; **=p<0.01; ***=p<0.001 
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 CD8+ T cell differentiation patterns are altered in the skin 4.3.2.3
compared to the blood but show all four differentiation subsets 
CD45RA/CD27 subset gates were applied to CD8+ T cells derived from the 
blood and skin of healthy individuals (Fig. 4-5A). As was the case with skin 
derived CD4+ T cells, CD8+ T cell CD45RA/CD27 subset frequency did not 
change significantly with age, although there seemed to be a trend towards 
increased abundance of TCM and decreased TEM in the older age groups (Fig. 
4-5B). TCM and TEM cells comprised on average 34±21% and 33±16% 
respectively, whilst naïve (17±12%) and TEMRA (16±15%) populations were also 
present. Paired blood and skin samples were compared in the young and old 
(Fig. 4-5C). In the young, skin derived CD8+ T cells were found to contain 
significantly less naïve and more TEM cells compared to the blood of the same 
donors (p= 0.0489 and 0.0432, respectively). Similar patterns were observed in 
the old, where they were not significant (p= 0.0724 and 0.0552). 
Therefore, based on their CD45RA/CD27 expression, CD8+ T cells in the 
healthy skin are comprised mainly of TEM and TCM, as well as lower levels of 
TEMRA and naïve-live cells. 
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Fig. 4-5: Change in CD8+ T cell subset distribution with age in skin compared to blood in 
healthy donors. 
CD45RA and CD27 expression were measured via flow cytometry in CD4+ T cells of healthy 
blood and skin donors. 
A: Representative flow cytometry plots show CD45RA and CD27 expression in blood derived 
and skin derived CD8+ T cells obtained from the same healthy donor. The diagram on the right 
highlights the names given to the four subsets. 
B: Relationship with age of subset frequencies in the skin (n=29) and blood (n=35) of healthy 
individuals. Lines of best fit were generated by linear regression and the correlation (r-value) 
and significance were assessed by Pearson and Spearman rank. 
C: Comparison of paired blood and skin T cell subset frequencies in young (n=4; aged 40 and 
younger) and old (n=5; aged 60 and older) healthy individuals. Percentages were compared 
using the paired T test or the Wilcoxon test. 
*=p<0.05; **=p<0.01; ***=p<0.001 
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 T cells in the skin do not display surface receptor patters 4.3.2.4
commonly associated with highly differentiated cells in the blood 
A number of surface marker combinations other than CD27/CD45RA are often 
used on blood derived T cells to distinguish cells at different stages of 
differentiation. This includes combined measurement of CD27 and CD28. T 
cells that express both CD27 and CD28 are thought to be the least 
differentiated, whilst double negative cells, which accumulate with age, are the 
most differentiated. This means that CD27+CD28+ cells typically comprise naïve 
and TCM cells, whilst CD27-CD28- cells include TEM and TEMRA cells. Cells that 
express either CD27 or CD28 are in an intermediate differentiation stage that 
mostly includes TCM (S. M. Henson et al. 2009; Appay et al. 2008).  
CD27 and CD28 coexpression was analyzed in the skin and blood of healthy 
individuals (Fig. 4-6). The majority of skin resident CD4+ (67±10%) and CD8+ T 
cells (44±14%) expressed CD28 but no CD27. Only 21±8% of skin resident 
CD4+ T cells expressed both CD27 and CD28, whilst 11±7% expressed neither. 
Cells that only expressed CD27 but no CD28 were virtually absent among skin 
resident CD4+ T cells (1±1%). Similarly, minor populations of CD27+CD28+ 
(16±8%) and CD27-CD28- (28±10%) cells could be detected among the skin 
resident CD8+ T cells. CD27+CD28- cells were also present among the skin 
CD8+ T cells (16±8%). 
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Fig. 4-6: CD27 and CD28 coexpression in skin and blood derived T cells of healthy 
individuals 
CD27 and CD28 were measured ex vivo by flow cytometry in blood and skin derived CD4+ and 
CD8+ T cells 
A: Representative flow cytometric dot plots showing CD27 and CD28 expression in CD4+ and 
CD8+ T cells derived from the blood and skin of a healthy individual. 
B: Cumulative data showing the distribution of subpopulations defined by CD27 and CD28 
expression in CD4+ (on the left) and CD8+ T cells (on the right) derived from the blood (n=34) 
and skin (n=16) of healthy individuals. Comparisons were made using the Student or paired t-
test. 
*=p<0.05; **=p<0.01; ***=p<0.001; ****=p<0.0001 
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As previously mentioned, KLRG1 and CD57 can also be used to identify highly 
differentiated cells and are increased in the blood on cells of the TEM and TEMRA 
subsets. KLRG1 and CD57 expression were therefore measured in T cells 
extracted from healthy skin and compared to levels in the blood (Fig. 4-7). The 
majority of skin resident T cells were negative for both CD57 and KLRG1 
(85±9% for CD4+ and 65±15 for CD8+ T cells), whilst double-expressing cells 
remained rare in the CD4+ T cells (1±2%) and low in the CD8+ T cells (9±12%; 
Fig. 4-7). Interestingly, a population of CD57+KLRG1- cells among the CD4+ 
(10±6%) and CD8+ T cells (20±10%) was detected in the skin, which was not 
present in the blood, as T cells in the blood cells were unlikely to express CD57 
in the absence of KLRG1.  
Therefore, based on commonly used differentiation-associated markers, the 
majority of skin resident T cells appeared to be of an intermediate (CD27-
CD28+CD57-KLRG1-) differentiation stage. 
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Fig. 4-7: Expression of senescence-associated markers KLRG1 and CD57 in the blood 
and skin T cells of healthy donors. 
KLRG1 and CD57 were measured ex vivo by flow cytometry in blood and skin derived CD4+ 
and CD8+ T cells of healthy donors. 
A: Representative flow cytometric dot plots showing KLRG1 and CD57 expression in CD4+ and 
CD8+ T cells derived from the blood and skin of the same individual. 
B: Cumulative data showing the distribution of subpopulations defined by KLRG1 and CD57 
expression in CD4+ (on the left) and CD8+ T cells (on the right) derived from the blood (n=27) 
and skin (n=21) of healthy individuals. Populations were compared using the Student or paired 
t-tests. 
*=p<0.05; **=p<0.01; ***=p<0.001; ****=p<0.0001 
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 CD45RA/CD27 T cell subsets in the skin have different 4.3.2.5
characteristics to CD45RA/CD27 subsets in the blood 
As described in the previous chapters, CD45RA and CD27 expression patterns 
in blood T cells reliably predict other phenotypic properties. TEMRA cells for 
example do not express CD28 but express high levels of the KLRG1 and CD57 
(Appay et al. 2008). To determine if this was also true in skin derived T cells, 
surface expression of CD28, KLRG1 and CD57 was measured in the 
CD45RA/CD27 subsets of skin derived T cells from healthy individuals and 
compared to the patterns in the blood subsets (Fig. 4-8). 
CD28 expression is known to decrease during differentiation in blood derived T 
cells and is therefore generally found to be highest in the naïve and TCM 
subsets, lower in the TEM and lowest in the TEMRA. It was confirmed that this was 
the case in blood derived CD4+ and CD8+ T cells of healthy individuals (Fig. 
4-8). CD28 expression followed a similar pattern in the skin, where CD28 was 
higher in the TCM cells compared to the TEM and lowest in the TEMRA cells in both 
CD4+ and CD8+ T cells. Interestingly, the majority of the naïve appearing skin 
CD8+ T cells did not express CD28. 
Expression of senescence associated markers KLRG1 and CD57 increases 
gradually with differentiation. Consequently, expression of both markers was 
found to be lowest in naïve and TCM, higher on TEM and highest in TEMRA in 
blood derived CD4+ and CD8+ T cells. However, skin T cell subsets did not 
follow this pattern: CD57 and KLRG1 were not markedly increased in the skin 
TEMRA compared to the other subsets and were particularly low in the TEM 
among of the CD8+ T cell compartment. 
Therefore CD45RA and CD27 surface expression was disconnected from 
senescence associated marker expression in the skin. Further, CD45RA+CD27+ 
naïve appearing CD8+ T cells in the skin are unlikely to be truly naïve as they 
expressed reduced levels of CD28.  
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Fig. 4-8: Expression of markers commonly used to define T cell differentiation in the 
blood in the CD45RA/CD27 subsets in the blood and skin of healthy individuals. 
CD28, KLRG1 and CD57 expression were measured ex vivo in blood and skin derived CD4+ 
(graphs on the left) and CD8+ (graphs on the right) T cell subsets. Naïve, TCM, TEM and TEMRA T 
cell subsets were based on CD45RA and CD27 expression as previously described. The bar 
graphs show means and standard errors. Populations were compared using one-way ANOVA 
or the Friedman test. Participant numbers were as follows for blood and skin donors 
respectively:  26 and 17 for CD28, 32 and 27 for KLRG1 and finally 27 and 21 for CD57 
measurements. 
*=p<0.05; **=p<0.005; ***=p<0.0005; ****=p<0.0001 
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 PD-1 but not CTLA-4 expression is increased in skin T cells from 4.3.2.6
healthy individuals compared to the blood. 
CTLA-4 and PD-1 play major roles in maintaining T cell tolerance and have 
been associated with T cell exhaustion (but not senescence) in various disease 
settings including cancer (Baitsch et al. 2011; Blackburn et al. 2009; 
Duraiswamy et al. 2013). In order to investigate expression of these receptors in 
tissue resident T cells in the absence of melanoma, PD-1 and CTLA-4 
expression were measured in skin derived T cells and compared to the blood of 
healthy individuals (Fig. 4-9). PD-1 expression was significantly increased in 
skin CD4+ and CD8+ T cells (35±18% and 51±18%, respectively) compared to 
the blood (CD4+: 10±6%, p= 0.0002; CD8+: 14±8%, p< 0.0001). Conversely, 
CTLA-4 expression levels were low in the skin and similar to levels in the blood 
in both CD4+ T cells (16±8% in the skin and 20±12% in the blood) and CD8+ T 
cells (5±5% in the skin and 8±7% in the blood). 
In the blood PD-1 and CTLA-4 expression were highest in the subsets of 
intermediate differentiation (TCM and TEM) in both CD4+ and CD8+ T cells (Fig. 
4-10). In the skin, PD-1 expression was increased in all the subsets, but highest 
in the TCM-like subsets, where 46±16% of CD4 and 60±19% of CD8+ TCM 
expressed this marker. CTLA-4 expression in the skin was low in all subsets 
apart from the TCM, where 38±15% of CD4+TCM and 10±6% of CD8+ TCM 
expressed the receptor. 
Therefore PD-1 (but not CTLA-4) was significantly increased in skin derived T 
cells compared to the blood, and the TCM-like subset in the skin expressed the 
highest levels of both these markers. 
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Fig. 4-9 Surface expression of the inhibitory/exhaustion markers PD-1 and CTLA-4 in 
blood and skin derived total CD4+ and CD8+ T cells derived from healthy individuals. 
Extracellular PD-1 expression was measured by flow cytometry ex vivo, intracellular CTLA-4 
expression following overnight stimulation of the cells with immobilized anti-CD3 antibody. 
A: Representative flow cytometry histograms and cumulative data showing PD-1 expression in 
total CD4+ and CD8+ T cells in the blood (n=12) and matched skin (n=12) of healthy individuals. 
Populations were compared using the paired t-test. 
B: Representative flow cytometry histograms and cumulative data showing CTLA-4 expression 
in total CD4+ and CD8+ T cells in the blood (n=19) and skin (n=14) of healthy individuals. 
Populations were compared using the Student t-test. 
Mean and standard deviation are shown. ***=p<0.001; ****=p<0.0001 
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Fig. 4-10: PD-1 and CTLA-4 expression in the CD45RA/CD27 subsets of skin and blood 
derived T cells in healthy individuals. 
PD-1 expression was measured by flow cytometry ex vivo, CTLA-4 expression following 
overnight stimulation of the cells with immobilized anti-CD3 antibody. Participant numbers were 
as follows: 35 blood and 29 skin donors for PD-1 measurements and 19 blood and 14 skin 
donors for CTLA-4 measurements. 
Means and standard error are shown, differences in PD-1 and CTLA-4 expression were 
calculated using one-way ANOVA or the Friedman test. 
*=p<0.05; **=p<0.01; ***=p<0.001; ****=p<0.0001 
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 CD4+ FoxP3+ Tregs in the skin are confined to the TCM subset 4.3.2.7
Suppressive CD4+FoxP3+ Treg cells are known to be important for immune 
tolerance in the skin and it was of interest to understand their phenotypic 
properties in that tissue. Consistent with previous findings (Sanchez Rodriguez 
et al. 2014), FoxP3+ Treg frequency in the CD4+ T cell compartment was 
increased in the skin compared to the blood (9±2% versus 4±2%, p= 0.0019), 
as measured by flow cytometry (Fig. 4-11A,B). Like circulating FoxP3+ Tregs, 
Tregs in the skin were found to be confined to the CD45RA-CD27+ TCM 
compartment but made up only 23±6% of the skin TCM compartment (Fig. 
4-11C,D). Compared to the total CD4+ T cells in the skin, skin FoxP3+ Tregs 
expressed lower levels of CD69 and increased levels of CTLA-4 (Fig. 4-11E). 
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Fig. 4-11 Frequency and phenotypic properties of FoxP3+ Tregs in healthy skin 
Skin and blood derived T cells were analysed by flow cytometry and gating was applied to 
identify total CD4+ T cells and FoxP3+CD25+CD127+ Tregs within the CD4+ compartment. 
A: Flow cytometric dot plot showing frequency of FoxP3+CD127- cells in the blood and skin of 
healthy individuals. 
B: Frequency of FoxP3+CD25+CD127+ Tregs in the CD4+ T cell compartment in samples 
derived from the blood (n=6) and skin (n=5) of healthy individuals. Mean and standard deviation 
are shown. Populations were compared using the t-test. 
C: Flow cytometric dot plot showing CD45RA/CD27 surface expression on skin derived total 
CD4+ T cells and FoxP3+ CD4+ Tregs. 
D: Frequency of TCM among FoxP3+ Treg compartment and of FoxP3+ Treg cells in the TCM 
compartment of skin derived CD4+ T cells (n=4). Mean and standard deviation are shown. 
E: Flow cytometry histogram showing CD69 and CTLA-4 expression in total skin CD4+ T cells 
and FoxP3+ CD4+ Tregs. 
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 The majority of skin resident CD8+ T cells do not express 4.3.2.8
granzyme B or perforin 
Memory cells expressing high levels of the cytotoxic granule components 
perforin and granzyme B can be detected in the blood of healthy individuals and 
are generally associated with a more differentiated phenotype (Henson et al. 
2014). Whilst these cells therefore have low proliferative capacity and reduced 
functional plasticity due to their lineage commitment, they are thought to confer 
immediate protection against infected and malignant cells compared to other 
less differentiated cells types that would need more time to synthesize effector 
proteins upon activation. The expression of cytotoxic granule components and 
markers associated with cytotoxicity have yet to be fully investigated in skin 
resident T cells. 
Intracellular granzyme B and perforin expression were therefore measured in 
the blood and skin derived CD8+ T cells of healthy individuals by flow cytometry 
(Fig. 4-12). Whilst granzyme B and perforin could be detected in blood samples 
in varying amounts ranging from 5-57% and 3-35% respectively, skin CD8+ T 
cells consistently expressed low levels of granzyme B (averaging at 6±3%, 
maximum 11%), and no perforin (2±2%).  
In order to verify that the process of skin cell extraction was not the reason for 
the low levels of perforin and granzyme B measured, immunofluorescent 
staining of frozen skin sections was performed. Staining for either granzyme B 
or perforin together with CD8 confirmed that the majority of skin resident T cells 
did not express granzyme B or perforin in situ (Fig. 4-13). 
 145 
 
Fig. 4-12: Perforin and Granzyme B expression in CD8+ T cells derived from blood or skin 
of healthy individuals. 
A: Representative dot plots showing typical granzyme B and Perforin expression patterns in 
blood and skin derived CD8+ T cells.  
B: Percentage of CD8+ T cells expressing granzyme B or perforin in the skin compared to the 
blood of the same donor. Populations were compared using the paired t-test.  
*=p<0.05 
 
Fig. 4-13: Immunofluorescent staining of healthy skin for granzyme B or perforin and 
CD8+ T cells. 
Immunofluorescence stain performed on frozen sections of healthy skin using CD8 (green), 
DAPI (blue) and either granzyme B or perforin (both red). The white arrow indicates the 
presence of a rare CD8 and granzyme B double positive staining cell. The first row shows full 
staining, whilst the second row shows control stains using only the appropriate 2° antibodies, 
omitting primary antibodies for granzyme B and CD8 (on the left) and antibodies for perforin and 
CD8 (on the right). 
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 Disconnection between CD45RA/CD27 defined subsets and 4.3.2.9
expression of cytotoxic markers in the skin 
Among memory T cells in the blood, perforin and granzyme B expression are 
associated with a highly differentiated phenotype. Cells carrying these cytotoxic 
granule components therefore mainly belong to the TEM and TEMRA phenotypes 
and express low levels of the costimulatory marker CD28 and high levels of the 
senescence-associated marker KLRG1 (Henson et al. 2014; Appay et al. 2008; 
Speiser et al. 1999). It was confirmed that in the blood CD8+ T cells, granzyme 
B expression was highest among the TEM and TEMRA (Fig. 4-14) and was 
strongly associated with low levels of CD28 and high levels of KLRG1 (Fig. 
4-15). Among the skin derived CD8+ T cells, granzyme B and perforin were only 
expressed in a minority of TEMRA cells (16±16% and 12±15% respectively) and 
particularly low in the TEM-like subset (8±10% and 2±5% respectively; Fig. 
4-14).  
Loss of CD28 in skin CD8+ T cells did not correlate with an increase in 
granzyme B as it did in the blood (Fig. 4-15B). Indeed, cells in the skin that 
expressed granzyme B and those that did not comprised equal levels of CD28 
expressing cells (60±12% and 62±15% respectively; Fig. 4-15C). Interestingly, 
granzyme B expressing cells in the skin showed increased levels of KLRG1 
(22±10%) compared to granzyme B negative CD8+ skin T cells (5±4%; 
p=0.0002; Fig. 4-15). However, KLRG1 was not a suitable marker for granzyme 
B expression in the skin, as the majority of Granzyme B expressing skin T cells 
did in fact not express KLRG1. 
CD8+ T cells in the skin therefore appear to have low cytotoxic potential under 
steady state conditions, as they only express low levels of cytotoxic granule 
components. Further, the small fraction of cells expressing granzyme B in the 
skin did not display the surface markers commonly associated with a cytotoxic 
phenotype in memory T cells in the blood. 
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Fig. 4-14: Expression of the cytotoxic granule components granzyme B and perforin in 
the CD8+ T cell subsets derived from the skin and the blood of healthy donors. 
A: Representative flow cytometry dot plots showing the expression of Perforin and Granzyme B 
in the subsets of skin and blood derived T cells. 
B: Histograms showing the frequency of granzyme B and perforin expressing cells in the CD8+ 
T cell subsets in the blood (n= 34) and in the skin (n=17) of healthy volunteers. Mean and 
standard error are shown, populations were compared using one-way ANOVA. 
*=p<0.05; ****=p<0.0001 
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Fig. 4-15: Correlation of surface CD28 and KLRG1 to intracellular granzyme B expression 
in CD8+ T cells derived from skin and blood of healthy individuals. 
A: Representative flow cytometry dot plots showing CD28 and KLRG1 expression in relation to 
Granzyme B expression in blood and skin derived CD8+ T cells. 
B: Correlations between percentage CD28 or KLRG1 expressions with percentage granzyme B 
expression in blood and skin derived CD8+ T cells. Lines of best fit, r values and significance are 
shown. 
C: Cumulative data showing frequencies of CD28 or KLRG1 expressing cells in granzyme B 
positive (GranB+) and granzyme B negative (GranB-) blood and skin derived CD8+ T cells. 
Averages and standard errors are shown. Populations were compared using the paired t-test. 
***p<0.001, ****p<0.0001. 
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  Discussion 4.4
 Optimizing a protocol to isolate T cells from the skin 4.4.1
The fact that isolation of skin resident T cells is technically challenging has long 
hampered advances in skin immunology research. However, a number of 
protocols have been published, most relying on enzymatic digestion or crawl-
out methods. In 2006 Clark and colleagues described a technique yielding in 
average about 250,000 T cells per cm2 of skin, by using a method involving 
culture of skin explants for up to 21 days and harvesting cells spilling out from 
the tissue (Clarket al. 2006a; Clark et al. 2006b). The authors argued that this 
technique yielded unaltered cells and was therefore superior to collagenase 
digestion, which caused degradation of surface markers such as CCR4 and 
yielded on average only around 2 000 T cells per cm2.  
However, culture conditions and relying on a cell’s ability to migrate out of the 
skin sample might affect compositions and phenotypes of cell populations 
harvested. An enzymatic digestion based method was therefore adopted for this 
work in order to reduce the time samples spent in culture. Methods for 
mechanical skin disaggregation were tested to further reduce processing time 
but were found to be unsatisfactory for efficient skin cell recovery. Using an 
optimized method of overnight collagenase-based skin digestion, an average of 
50,000 cells were recovered per cm2 of skin, although this count likely included 
cell types other than T cells due to morphological similarities when viewed 
under the light microscope. Surface marker degradation was prevented reliably 
by increasing the concentration of FBS in the digestion medium from 10% to 
20% as recommended by Mulder and colleagues, who proposed that this would 
block contaminating proteases in the commercial collagenase preparations 
(Mulder et al. 1994). 
It is estimated that a million cells reside in each cm2 of healthy skin under 
steady state conditions (Clark et al. 2006) and the technique used here only 
allowed for the recovery of a fraction of these cells for analysis. However, we 
are confident that the cells recovered (and therefore the data presented here) 
are a reliable representation of skin cells in vivo, as a majority of results 
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matched previously published results and/or were matched by histological 
evidence. 
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 Characterizing skin derived T cells 4.4.2
It is often reported that skin resident T cells are TEM-like (Schenkel and 
Masopust 2014; Natsuaki et al. 2014). The findings described here on healthy 
skin T cells suggest that the majority of skin resident CD4+ and CD8+ T cells 
may appear indeed TEM-like on the basis that most expressed neither CD45RA 
nor CD27. However, further phenotyping revealed high levels of CD28 
expression (commonly found on less differentiated cells) and low levels of 
CD57, KLRG1, granzyme B and perforin, which are commonly associated with 
the TEM subset (Appay et al. 2008) . Therefore, based on the associations made 
in the blood (by us and others) between surface marker expression patterns 
and T cell differentiation, one might deduce that skin resident T cells have an 
intermediate differentiation phenotype. However such projection of rules 
established in the blood onto cells in the skin should be made with care: Cell 
surface markers might have different physiological functions in the tissue and 
correlations made between these markers and cellular differentiation might be 
circumstantial rather than casual, as their role in T cell differentiation is still 
poorly understood. The fact that phenotypic markers established in the blood 
might not hold true in the context of skin resident T cells is supported by our 
observation that the CD45RA/CD27 defined subsets in the skin predicted poorly 
the expression of CD28, KLRG1 and CD57 compared the blood. Similarly, 
markers commonly associated with cytotoxic potential in the blood were not 
applicable to granzyme B expressing cells in the skin.  
The question on how differentiated resting skin resident T cells are therefore 
remains enigmatic. A recent study on mice showed that skin T cells were 
predominantly KLRG1+ during the effector phase shortly after activation, whilst 
the long-lived memory cells remaining after disease resolution were KLRG1-. 
Interestingly, these memory cells were not derived from the dominant KLRG1+ 
population, but instead from a minor KLRG1- memory precursor population 
generated early during infection (Mackay et al. 2013). The predominantly 
KLRG1- memory T cells observed in the healthy human skin might therefore 
similarly be derived from such precursor cells with low differentiation rather than 
more differentiated cells with effector properties. Future experiments should 
include measurements of the telomere length and proliferative capacity of the 
skin resident T cells in order to confirm their relative state of differentiation.  
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PD-1 and CTLA-4 are inhibitory markers involved in immune regulation and 
maintenance of tolerance (Waterhouse et al. 1995; Nishimura et al. 1999). In 
the context of persistent disease, they have also been associated with immune 
exhaustion (Nakamoto et al. 2009; Ahmadzadeh et al. 2009; Pentcheva-Hoang 
et al. 2014). Skin derived T cells displayed significantly increased levels of PD-1 
compared to blood derived cells, whilst CTLA-4 levels were similar between the 
two organs. Previous studies have shown that PD-1 levels are also increased 
(compared to the blood) on T cells in other healthy non-lymphoid tissues such 
as the brain and gastric mucosae (Sadagopal et al. 2010; Saito et al. 2013). 
This suggests that PD-1 may be important in regulating tissue resident T cells in 
the skin and other peripheral organs. 
Despite the often-stated assumption that skin resident T cells are readily poised 
effector cells, granzyme B and perforin expression were low in healthy skin. 
This observation has been made previously by others who confirmed low 
expression of both enzymes at protein and mRNA levels in situ. Interestingly, 
the same authors noted an increase in these molecules in the skin during 
vitiligo, Lichen sclerosus, psoriasis and atopic dermatitis, confirming that T cells 
can express granzyme B and perforin in the skin during inflammatory conditions 
(van den Wijngaard et al. 2000; N. Yawalkar et al. 2001; Hunger et al. 2007). 
Granzyme B is not only important for target cell killing, but can also, when 
secreted, promote inflammation and extracellular matrix degradation and 
threaten skin matrix integrity (Hiebert and Granville 2012). Perforin and 
granzyme B expression might therefore be maintained at low levels in healthy 
skin in order to limit immune-mediated tissue damage. 
Finally, it was noted that the skin is not formed of phenotypically uniform CD4+ 
and CD8+ T cells. The CD4+ T cell compartment for example included a TCM-like 
population, which contained FoxP3+ Treg cells expressing high levels of CTLA-
4 but no CD69. Confirming previous reports, Treg frequency was higher in the 
skin compared to blood (Clark and Kupper 2007; Booth et al. 2010; 
Vukmanovic-Stejic et al. 2013; Sanchez Rodriguez et al. 2014). FoxP3+ Tregs 
are known to have strong immunosuppressive functions and their role in 
maintaining immune tolerance in the skin has been highlighted in knockout 
models in mice (Dudda et al. 2008). Other smaller populations of skin resident T 
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cells that might deserve special attention are the KLRG1-CD57+ cells not 
present in the blood. 
In summary, the results in this chapter suggest that the majority of skin resident 
T cells are at an imbalance with T cells from the blood. They appear to have an 
intermediate differentiation phenotype with low cytotoxic potential and may be 
regulated through surface expression of PD-1. The signals involved in licensing 
skin resident T cells to become potent effector cells will be explored in the final 
results chapter. First, T cell differentiation of melanoma patients’ skin T cells will 
be examined in the following chapter. 
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5 T cell differentiation in the skin of patients with 
melanoma 
 Introduction 5.1
Much research has been devoted to phenotyping melanoma specific cells in the 
circulation, whilst little is known about the T cells in the skin of the patients. This 
is despite the fact that frequency and phenotypes of circulating melanoma 
specific cells do not correlate with disease outcome, whilst immune processes 
in the uninvolved skin as well as lesions of the patients have prognostic value. 
For example, the presence of tumour infiltrating lymphocytes has been shown 
to be a positive prognostic factor in a number of studies (Ladányi et al. 2004; 
Haanen et al. 2005). Similarly, delayed type hypersensitivity responses in 
melanoma vaccination studies were very good indicators of treatment efficacy 
(A. Baars et al. 2000). 
After establishing differentiation marker expression patterns in the skin of 
healthy donors, we therefore investigated if and how differentiation patterns 
might be altered in the skin T cells of melanoma patients. In this study, the 
majority of melanoma skin samples were derived from wide local excision skin, 
as described in Fig. 5-1. Skin specimens available for research were removed 
from the outermost margins of the excision, which was deemed unlikely to 
contain tumour cells. Primary melanoma tissue itself was only available for 
research purposes on very rare occasions (when the lesion had grown very 
large), as these samples were needed for clinical histological grading. 
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Fig. 5-1: Schematic diagram outlining the procedure for obtaining skin from melanoma 
patients for research purposes. 
Step (1): The patient presents a suspicious mole and a biopsy is taken from the site. The biopsy 
is analysed by histology to confirm malignancy. 
Step (2): After confirmation of malignancy (typically 2 weeks after the first visit), the patient 
undergoes surgical removal of a wide area around the melanoma lesion. This wide local 
excision is performed by removing the skin surrounding the primary melanoma in a margin of at 
least 2cm in order to ensure total removal of tumour cells from the skin of the patients. 
Step (3): Skin from the outermost areas of the wide local excision is made available for research 
purposes. 
WLE= wide local excision 
 
 Aims 5.2
The aim of this chapter was to investigate T cell differentiation in uninvolved 
skin and sites of tumour invasion in melanoma patients and compare the 
phenotypes where possible to T cells derived from the skin of healthy controls. 
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 Results 5.3
 Assessing T cell differentiation in the wide local excision skin of 5.3.1
patients with melanoma 
 Imbalance of phenotypic properties between melanoma patient 5.3.1.1
skin and blood T cells 
First, phenotypic properties were compared between the blood and skin of 
patients with melanoma, as skin derived T cells were found to differ markedly 
from their circulating counterparts in healthy individuals (see chapter 4). 
Frequencies of CD45RA and CD27 defined subsets were measured by flow 
cytometry and compared between the blood and the skin of patients with 
melanoma (Fig. 5-2). Compared to the cells in the circulation, skin T cells of 
melanoma patients displayed a significant increase in CD4+ and CD8+ TCM (p= 
0.0002 and p< 0.0001, respectively). This was accompanied by a decrease in 
naïve CD4+ T cells (p< 0.0001) and CD8+ T cells (p= 0.0273), an increase in 
CD4+ TCM (p= 0.0002) and a decrease in CD8+ TEMRA (p= 0.0100). 
In circulating T cells, CD28 expression is lost and KLRG1 expression is gained 
with differentiation. Naïve and TCM in the blood therefore have high CD28 and 
low KLRG1, whilst TEM and TEMRA have low levels of CD28 and high levels of 
KLRG1 (Appay et al. 2008). To determine whether this was also true in skin 
derived T cells from patients with melanoma, matched blood and skin samples 
of patients were analysed via flow cytometry for these markers (Fig. 5-3). Whilst 
blood derived CD4+ and CD8+ T cell subsets of the patients followed the 
expected pattern, TEM and TEMRA cells in the skin expressed high CD28 and 
decreased KLRG1 compared to their circulating counterparts. 
Similarly to previous observations in healthy individuals, melanoma patients 
therefore presented with altered T cell subset compositions in the skin 
compared to the blood and a disconnection was found between the skin T cell 
subsets and markers of differentiation.  
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Fig. 5-2: CD45RA/CD27 subset distribution patterns of CD4+ and CD8+ T cells derived 
from melanoma wide local excision skin compared to the blood of the same donor. 
T cell CD45RA/CD27 subset distributions were measured by flow cytometry in cells derived 
from paired skin and blood samples from patients with melanoma (n=10). 
A: Representative flow cytometric dot plot showing CD45RA/CD27 expression in the blood and 
skin derived CD4+ and CD8+ T cell compartments of the same donor. The diagram on the right 
highlights the names given to the four subsets. 
B: Direct intraperson comparison of skin and blood T cell subset distribution. Populations were 
compared using the paired t-test. 
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Fig. 5-3: CD28 and KLRG1 expression in CD4+ and CD8+ T cell subsets in the skin 
compared to the blood in melanoma patients. 
CD28 (n=3) and KLRG1 (n=9) were measured by flow cytometry in the CD27/CD45RA subsets 
of CD4+ and CD8+ T cells derived from paired blood and skin samples from patients with 
melanoma. Mean and standard deviation are shown. 
Frequencies of positive cells in each subset were compared between blood and skin using the 
paired t-test. 
*=p<0.05; **=p<0.01; ***=p>0.001 
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 CD45RA/CD27 subset distribution is altered in the skin derived T 5.3.2
cells of melanoma patients compared to healthy controls 
Next, CD45RA/CD27 CD4+ T subset distribution was assessed in the skin of 
melanoma patients and compared to healthy controls (Fig. 5-4A). In healthy 
individuals, the skin CD4+ T cells were mostly TEM with a smaller proportion of 
TCM-like cells and this did not change with age. Melanoma patients on the other 
hand displayed an age dependent change in subset distribution by displaying a 
significant decrease of TCM-like cells (p=0.0082) and an increase of TEM-like 
cells (p=0.0069) with age (Fig. 5-4B). Young (aged under 40) melanoma 
patients’ CD4+ T cells showed high levels of TCM-like cells that were significantly 
increased compared to age matched healthy controls (79±11% compared to 
27±9% in healthy; p<0.0001) and this was accompanied by a significant 
reduction in TEM (16±11% compared to 67±11%; p<0.0001) and TEMRA-like cells 
in the patients (0.6±0.6% compared to 5±4%; p=0.0494; Fig. 5-4C). Old 
melanoma patients (aged 60 and above) showed lower levels of TCM compared 
to young patients, but these levels were still increased compared to healthy age 
matched controls (49±18% in old melanoma compared to 32±11% in old 
healthy skin, p=0.0266; Fig. 5-4C). Old melanoma patients also displayed a 
significant decrease in TEMRA-like cells compared to healthy controls (2±2% 
versus 10±9% in healthy; p=0.0182), whilst TEM levels were at similar levels 
(46±19% versus 53±14% in healthy; p=0.2731). 
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Fig. 5-4: CD4+ T cell CD45RA/CD27 subset distribution patterns in the wide local excision 
skin of melanoma patients compared to skin derived cells of healthy controls. 
CD4+ T cell CD45RA/CD27 subset distributions were measured by flow cytometry in cells 
derived from the skin of melanoma patients and healthy controls of all ages.  
A: Representative flow cytometric dot plot showing CD45RA/CD27 expression in the CD4+ T 
cell compartment in skin derived cells of a melanoma patient and a healthy individual. The 
diagram on the right highlights the names given to the four subsets. 
B: Cumulative data showing CD4+ T cell subset distribution with age in skin derived cells from 
melanoma patients (n=17) and healthy controls (n=29). Lines of best fit were generated by 
linear regression and the correlation (r-value) and significance were assessed by Pearson or 
Spearman rank. 
C: Direct comparison of CD4+ T cell subset distribution in melanoma patients and healthy 
controls in the young (aged under 40 years; n=3 for melanoma and n=13 for healthy) or old 
(aged 60 and above; n=8 for melanoma and n=7 for healthy) cohorts. Populations were 
compared using the unpaired T test. 
*=p<0.05; ****=p<0.0001 
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Changes in the CD8+ T cell compartment in the skin of melanoma patients 
resembled those observed in the CD4+ T cells and again, age-dependent 
changes is subset frequencies were found in melanoma patients but not healthy 
controls. In melanoma patients, TCM and naïve-like frequencies decreased (not-
significant and p=0.0181 respectively) and TEM levels increased (p=0.0007) with 
age (Fig. 5-5B). When comparing subset frequencies in patients and controls, 
young melanoma patients’ CD8+ T cells displayed an increase in TCM-like cells 
compared to age matched healthy controls (76±5% compared to 25±14% in 
healthy; p< 0.0001), and this was accompanied by a significant decrease in TEM 
(5±2% vs 39±15%; p=0.0021) and TEMRA-like cells (2±1% vs 17±11; p=0.0384), 
whilst naïve-like cells remained at similar levels (17±4% for melanoma and 
19±11% for healthy young donors). Conversely, old melanoma patients 
exhibited similar levels of subset frequencies as healthy controls, apart from 
displaying a significant decrease of naïve-like cells (11±5% in melanoma 
patients compared to 21±12% in healthy controls; p=0.0495). 
Based on CD45RA/CD27 expression, melanoma patients’ skin derived CD4+ 
and CD8+ T cells therefore appeared to display an increase in TCM-like cells and 
decrease in TEM-like cells compared to healthy controls, particularly at younger 
age. 
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Fig. 5-5: Changes in CD8+ T cell subset distribution patterns in the skin of melanoma 
patients compared to healthy controls 
CD45RA/CD27 subset distributions were measured by flow cytometry in the skin derived CD8+ 
T cells of melanoma patients and healthy controls of all ages.  
A: Representative flow cytometric dot plot showing CD45RA/CD27 expression in the CD8+ T 
cell compartment in skin derived cells of a melanoma patient and a healthy individual. The 
diagram on the right highlights the names given to the four subsets. 
B: Cumulative data showing CD8+ T cell subset distribution with age in skin derived cells from 
melanoma patients (n=17) and healthy controls (n=29). Lines of best fit were generated by 
linear regression and the correlation (r-value) and significance were assessed by Pearson or 
Spearman rank. 
C: Direct comparison of CD8+ T cell subset distribution in melanoma patients and healthy 
controls in the young (aged under 40 years; n=3 for melanoma and n=13 for healthy) or old 
(aged 60 and above; n=8 for melanoma and n=7 for healthy) cohorts. Populations were 
compared using the unpaired T test. 
*=p<0.05; **=p<0.005; ****=p<0.0001 
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 CD45RA/CD27 subset distribution in primary melanoma lesions 5.3.2.1
resembles that of melanoma skin  
Our observations made on T cell phenotypes in the skin of melanoma patients 
were based on wide local excision skin, as this was the tissue most readily 
available. We were also able to obtain tissue from primary melanoma lesions 
from old donors on 3 occasions. We extracted resident T cells from these 
primary lesions via collagenase digestion and measured CD45RA and CD27 
surface expression via flow cytometry.  T cell subset distribution of primary 
melanoma derived cells was compared to cells from wide local excision skin 
and healthy skin of age matched individuals (Fig. 5-6). T cells from primary 
melanoma lesions from old donors displayed similar CD45RA/CD27 expression 
patterns to those from old melanoma wide local excisions and increased TCM 
levels compared to T cells from the skin of old healthy individuals, particularly 
among the CD4+ T cells (p=0.0269). T cell subset distribution in primary 
melanoma lesions therefore appears to follow similar patterns to wide local 
excision skin by displaying an increase in TCM-like cells. However, more primary 
melanoma lesions should be collected in the future to confirm this.  
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Fig. 5-6:  CD27 and CD45RA subset distribution in T cells derived from primary 
melanoma lesions compared to melanoma patient skin from wide local excisions and 
skin from healthy controls. 
Cells were extracted from tissues using collagenase digestion and analysed via flow cytometry. 
All participants were aged 60 or above. CD45RA and CD27 expression was compared between 
CD4+ and CD8+ T cells from primary melanoma lesions (n=3) , melanoma skin from wide local 
excisions (WLE; n=8) and healthy skin (n=7). 
A: Representative flow cytometric dot plots showing CD45RA and CD27 expression in CD4+ T 
cells and CD8+ T cells in the three different conditions. The diagram on the right highlights the 
names given to the four subsets. 
B: Cumulative data showing average percentages and standard deviation of each 
CD45RA/CD27 subset in healthy skin, wide local excision skin and primary melanoma skin.  
Percentages in different conditions were compared using the standard T-test. *=p<0.05 
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 CD28 expression is increased on T cells in the skin of patients 5.3.2.2
with melanoma compared to healthy controls 
CD27 and CD28 are costimulatory markers which are lost on highly 
differentiated cells (Appay et al. 2008). Because we found an increase in CD27 
expressing cells in the skin of patients with melanoma compared to healthy 
controls, we investigated whether this was also true for CD28. We measured 
CD28 expression on the T cells extracted from the skin of patients with 
melanoma and compared levels to the T cells extracted from the skin of healthy 
individuals (Fig. 5-7). Because expression of CD28 did not change with age in 
both patients and controls, participants were compared across all age groups. A 
significant increase of CD28 could be detected among the CD4+ T cells of 
melanoma patients as 96±4% expressed the receptor compared to 89±8% in 
healthy individuals (p=0.0157). CD28 was also increased on the CD8+ T cells of 
some melanoma patients compared to healthy controls but this difference was 
not significant (75±21% compared to 61±14% in healthy individuals; p=0.0693). 
Therefore, like CD27, CD28 was increased on the T cells of patients with 
melanoma. 
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Fig. 5-7: Comparison of CD28 expression in T cells derived from the skin of melanoma 
patients and healthy individuals. 
CD28 expression was measured by flow cytometry ex vivo in T cells derived from the skin from 
melanoma patients (n=7) and healthy controls (n=17) across all age groups. H= healthy skin. 
Mel= melanoma skin. 
A: representative graph and cumulative data showing CD28 expression in CD4+ T cells. 
B: representative graph and cumulative data showing CD28 expression in CD8+ T cells.  
Mean and standard deviation are shown. Cohorts were compared using the standard T-test.  
*=p<0.05 
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 Skin derived CD8+ T cells of melanoma patients show an increase 5.3.2.3
in CD57 and KLRG1 expression. 
As described in the previous chapters, KLRG1 and CD57 are expressed on 
highly differentiated cells in the blood. KLRG1 and CD57 coexpression were 
measured in skin derived T cells of melanoma patients and compared to healthy 
individuals. Although expression of both markers increases with age in blood T 
cells, this was not found to be the case in the skin. Participants were therefore 
compared across all age groups (Fig. 5-8A,B). CD4+ T cells in the skin of 
melanoma patients expressed similar levels of CD57 and KLRG1 compared to 
healthy controls and were predominantly CD57-KLRG1-. Skin derived Skin 
CD8+ T cells from melanoma patients showed a small but significant increase of 
CD57+KLRG1+ expressing cells, as 21±20% of CD8+ T cells were positive for 
both markers among the patients compared to 9±12% in healthy individuals 
(p=0.0169). This was accompanied by a significant reduction in cells not 
expressing either marker (45±18% compared to 65±15%, p=0.0083). 
CD57+KLRG1+ CD8+ T cells were further analysed for CD45RA and CD27 
coexpression in order to determine which T cell subset they belonged to (Fig. 
5-8C). Whilst in healthy skin these CD57+KLRG1+ CD8+ T cells clustered in 
both, the TCM and TEMRA compartments. CD57+KLRG1+ CD8+ T cells in 
melanoma patients belonged predominantly to the TCM compartment. Therefore, 
a significant increase of KLRG1 and CD57 coexpressing cells could be found in 
the skin CD8+ T cells of the melanoma patients. However, these cells belonged 
predominantly to the TCM compartment and not to the TEM or TEMRA 
compartments, which are commonly associated with increased differentiation 
and CD57 and KLRG1 expression in the blood. 
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Fig. 5-8: KLRG1 and CD57 expression in CD4+ and CD8+ T cells derived from the skin of 
melanoma patients and healthy controls. 
CD57 and KLRG1 and other surface markers were measured ex vivo by flow cytometry in cells 
extracted from the skin of melanoma patients (n=21) and healthy controls (n=21).  
A: Representative FACS dot plot showing KLRG1 and CD57 expression in skin CD4+ and CD8+ 
T cells in a healthy individual and melanoma patient. 
B: CD4+ and CD8+ T cells were divided into four subgroups according to KLRG1 and CD57 
expression and frequencies of each subgroup were compared between patients (n=7) and 
healthy controls (n=21) using the Student t-test. 
C: CD45RA/CD27 subset distribution of CD57+KLRG1+ CD8+ T cells in the skin of healthy 
individuals and patients with melanoma. Horizontal bars in grey highlight significant differences 
in the melanoma patients’ subset frequencies, calculated using one-way ANOVA. 
Mean and standard deviation are shown. Differences between patients and healthy controls 
were compared using the Student T-test or the Mann-Whitney test. *=p<0.05; **=p<0.005 
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 PD-1 is increased in the skin of young but not old melanoma 5.3.2.4
patients compared to healthy controls. 
PD-1 is an inhibitory marker often associated with immune exhaustion and with 
reduced T cell function in anti-tumour immune responses (Chapon et al., 2010). 
Surface expression of the inhibitory marker PD-1 was measured on skin derived 
T cells from melanoma patients and healthy controls via flow cytometry (Fig. 
5-9).  In healthy individuals, PD-1 increased with age on skin T cells (p=0.0060 
for CD4+ and p=0.0017 for CD8+ T cells). Young melanoma patients were 
therefore found to have significantly increased PD-1 expression compared to 
healthy controls (31±14% versus 54±8%; p=0.0177 for CD4+ T cells and 
38±14% versus 67±8%; p=0.0039 in the CD8+ T cells), whilst PD-1 was not 
increased further in old melanoma patients compared to healthy age matched 
controls (49±8% of CD4+ and 65±18% of CD8+ T cells in old healthy individuals 
expressed PD-1, compared to 51±20% of CD4+ and 60±19% of CD8+ T cells in 
old melanoma patients). 
This meant that although PD-1 levels were high on skin derived T cells of 
melanoma patients across all age groups, PD-1 levels were only significantly 
increased compared to healthy controls in the younger age groups. 
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Fig. 5-9 Ex vivo PD-1 expression in CD4+ and CD8+ T cells derived from the skin of 
melanoma patients and healthy controls. 
Surface PD-1 expression was measured by flow cytometry in T cells derived from the skin of 
melanoma patients and healthy controls. H= healthy skin. Mel= melanoma skin. 
A: Representative histograms showing PD-1 expression in CD4+ and CD8+ T cells derived 
from the skin of young and old melanoma patients and healthy controls. 
B, D: Percentage of PD-1 expressing cells by age in the CD4+ and CD8+ T cells derived from 
the skin of melanoma patients (n=19) and healthy controls. Lines of best fit were generated by 
linear regression and the correlation (r-value) and significance were assessed by Pearson rank. 
C, E: Percentage of PD-1 positive cells in the CD4+ and CD8+ T cells derived from the skin of 
young (aged under 40) melanoma patients (n=3) and healthy controls (n=13) and old (aged 60 
or above) melanoma patients (n=10) and healthy controls (n=7). 
*=p<0.05; **=p<0.005 
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 CTLA-4 expression is increased in CD4+ and CD8+ T cells in the 5.3.2.5
skin of patients with melanoma 
Similar to PD-1, CTLA-4 is a receptor associated with immune regulation and 
immune exhaustion and with reduced T cell function among melanoma 
infiltrating T cells (Curran et al. 2010). CTLA-4 was measured on stimulated 
CD4+ and CD8+ T cells extracted from the skin of melanoma patients and levels 
were compared to cells from healthy skin. Due to the low numbers of 
participants, it was not possible to assess differences of expression with age 
and participants were therefore compared across all age groups. We found that 
CTLA-4 expression was significantly increased in both CD4+ and CD8+ T cells 
of melanoma patients compared to healthy controls. 44±26% of melanoma 
patients’ CD4+ T cells expressed CTLA-4 compared to only 16±8% of CD4+ T 
cells in healthy controls (p=0.0012). In healthy skin, only 5±5% of CD8+ T cells 
express CTLA-4, which was increased to 23±26% in melanoma (p=0.0023). 
CTLA-4 expressing CD4+ and CD8+ T cells were further analysed for their 
CD45RA and CD27 expression in order to identify if they were more likely to 
associate with a particular differentiation subset. Indeed, CTLA-4+ T cells were 
detected more frequently in the TCM and TEM subsets than the Naïve and TCM 
subsets. CTLA-4 was therefore increased on the skin T cells of patients with 
melanoma. 
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Fig. 5-10: Comparison of CTLA-4 expression in T cells derived from the skin of melanoma 
patients and healthy individuals. 
CTLA-4 expression was measured following overnight stimulation with immobilized anti-CD3 
antibody in the skin from melanoma patients (n=6) and healthy controls (n=14) across all age 
groups. H= healthy skin. Mel= melanoma skin. 
A: representative graph and cumulative data showing CTLA-4 expression in CD4+ T cells. 
B: representative graph and cumulative data showing CTLA-4 expression in CD8+ T cells.  
C: CD45RA/CD27 subset distribution of CTLA-4 expressing CD4+ and CD8+ T cells in the skin 
of healthy individuals and patients with melanoma. Horizontal bars in grey highlight significant 
differences in the melanoma patients’ subset frequencies, calculated using one-way ANOVA. 
Mean and standard deviation are shown. Melanoma and healthy cohorts were compared using 
the Student t-test.  
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 CD69 expression is decreased in the skin of patients with 5.3.2.6
melanoma across all age groups 
We next examined cell surface expression of CD69, a marker for tissue 
retention, in the CD4+ and CD8+ T cells derived from the skin of melanoma 
patients and healthy controls using flow cytometry (Fig. 5-11). CD69 expression 
did not change significantly with age but was significantly decreased in 
melanoma patients compared to healthy controls. 58±14% of CD4+ T cells of 
melanoma patients expressed CD69 compared to 80±8% in healthy controls 
(p< 0.0001), as did 66±19% of CD8+ T cells in melanoma patients compared to 
91±5% among controls (p< 0.0001). 
As CD69 negative cells in tissues are thought to be more mobile compared to 
those that express the receptor (Mackay et al. 2013), we asked next whether 
the CD69 negative cells in melanoma patients were phenotypically distinct from 
the CD69 positive cells. CD27, PD-1 and KLRG1 surface expression were 
compared between CD69 positive and CD69 negative cells in the melanoma 
patients (Fig. 5-12). In the CD4+ T cells of melanoma patients, CD69 negative 
cells expressed significantly more CD27 (p< 0.0001) and less PD-1 (p< 0.0001), 
whilst KLRG1 expression was similar between the two populations. Conversely, 
CD69 negative cells of the CD8+ skin T cells of melanoma patients displayed no 
change in CD27 expression compared to CD69 positive cells, whilst showing a 
significant reduction in PD-1 (p< 0.0001) and increase in KLRG1 (p=0.0026). 
Therefore T cells in the skin of melanoma patients showed an increase in cells 
negative for the tissue retention marker CD69 compared to healthy controls. 
These CD69 negative cells expressed less PD-1, and more CD27 among the 
CD4+ and more KLRG1 among the CD8+ T cells compared to CD69 negative 
cells. 
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Fig. 5-11: CD69 expression on skin derived CD4+ and CD8+ T cells in melanoma patients 
compared to healthy controls 
CD69 expression was measured ex vivo in T cells extracted from the skin of patients with 
melanoma (n=17) or healthy individuals (n=24) across all age groups. H= healthy skin. Mel= 
melanoma skin. 
A: Representative graph and cumulative data showing CD69 expression in CD4+ T cells. 
B: Representative graph and cumulative data showing CD69 expression in CD8+ T cells.  
Mean and standard deviation are shown. Cohorts were compared using the standard T-test.  
**=p<0.005 
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Fig. 5-12 Comparing CD27, PD-1 and KLRG1 expression between CD69 positive and 
CD69 negative CD4+ and CD8+ T cells derived from the skin of melanoma patients. 
Surface receptors were measured by flow cytometry in cells extracted from the skin of 
melanoma patients of all ages. Statistical differences of surface marker expression between 
CD69 positive and CD69 negative cells were calculated using the paired T-test or Wilcoxon test. 
**=p<0.005; ****=p<0.0001 
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 Skin CD8+ T cells in patients with melanoma have low cytotoxic 5.3.2.7
potential 
The cytotoxic granule components perforin and granzyme B are thought to be 
important for tumour cell killing (Medema et al. 2001; Cullen et al. 2010). We 
assessed intracellular expression of these proteins in skin derived T cells of 
melanoma patients by flow cytometry and compared measurements to healthy 
controls.  
Although granzyme B and perforin expressing T cells increase in frequency with 
age in the circulation, this was not found to be the case in the skin in both 
healthy and patients groups. We therefore compared expression in CD8+ skin T 
cell of participants across all ages (Fig. 5-13). Whilst only 8±5% of skin resident 
CD8+ T cells expressed granzyme B in healthy individuals, 23±6% CD8+ T cells 
in melanoma patients were positive for this protease (p< 0.0001). Conversely, 
perforin expression was found to remain low in melanoma patients’ skin (4±3%) 
and at a similar level to healthy individuals (3±3%; p=0.1915).  
To test how these results based on wide local excision skin compared to 
cytotoxic potential in primary lesions, we performed histological staining for 
granzyme B or perforin in combination with CD8 on a primary melanoma 
section of a lesion. As can be seen in Fig. 5-14, the CD8+ T cells infiltrating in 
this melanoma lesion did not express granzyme B or perforin.  
We were also interested in finding out whether the few granzyme B expressing 
cells in wide local excision skin of melanoma patients showed increased 
differentiation compared to the granzyme B negative cells of the same patients. 
We compared CD27 and CD28 expression by flow cytometry, but did not find a 
significant difference in these receptors levels between granzyme B positive 
and negative CD8+ T cells in the melanoma patients (Fig. 5-15). 
CD8+ T cells in the skin of melanoma patients therefore appeared to express 
more granzyme B but not perforin compared to healthy controls. Further, 
granzyme B expressing cells in the patients maintained high levels of CD27 and 
CD28.  
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Fig. 5-13: Ex vivo expression of the cytotoxic granule components perforin and 
granzyme B in the CD8+ T cells derived from the skin of melanoma patients and healthy 
controls. 
Skin cells were extracted using collagenase digestion and analysed using flow cytometry. H= 
healthy skin. Mel= melanoma skin. 
A: Representative flow cytometry dot plot showing granzyme B and perforin expression in the 
CD8+ T cells extracted from the skin of a melanoma patient and a healthy individual. 
B: Cumulative data showing granzyme B and perforin expression in the skin of melanoma 
patients (n=7) and healthy controls (n=17). Mean and standard deviation are shown. Groups 
were compared using the standard t-test. Participants were from all age groups. 
****=p<0.0001 
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Fig. 5-14: Immunofluorescent staining for granzyme B or perforin in CD8+ cells infiltrating 
a primary melanoma lesion. 
Immunofluorescence staining was performed on frozen sections of a primary melanoma lesion 
using CD8 (green), DAPI (blue) and either granzyme B, shown on the left, or perforin, shown on 
the right (both red).  
 
 
 
Fig. 5-15: CD27 and CD28 expression in granzyme B positive and negative CD8+ T cells 
derived from the skin of healthy individuals and patients with melanoma. 
CD27, CD28 were measured extracellularly and granzyme B intracellularly by flow cytometry in 
CD8+ T cells derived from the skin of melanoma patients (n=7) and healthy individuals (n=17). 
Surface marker expression on granzyme B positive cells was compared to granzyme B negative 
cells using the paired T-test. 
Mean and standard error are shown. 
***=p<0.0005 
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 Discussion  5.4
T cells extracted from wide local excisions of young melanoma patients 
displayed increased expression of the inhibitory receptors PD-1 and CTLA-4 
and the costimulatory receptors CD27 and CD28, whilst showing reduced levels 
of the tissue retention marker CD69 compared to age matched healthy controls. 
Uninvolved skin in old melanoma patients showed similar changes. PD-1 levels 
were high in the T cells of these individuals but not significantly different from 
age matched healthy controls, as healthy individuals expressed increased 
levels of PD-1 with age. Proportions of TCM were decreased in the skin of old 
compared to young melanoma patients. However, cells extracted from the 
primary melanoma of old individuals did display high levels of TCM-like cells, 
suggesting that an increase in TCM is inherent to T cells associated with primary 
melanoma lesions of all ages. This is further supported by published data 
showing high CD27 expression levels (>90%) in T cells of primary melanomas 
(Pepe et al. 2011). 
Perforin and granzyme B are normally absent from T cells in healthy skin. 
However, cells expressing granzyme B and perforin have been shown to occur 
in T cells during vitiligo, which involves autoimmune destruction of healthy 
melanocytes (van den Wijngaard et al. 2000). Further, a retrospective study 
showed that absence of granzyme B in primary melanoma infiltrating T cells 
correlated with occurrence of metastases in draining lymph nodes and distant 
organs (van Houdt et al. 2009). These observations suggest that granzyme B 
and perforin are important for T cell mediated killing of healthy or malignant 
melanocytes in the skin. In this study, 20% of CD8+ T cells in the skin of 
patients with melanoma expressed granzyme B but less than 5% expressed 
perforin. This is interesting, as perforin is absolutely essential for granzyme 
mediated cytoloytic activity (Browne et al. 1999). Therefore, CD8+ T cells in the 
skin of melanoma patients seem to lack effector molecules essential to kill the 
local tumour cells. It is possible that skin resident T cells in the patients 
expressed low intracellular cytotoxic granule components due to recent 
degranulation events. Measurement of perforin mRNA in these cells could 
address this.  
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Acquisition of effector functions such as cytotoxic granule components involves 
differentiation and is associated with phenotypic changes in T cells. In the 
blood, this includes increased expression of KLRG1 and CD57 and a decrease 
in CD27 and CD28 (Speiser et al. 1999; Appay et al. 2008). Resting T cells in 
healthy skin expressed high levels of CD28 and literature suggests that CD28 
can be downregulated in T cells during the inflammatory autoimmune condition 
psoriasis (De Rie et al. 1996). CD8+ T cells in the skin of melanoma patients 
expressed high levels of CD27 and CD28, but also showed increased 
expression of KLRG1,CD57 and granzyme B in absence of perforin. This 
suggests that full maturation to an effector phenotype does not occur in skin T 
cells of melanoma patients. Similar findings on a lack of effective T cell 
differentiation into cytotoxic effectors have been published on CD8+ T cells 
extracted from melanoma lymph node metastases, where the majority of cells 
had a non-differentiated CCR7+CD45RA+CD27+CD28+perforin- phenotype and 
on CD8+ T cells derived from distant metastases, which were 
CD27+CD28+CD57+GranzymeB+ and expressed little or no perforin (Mortarini et 
al. 2003; Wu et al. 2012). The findings in this chapter therefore indicate that 
CD8+ T cells in the skin of melanoma patients fail to mature into potent cytotoxic 
T cells that might mediate tumour cell killing.  
The inhibitory receptors PD-1 and CTLA-4 were found to be significantly 
increased on skin derived CD4+ and CD8+ T cells of patients with melanoma 
compared to healthy controls. Expression of both PD-1 and CTLA-4 on the 
surface of CD8+ T cells has been associated with reduced proliferative capacity 
and cytokine production upon challenge (Duraiswamy et al. 2013). This 
functional state, maintained by inhibitory receptor signalling, is known as T cell 
exhaustion and has been shown to occur in the context of chronic antigen 
stimulation during persistent viral diseases and in a number of tumours 
including melanoma (Ahmadzadeh et al. 2009; Duraiswamy et al. 2013; Baitsch 
et al. 2011). Upon ligation, PD-1 and CTLA-4 are thought to inhibit T cell 
activation through separate intracellular signalling pathways, as dual blockade 
of the receptors shows synergistic effects in vitro and in mouse models in vivo 
(Duraiswamy et al. 2013; Parry et al. 2005; Curran et al. 2010). PD-1 and 
CTLA-4 mediated inhibition might therefore have contributed to the lack of 
 181 
cytotoxic granule components observed in the skin resident T cells in the 
melanoma patients. 
High expression of CD27 and CTLA-4 observed on skin T cells in patients with 
melanoma might also be associated with an increase in Tregs. Skin resident 
CD4+ Tregs are restricted to the CD27 expressing TCM compartment in healthy 
individuals and express high levels of CTLA-4 but low levels of CD69 (see 
section 4.3.2.7). Investigating the frequency and suppressive activity of Tregs in 
the skin of the melanoma patients was beyond the scope of this work because 
of limited sample availability. However, previous reports suggest increased 
levels of CD4+ FoxP3+ Tregs in melanoma patients’ primary lesions and 
metastases (Jacobs et al. 2012). Tregs might therefore contribute to the 
observed increase in TCM in melanoma patients and might inhibit effector T cell 
maturation through CTLA-4 mediated signalling (Takahashi et al. 2000).  
Changes in T cell phenotypes in melanoma patients could be explained by 
increased T cell infiltration and/or local modulation of cells. CD69 is a marker for 
tissue retention in T cells. Mouse experiments have shown that T cells which 
have recently entered the skin during inflammation do not initially express CD69 
but will do so upon memory formation (Mackay et al. 2013). In this chapter, we 
observed a reduction in CD69 expression among skin derived T cells from 
melanoma patients, suggesting an increase in T cell infiltration. The overall 
increase in TCM-like cells that expressed high levels of PD-1, CD27 and CD28 in 
the skin of melanoma patients might therefore be due to preferential recruitment 
from the circulation of cells with this phenotype. However, the CD69 negative 
cells expressed less PD-1 than CD69 positive resident cells in the same patient. 
PD-1 is low on cells in the circulation but increased in skin resident T cells of 
healthy individuals, suggesting that additionally to being recruited, cells 
infiltrating into the skin of the melanoma patients are undergoing local 
modulation, possibly as a result of the skin microenvironment created directly or 
indirectly by the tumour. 
A number of cytokines and chemokines are differentially expressed in stressed 
skin or by melanoma cells and might actively inhibit T cell differentiation or 
promote expression of inhibitory receptors. The immunosuppressive cytokine 
TGFβ is often increased in the tumour microenvironment and can prevent the 
expression of cytotolytic genes in CD8+ T cells or enhance cell death in 
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cyototoxic T cells (D. A. Thomas and Massagué 2005; Cumont et al. 2007). 
Indeed, exogenous addition of TGFβ prevented differentiation and upregulation 
of granzyme B and perforin in melanoma metastases derived stimulated T cells 
in vitro (Wu et al. 2012).  
It is also possible that the stimulatory signals required for cytotoxic 
differentiation are simply not present in the skin of the melanoma patients. 
CD27 can be initially upregulated on T cells upon CD3 ligation, but exposure to 
IL-2 and CD70 ultimately lead to CD27 downregulation (Hintzen et al. 1993; 
Huang et al. 2006). Partial activation through the TCR but suboptimal levels of 
CD70 or IL-2 in the skin of the melanoma patients might therefore explain the 
high levels of CD27 observed on the T cells in this study. Immature dendritic 
cells, which occur in melanoma lesions and normal skin, may be responsible for 
such signals or lack thereof (Polak et al. 2012; Vermi et al. 2003). It would be 
interesting to include staining for IL-2 and CD70 in future histological studies of 
primary melanoma lesions. 
Finally, it should be noted that the skin obtained in this study was generally 
derived from sun exposed sites (such as arms, legs, head and neck) and a 
mixed gender pool in the case of melanoma patient samples and from sun 
protected sites (breast, abdomen) from a healthy volunteer pool that was mostly 
female. It has been shown that sun exposure can alter composition of immune 
cells in the skin and might therefore play a role in the results obtained (Di Nuzzo 
et al., 2009). Other studies however reported no significant difference between 
phenotypes in T cells derived from sun exposed and sun unexposed skin (Clark 
et al. 2006). In order to confirm that the results presented here were not due to 
sun exposure on the melanoma patient skin, the panels used could be repeated 
on skin samples from sun exposed and sun-unexposed sites, preferably within 
the same individual.  
A further point of consideration is the fact that the majority of data described in 
this chapter is based on skin derived from wide local excisions. This skin was 
taken from areas that were declared tumour-free, but might have been 
influenced by soluble factors emitted from the melanoma lesion. This means 
that T cells derived from the skin of wide local excisions are neither completely 
uninvolved, nor directly involved with the tumour. Another factor to consider is 
the effect of wound healing from the biopsy taken within the melanoma lesion 
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prior to performing the wide local excision. However, the striking increase in 
CD27 expressing cells observed in the wide local excision skin in many of the 
patients was also found to occur in T cells in primary melanoma lesions by us 
and others (Pepe et al. 2011), suggesting that this phenomenon is a true 
attribute of melanoma rather than a side effect from the wound healing. 
In summary, the results presented in this chapter indicate increased T cell 
infiltration in the skin of patients with melanoma. These skin derived T cells 
expressed the hallmarks of immune exhaustion, with high levels of 
costimulatory and inhibitory receptors but few cytotoxic granule components. 
This suggests that T cells are being attracted into the skin of patients but are 
unable to undergo full cytotoxic maturation. The following chapter will therefore 
investigate what signals might directly modulate effector functions in skin-
derived T cells (such as inflammatory cytokines or PD-1 signalling). 
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6 Modulation of T cell functionality in the blood and 
skin 
 Introduction 6.1
Standard treatments for melanoma currently rely on surgery, radio- and 
chemotherapy and are often insufficient to treat advance stage disease. Whilst 
melanoma is highly immunogenic and can lead to melanoma specific immune 
responses in the patients, various levels of immune dysfunction may occur, 
such as immune exhaustion and increased frequencies of regulatory cells 
(Robert et al. 2011). Recent years have therefore seen an increasing interest in 
immune based therapies that aim to restore anti-melanoma immune function in 
patients. 
Although many recent clinical trials for melanoma immunotherapies have 
focussed on blocking inhibitory receptors associated with immune exhaustion, 
such as PD-1 and CTLA-4 (Ahmadzadeh et al., 2009, Fourcade et al. 2009), 
these markers were not found to be markedly increased on the surface of 
overall circulating CD8+ T cells in melanoma patients (see chapter 3). Instead, 
we identified increased frequencies of highly differentiated TEMRA cells in the 
blood of old patients, which expressed high levels of effector molecules but 
showed aberrant proliferation and IL-2 production. Although it could not be 
determined whether these cells were melanoma specific, melanoma patients 
might therefore benefit from restoring these functions in this cell subset. The 
highly differentiated TEMRA cells express high levels of p38 and show increased 
proliferation upon p38 inhibition in healthy individuals (Di Mitri et al, 2011). 
TEMRA cells in old melanoma patients might therefore similarly respond to p38 
blockade. The first part of this chapter will therefore address if p38 blockade can 
boost proliferation and cytokine production in the CD8+ T cell compartment of 
old melanoma patients. 
The previous chapters in this thesis have also highlighted that both, melanoma 
and healthy skin CD8+ T cells only express low levels of the cytotoxic granule 
components granzyme B and perforin. Because these molecules are important 
in T cell mediated tumour killing (Medema et al. 2001; Cullen et al. 2010), it was 
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of interest to identify mechanisms that can license skin resident T cells to 
become effective killers. The second part of this chapter therefore investigates 
the role of positive and negative signals that might influence effector functions in 
skin derived T cells. 
 Aims 6.2
The aim of this chapter was to investigate ways to manipulate blood and skin 
derived CD8+ T cells in order to boost T cell function and therefore potentially 
enable anti-tumour immune responses in patients with melanoma. 
 
 186 
 Results 6.3
 Restoring T cell function in blood derived CD8+ T cells of old 6.3.1
melanoma patients 
As described in chapter 3, old melanoma patients showed increased markers of 
highly differentiated TEMRA cells in the circulation compared to healthy controls. 
These cells display high levels of p38 phosphorylation (Fig. 6-1), whose 
signalling is thought to be actively involved in the maintenance of their 
senescent state (Henson et al. 2014). This is supported by the fact that the 
small molecule inhibitor for p38, BIRB 796, which inhibits all four isoforms of 
p38, was previously shown to partially restore proliferation and telomerase 
activity in CD4+ and CD8+ TEMRA cells (Di Mitri et al. 2011; Henson et al. 2014). 
This section therefore explores if p38 blockade can restore TEMRA CD8+ T cell 
function of old melanoma patients. 
 
Fig. 6-1: P38 phosphorylation levels in CD8+ T cell subsets in the blood of melanoma 
patients 
Levels of phosphorylated p38 (pp38) were measured via phosphoflow as described in the 
material and methods section in the CD8+ T cell subsets of patients with melanoma (n=3). The 
antibody used recognizes phosphorylation of the conserved T180/Y182 in all four p38 isoforms: 
α, β, γ, and δ. 
A: Representative flow cytometry histograms showing expression and median fluorescence 
intensity (MFI) for intracellular pp38 levels in CD8+ T cell subsets of a melanoma patient. 
B: Cumulative data showing average and standard error for pp38 MFI, measured in 3 
melanoma patients. 
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 Effect of p38 signalling blockade on T cell proliferation 6.3.1.1
As p38 blockade has previously been shown to reinstate proliferation in highly 
differentiated T cells, it was investigated whether this would also be true for the 
highly differentiated T cells in old melanoma patients (Di Mitri et al. 2011; 
Henson et al. 2014). Proliferation was measured via ki67 expression in total 
PBMCs or sorted CD8+ T cell subsets stimulated overnight with anti-CD3 
antibody in the presence or absence of the p38 inhibitor BIRB796 (Fig. 6-2). 
Cell sorting before stimulation was essential to analyse proliferation in the CD8+ 
T cell subsets, as the expression of the markers used to identify these cells 
(CD45RA and CD27) can be altered after 3 days in culture. A significant 
increase in ki67 was measured in total CD8+ T cells incubated with the p38 
inhibitor (p=0.0055). However, changes in Ki67 expression following p38 
inhibitor treatment in sorted CD8+ T cell subsets varied among patients, with 
some showing an increase and others a decrease in proliferation in TEMRA cells 
following treatment. P38 blockade was therefore shown to boost proliferation of 
total CD8+ T cells in melanoma patients, but did not significantly increase 
proliferation in the TEMRA compartment. 
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Fig. 6-2: Changes in proliferation in response to p38 blockade in blood-derived CD8+ T 
cells derived from old melanoma patients. 
Ki67 expression was measured by intracellular flow cytometry as marker of proliferation in 
whole PBMCs or sorted CD8+ T cell subsets stimulated for 3 days with 0.5µg/ml immobilized 
anti-CD3 in the presence of 500nM of the p38 inhibitor BIRB796 or 0.1% DMSO as control. 
Sorted T cells further required the presence of autologous irradiated antigen presenting cells as 
source of co-stimulation. All participants were old melanoma patients. 
A: Percentage of ki67 expressing cells in total CD8+ T cells. Whole PBMCs were stimulated in 
this assay (n=7). 
B: Percentage cells expressing ki67 in CD8+ T cells subsets. CD8+ CD45RA/CD27 T cell 
subsets of old melanoma patients were FACS sorted and incubated for 3 days with anti-CD3 
and irradiated autologous antigen presenting cells (n=5).  
P38 treated samples were compared to control samples using the paired T-test. 
*=p<0.05; **=p>0.01 
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 p38 signalling blockade enhances IL-2 and IFNγ cytokine 6.3.1.2
production in TEMRA 
As described in the introduction and chapter 3, highly differentiated TEMRA cells 
in melanoma patients and healthy individuals express the lowest levels of IL-2 
out of all the differentiation subsets, whilst maintaining production of effector 
cytokines such as IFNγ and TNFα. We therefore investigated whether p38 
blockade might also affect cytokine production in these cells. 
PBMCs from old melanoma patients were stimulated overnight with immobilized 
anti-CD3 in the presence or absence of the p38 blocking agent and cytokine 
production was measured the following day via intracellular flow cytometry (Fig. 
6-3). Whilst TNFα levels were not significantly altered in any CD8+ T cell 
subsets following p38 blockade, we observed that both IL-2 and IFNγ 
production were significantly enhanced in the TEM and TEMRA subsets following 
treatment (p=0.0151 for TEM and p=0.0122 for TEMRA IL-2 production and 
p=0.0024 for TEM and p=0.0171 for TEMRA IFNγ production). 
Therefore, IL-2 and IFNγ but not TNFα production could be enhanced in 
differentiated CD8+ T cells of old melanoma patients by p38 blockade during 
stimulation. 
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Fig. 6-3: Changes in cytokine production in stimulated, blood-derived CD8+ T cell subsets 
of old melanoma patients following p38 blockade 
PBMCs of old melanoma patients were incubated overnight with immobilized 0.5µg/ml anti-CD3 
and the presence of 500nM of p38 inhibitor BIRB796 or 0.1% DMSO as control. Intracellular IL-
2, IFNγ and TNFα levels were measured via flow cytometry in the CD8+ T cell subsets. 
A: Representative FACS dot plots showing changes in IL-2, IFNγ and TNFα expression in CD8+ 
TEMRA after treatment with the p38 inhibitor compared to the control. 
B,C,D: Cumulative data showing IL-2 (n=7), IFNγ (n=13) or TNFα (n=13) production in CD8+ T 
cell subsets in untreated or p38 inhibitor treated cells. Populations were compared statistically 
using the paired t-test or Wilcoxon test. Mean and standard error are shown. 
*=p<0.05; **p<0.01 
 
 
0 102 103 104 105
6.9
0 102 103 104 105
6.55
0
2
4
6
8
%
 IL
-2
+
- + - + - + - + p38 Block
Naive TCM TEM TEMRA
*
*
A"
B"
Gated&on&CD8+&TEMRA&
An%&CD3"
An%&CD3"
+p38"Block"
IL42&
0 102 103 104 105
1.29
0 102 103 104 105
0.15
0
5
10
15
20
%
 T
N
Fα
+
- + - + - + - + p38 Block
Naive TCM TEM TEMRA
0
10
20
30
40
%
 IF
N
γ+
- + - + - + - + p38 Block
Naive TCM TEM TEMRA
*
**
*
C" D"
TNFα&IFNγ&
0 102 103 104 105
7.07
0 102 103 104 105
4.6
 191 
 p38 signalling blockade enhances degranulation during anti-CD3 6.3.1.3
stimulation 
In the previous chapter, TEMRA cells were also shown to have the highest levels 
of cytotoxic granule components out of all the CD8+ T cell subsets but failed to 
show equally high levels of degranulation as measured by CD107a staining 
following overnight stimulation with anti-CD3. The potential of p38 blockade to 
enhance degranulation in highly differentiated T cells of old melanoma patients 
was therefore investigated. PBMCs from patients were stimulated with anti-CD3 
overnight in the presence of CD107a antibody and in the presence or absence 
of the p38 inhibitor BIRB796. CD107a and granzyme B levels were measured 
by flow cytometry. P38 inhibition during in vitro stimulation was found to cause a 
small but significant decrease in granzyme B (p=0.0391 for TEM and p= 0.0416 
for TEMRA) and a marked increase in CD107a (p=0.0004 for TEM and p=0.0002 in 
TEMRA) in CD8+ TEM and TEMRA of old melanoma patients. 
Therefore, inhibition of p38 signalling during in vitro stimulation resulted in an 
increase in degranulation and might therefore be beneficial in enhancing 
cytotoxic function in highly differentiated TEMRA cells in patients with melanoma. 
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Fig. 6-4 Changes in expression of cytotoxicity markers CD107a and granzyme B in 
stimulated, blood-derived CD8+ T cell subsets from old melanoma patients induced by 
p38 signalling blockade. 
PBMCs from old melanoma patients (n=8) were stimulated overnight with plate-bound 0.5µg/ml 
anti-CD3 in the presence of 500nM of the p38 inhibitor BIRB796 or 0.1% DMSO as control. 
CD107a antibody was added to the cells prior to stimulation. Samples were harvested the 
following day and stained extra- and intracellularly. Percentage cells expressing CD107a and 
granzyme B in CD8+ T cells subsets were measured via flow cytometry. 
A: Representative flow cytometry histograms showing granzyme B and CD107a staining in 
stimulated T cell subsets treated with or without p38 inhibitor. 
B: Cumulative data showing changes in granzyme B and CD107a expression in stimulated p38 
treated CD8+ T cell subsets compared to untreated samples. Treatment groups were compared 
using the paired T-test or Wilcoxon test. Mean and standard error are shown. 
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 Increasing cytotoxic potential in skin derived T cells 6.3.2
Results shown in previous chapters indicate that although old melanoma 
patients present with increased T cell differentiation in the blood, T cells in their 
skin fail to differentiate into cytotoxic effectors. Cytotoxic granule components 
are important for T cell mediated tumour cell killing (Browne et al. 1999), but T 
cells in healthy skin do not normally express perforin or granzyme B. We 
therefore explored what signals might influence cytotoxic maturation of T cells in 
the skin in order to identify mechanisms that might boost T cell function in the 
skin of patients with melanoma. First, we investigated the role of inflammatory 
cytokines and then the role of PD-1 signalling in the cytotoxic maturation of skin 
resident T cells. Because skin from patients with melanoma was not available in 
sufficient amounts to perform the assays required, skin from healthy individuals 
was used for this purpose. 
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 IL-2, IL-15 and CD3/CD28 induce granzyme B and perforin 6.3.2.1
expression in skin T cells in vitro 
Although cytotoxic effector-like T cells are not present in healthy skin, previous 
studies have shown that T cells bearing cytotoxic granule components are 
present in this organ under certain inflammatory conditions (van den Wijngaard 
et al. 2000; Yawalkar et al. 2001). We therefore hypothesised that the 
inflammatory cytokines IL-2 and IL-15 as well as strong signalling through the 
CD3 and CD28 receptors may induce cytotoxic maturation in skin resident T 
cells, especially as these signals have previously been shown to induce 
cytotoxic T cell functions in blood-derived cells (Salcedo et al. 1993; Alves et al. 
2003; Geginat et al., 2003).  
In order to test whether these signals would also induce granzyme B and 
perforin expression in T cells derived from the skin, PBMCs or skin derived cells 
were incubated with recombinant TNFα, IL-2 or IL-15 or CD3/CD28 beads. After 
4 days in culture, intracellular perforin and granzyme B were analysed by flow 
cytometry (Fig. 6-5). 21±15% of untreated blood-derived CD8+ T cells were on 
average granzyme B positive and remained unchanged after treatment with 
TNFα, but increased slightly to 26±16% in cells treated with IL-2 (p=0.0017) and 
to 34±16% in cells treated with IL-15 (p=0.0001), as well as showing a very high 
increase to 68±30% after treatment with anti-CD3/CD28 (p=0.0001). Granzyme 
B expression in skin derived T cells averaged 10±7% and was also unaffected 
by TNFα but increased to 19±11% after treatment with IL-2 (p=0.0042), to 
37±20% with IL-15 (p=0.0006) and to 60±20% in response to anti-CD3/CD28 
stimulation (p<0.0001). 
Perforin expression followed similar patterns but remained overall lower: 
Untreated blood derived CD8+ T cells expressed on average 4±4% perforin and 
this increased to 8±11% after IL-2 (p=0.0371), to 12±15% after IL-15 (p=0.0059) 
and to 12±12% after anti-CD3/CD28 treatment (p=0.0039). Similarly, only 2±2% 
of untreated skin CD8+ T cells expressed perforin, but this increased slightly to 
3±4% after IL-2 (p=0.0078) and to 4±4% after IL-15 (p=0.0039) treatment and 
increased greatly to 19±17% after anti-CD3/CD28 treatment (p=0.0078). 
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Although not expressing perforin and granzyme B under steady state, skin 
derived T cells were therefore shown to upregulate these cytotoxic granule 
components given the appropriate signals in vitro. 
 
 
 
Fig. 6-5: Changes in Granzyme B and Perforin expression in blood and skin-derived CD8+ 
T cells of healthy individuals in response to cytokines or anti-CD3/CD28 stimulation. 
PBMCs or collagenase digested skin samples from healthy individuals were incubated for 4 
days in the presence or absence of 5ng/ml IL-2, 10ng/ml IL-15, 10ng/ml TNFα or anti-
CD3/CD28 microbeads, before being analyzsed by flow cytometry.  
A, C: Representative histograms for granzyme B and perforin expression in blood and skin 
derived CD8+ T cells following incubation with the various stimuli. 
B: Cumulative data showing average granzyme B expression following the various treatments 
in the CD8+ T cells derived from the blood (n=12) and skin (n=10) of healthy donors 
D: Cumulative data showing average perforin expression following the various treatments in the 
CD8+ T cells derived from the blood (n=10) and skin (n=9) of healthy donors. 
Data was analysed by one-way ANOVA. 
*=p<0.05; **p>0.01, ***p>0.001, ****p>0.0001 
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 Skin derived T cells acquire granzyme B in the absence of 6.3.2.2
proliferation 
Increased frequencies of granzyme B expressing cells can be caused by 
proliferation of cells that already express the marker or alternatively by an 
increase of granzyme B expression in cells that previously did not. In order to 
test which of these cases was true in skin derived T cells, cells were labelled 
with CFSE before stimulation with IL-2, IL-15 or CD3/CD28 for 4 days (Fig. 
6-6A). 
The percentage of proliferating cells among the granzyme B expressing skin 
CD8+ T cells was compared to the relative increase (compared to the untreated 
control) in granzyme B expressing cells for each treatment (Fig. 6-6B). 
Proliferation among the granzyme B expressing cells remained low, with only 
6±4% of IL-2, 5±4% and 22±3% of granzyme B treated cells showing reduced 
CFSE in response to IL-2, IL-15 and anti-CD3/CD28 bead treatment 
respectively. These proliferation rates were lower than the relative gain in 
granzyme B expressing cells, which were 16±5% for IL-2, 30±5% for IL-15 and 
35±15%. The increase in granzyme B expression among skin T cells was 
therefore not due to increased proliferation of granzyme B expressing cells. 
Instead, it seems that IL-2, IL-15 and anti-CD3/CD28 stimulation induced 
granzyme B expression in the majority of skin cells de novo. 
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Fig. 6-6: Proliferation among granzyme B expressing cells derived from the skin of 
healthy individuals, after stimulation with IL-2, IL-15 or anti-CD3/CD28 
CFSE labelled skin derived cells were cultured for 4 days in the presence of 5ng/ml IL-2, 
10ng/ml IL-15 or anti-CD3/CD28 beads. Loss of CFSE staining indicates cell proliferation. 
A: Representative flow cytometry scatter dot plots showing CFSE and Granzyme B staining in 
skin derived CD8+ T cells following treatment. 
B: Cumulative data showing the increase of granzyme B expressing cells per treatment relative 
to the unstimulated control (in black) compared to the percentage of proliferating cells amongst 
total Granzyme B expressing CD8+ T cells (in grey) in samples derived from the skin (n=3). 
Populations were compared using the paired T-test. Mean and standard error are shown. 
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 The role of PD-1 signalling in T cell function in the skin 6.3.3
Whilst skin resident CD8+ T cells of melanoma patients and healthy controls 
expressed low levels of cytotoxic granule components, levels of the inhibitory 
receptor PD-1 were high among these cells. We therefore hypothesised that 
PD-1 signalling might play a role in blocking acquisition of effector functions in 
skin resident T cells. In order to explore the role of PD-1 signalling in skin T cell 
function, skin derived T cells were treated with anti-PDL-1 and PDL-2 blocking 
antibodies during anti-CD3 stimulation in vitro. A suboptimal dose of 0.05µg/ml 
of plate coated anti-CD3 antibody was chosen for this purpose as previous 
studies have shown that saturating conditions of TCR activation may overcome 
the effects of PDL-1 blockade (Freeman et al. 2000). 
The production of granzyme B and perforin as well as proliferation were 
analysed in blood and skin derived CD8+ T cells in response to PD-1 ligand 
blockade. Again, these assays used cells derived from healthy skin due to a 
lack of sufficient amounts of skin of melanoma patients. Additionally, skin blister 
cells were used and skin samples obtained by collagenase digestion needed to 
undergo FACS sorting due to the technical implications discussed below.  
 Skin debris interferes with functional assays 6.3.3.1
Collagenase digestion allows the generation of single cell suspensions of 
immune cells that can be manipulated in vitro. Whilst cells extracted using this 
method responded to soluble or microbead-based stimuli, these cells did not 
respond to stimuli that relied on cell-to-cell contact or contact with plate-bound 
antibody. The reason for this was found to be the high amount of debris present 
in the cell preparations (Fig. 6-7A). 
Further filtration, magnetic-bead based sorting and density gradient 
centrifugation techniques (using Ficoll or Percoll) were tested, but did not yield 
the desired debris-free single cell suspensions required (data not shown). 
Finally, FACS-based sorting of live CD3+ and antigen presenting cells was 
found to successfully isolate viable cells that could be used for PD-1 ligand 
blocking assays (Fig. 6-7B). Simultaneously to using FACS-sorted skin cells, we 
tested PD-1 ligand blockade on skin suction blister derived cells, as this method 
also allowed effective isolation of viable, debris-free immune cells from human 
skin without the need for cell sorting. 
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Fig. 6-7: Effect of skin debris on functional assays. 
Cell suspensions extracted via collagenase digestion from healthy skin underwent FACS-based 
cell sorting in order to remove skin debris. Sorting involved selection of viable cells suitable for 
functional assays via staining using a live/dead dye, anti-CD3 antibodies and a cocktail of 
antibodies selecting for antigen presenting cells in the skin as described in detail in the material 
and methods section. Skin samples were obtained from healthy donors. 
A: Comparison of forward scatter (FSC-A)– side scatter (SSC-A) profiles of skin cell 
preparations before and after cell sorting. 
B: Whole digested skin or FACS sorted digested skin cells from a healthy individual were 
incubated for 3 days in the presence of 0.05µg/ml plate-bound anti-CD3 antibody. Intracellular 
Ki67 staining was performed as measure of proliferation. 
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 Granzyme B expression is increased in stimulated skin CD8+ T 6.3.3.2
cells after PDL-blockade. 
After optimizing conditions to successfully stimulate skin-derived T cells in vitro 
in a contact dependent manner, we tested whether blockade of the PD-1 
ligands PDL-1 and PDL-2 during T cell stimulation might influence cytotoxic 
granule component production in skin derived T cells. For this purpose, we 
stimulated PBMCs, blister-fluid derived cells and sorted skin cells from healthy 
individuals with anti-CD3 antibody in the presence of PDL-1 and PDL-2 blocking 
antibodies or the appropriate isotype control. After 3 days of stimulation, 
intracellular levels of granzyme B and perforin were measured using flow 
cytometry in the CD8+ T cells and treatment groups were compared statistically 
(Fig. 6-8). 
Granzyme B was significantly increased after PD-1 ligand blockade compared 
to the isotype control in CD8+ T cells derived from the blood (p= 0.0198), blister 
(p=0.0316) and skin (p= 0.0170). Conversely, perforin was only significantly 
increased after PD-1 ligand blockade in blood derived CD8+ T cells (p= 0.0234), 
but not in blister or skin derived cells. 
Therefore, PD-1 signalling seems to negatively regulate granzyme B expression 
in stimulated skin derived CD8+ T cells. 
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Fig. 6-8: Granzyme B and perforin expression after PD-1 ligand blockade in CD8+ T cells 
derived from blood, blister fluid or skin of healthy individuals. 
Whole PBMCs, whole blister cells and sorted skin cells (sorted for CD3 positive and antigen 
presenting cells; described in detail in the material and methods section) from healthy donors 
were stimulated with 0.05µg/ml plate coated anti-CD3 antibody in the presence of 10µg/ml of 
anti-PDL-1 and anti-PDL2 antibodies or isotype control antibody. Cells were harvested after 3 
days of stimulation and stained for flow cytometric analysis. Perforin and granzyme B were 
detected using intracellular staining. 
A: Representative flow cytometry plot showing Granzyme B expression in anti-PDL or isotype 
treated, stimulated CD8+ T cells derived from blood, blister or skin of healthy donors. 
B: Cumulative data showing changes in Granzyme B expression in anti-PDL treated CD8+ T 
cells compared to isotype controls derived from the blood (n=8), blister (n=3) and skin (n=6). 
C: Representative flow cytometry plot showing Perforin expression in anti-PDL or isotype 
treated, stimulated CD8+ T cells derived from blood, blister or skin of healthy donors. 
D: Cumulative data showing changes in Perforin expression in anti-PDL treated CD8+ T cells 
compared to isotype controls derived from the blood (n=8), blister (n=3) and skin (n=6). 
Treatment and control groups were compared using the paired T-test or Wilcoxon test. 
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 Effects of PD-1 blockade on T cell proliferation  6.3.3.3
PD-1 is an inhibitory receptor that downmodulates contact-dependent signalling 
during T cell activation (Freeman et al. 2000). In order to find out if PD-1 
regulates functions other than cytotoxic granule formation in skin derived T 
cells, CD8+ T cell proliferation was also examined in the context of PD-1 ligand 
blockade. Proliferation was therefore measured indirectly via flow cytometric 
detection of intracellular Ki67 levels in stimulated blood, blister and skin derived 
T cells (Fig. 6-9). 
Ki67 levels were compared between anti-PDL-1/anti-PDL-2 or isotype treated 
cells in the CD8+ T cell compartment in various tissues. Whilst blood derived 
CD8+ T cells of half of the donors responded to PD-1 ligand blockade by 
showing increased proliferation, no overall significant difference was detected in 
the proliferation in blood CD8+ T cells after incubation with PDL-1 and PDL-2 
blocking antibodies. Further, PD-1 ligand blockade did not affect ki67 levels 
significantly in the CD8+ T cells derived from blisters or skin. Unlike granzyme B 
expression, proliferation was therefore not affected by PD-1 signalling in skin 
derived CD8+ T cells. 
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Fig. 6-9: Proliferation in response to PD-1 ligand blockade in stimulated CD8+ T cells 
derived from blood, blister fluid or skin of healthy individuals. 
Whole PBMCs, whole blister cells and sorted skin cells (sorted for CD3 positive and antigen 
presenting cells; described in detail in the material and methods section) from healthy donors 
were stimulated with 0.05µg/ml plate coated anti-CD3 antibody in the presence of 10µg/ml  of 
anti-PDL-1 and anti-PDL-2 antibodies or isotype control. Cells were harvested after 3 days of 
stimulation and stained for flow cytometric analysis. High intranucellular levels of ki67 were 
used as markers for proliferation. 
A: Representative flow cytomtry plot showing Ki67 expression in anti-PDL or isotype treated, 
stimulated CD8+ T cells derived from blood, blister or skin of healthy donors. 
B: Cumulative data showing changes in Ki67 expression in anti-PDL treated CD8+ T cells 
compared to isotype controls derived from the blood (n=8), blister (n=3) and skin (n=6). 
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 PDL-1 and PDL-2 expression in the skin 6.3.3.4
After having shown that PD-1 expression is high on skin derived CD8+ T cells in 
healthy individuals and melanoma patients, and that PD-1 signalling might 
regulate their function, we investigated PD-1 ligand expression in the skin. For 
this, frozen sections of skin biopsies from healthy individuals and primary 
melanoma lesions were stained separately by immunohistochemistry using 
antibodies against the PD-1 ligands PDL-1 and PDL-2. 
Expression of PDL-1 and PDL-2 was considered in young and old healthy 
individuals separately, as PD-1 expression on healthy skin resident T cells was 
previously found to be age-dependent (see section 5.3.2.4). PDL-1 and PDL-2 
expressing cells were successfully detected in the skin of some but not all 
healthy individuals, and was restricted to individual cells in the dermis (Fig. 
6-10). Three out of five young and three out of eight old healthy individuals 
presented with PDL-1 positive cells in their skin. The average frequency of PDL-
1 expressing cells in the skin of healthy individuals was 2±2 per mm2 in both 
age groups. PDL-2 expressing cells could be detected in all young skin sections 
and in four out of five old individuals. The average frequency of PDL-2+ cells 
also remained similar between both age groups, with 5±3 PDL-2+ cells per mm2 
in young and 6±5 in old donors. Overall, PDL-2+ cells were found more 
frequently than PD-1+ cells in healthy skin and this difference was significant if 
cell frequencies were compared irrespective of donor age (p=0.0125) 
PDL-1 and PDL-2 expression was also investigated in frozen skin sections of 
primary melanoma lesions of old patients (Fig. 6-11). Primary melanoma 
presented with 27±15 PDL-1+ cells per mm2 compared to 2±2 cells in the skin of 
old healthy individuals (p=0.0108). PDL-2 expression was similarly increased in 
the melanoma patients, who displayed 42±27 PDL-2+ cells per mm2 compared 
to 7±5 in the healthy controls (p=0.0146). Within the primary melanoma lesions, 
PDL-2+ cells were found more frequently than PDL-1+ cells (p=0.0374). 
In summary, PD-1 ligand expressing cells were more abundant in primary 
melanoma lesions than in healthy skin. Further, PDL-2 was more abundantly 
expressed than PDL-1 in both, healthy skin and primary melanoma. 
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Fig. 6-10: PDL-1 and PDL-2 expression in skin sections of young and old healthy donors 
Punch biopsies were taken from the skin of young and old healthy donors and indirect 
immunoperooxidase staining was performed on frozen healthy skin sections for PDL-1 and 
PDL-2 separately. PDL-1 and PDL-2 expressing cells were identified via marked red-brown 
circular staining. 
A: Representative stains for PDL-1 and PDL-2 in skin sections from young and old healthy 
donors. Boxed areas are shown in two-fold magnification in order to highlight individual positive 
staining cells. Only the representative skin section shown for anti-PDL-1 staining in a young 
donor highlights an area of intense staining that was not counted as staining was nut circular. 
B: Cumulative data showing frequency of cells expressing PDL-1 and PDL-2 in the skin of 
young (n=5 for both) and old donors (n=8 for PDL-1 and n=5 for PDL-2).  Scale Bar =100µm 
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Fig. 6-11: PDL-1 and PDL-2 expression in the primary melanoma lesions of old melanoma 
patients compared to age matched healthy controls. 
Indirect immunoperooxidase staining was performed for PDL-1 and PDL-2 on frozen skin 
sections from old healthy individuals and primary melanoma lesions from old patients. PDL-1 
and PDL-2 expressing cells were identified via marked red-brown circular staining. 
A: Representative stainings for PDL-1 and PDL-2 in the skin of healthy donors and lesions of 
melanoma patients. Boxed areas are shown in two-fold magnification in order to highlight 
individual positive staining cells. 
B: Cumulative data showing frequency of cells expressing PDL-1 and PDL-2 in the skin of old 
healthy donors (n=8 and n=5, respectively) and primary melanoma lesions of old patients (n=8 
for PDL-1 and n=10 for PDL-2).  
Patients and controls were compared using the Student t-test, PDL-1 and PDL-2 levels within 
participant groups were compared using the paired t-test. *p<0.05; Scale Bar =100µm 
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 Discussion 6.4
 Restoring circulating TEMRA CD8+ T cell function in melanoma 6.4.1
patients 
P38 signalling is actively involved in maintaining a state of replicative 
senescence in highly differentiated T cells, as previous reports have shown an 
increase in T cell proliferation in CD4+ and CD8+ TEMRA in healthy individuals 
after p38 inhibition (Di Mitri et al. 2011; S. M. Henson et al. 2014). Whilst 
proliferation was boosted after p38 blockade in melanoma patients’ total CD8+ T 
cells when they were stimulated with anti-CD3 in PBMC preparations, this effect 
was not observed in FACS sorted CD8+ TEMRA of all donors. Indeed, some 
donors displayed a decrease in proliferation after p38 blockade. This 
discrepancy in results might be due to the fact that p38 does not control T cell 
proliferation in some patients as it does in healthy controls. Alternatively, 
reduced proliferation in the TEMRA cells of melanoma patients after p38 blockade 
might have been caused by technical constraints of the assay as excessive 
stimulation can cause a decrease in cell viability in vitro (Shi et al. 2013). 
Previous reports mention that blockade of P38 signalling is associated with a 
decrease in TNFα production in T cells of healthy individuals (S. M. Henson et 
al. 2014). Here, TNFα production was not significantly affected by the blockade 
in CD8+ T cells of patients with melanoma. However, melanoma patients’ 
stimulated TEMRA cells displayed increased IL-2 and IFNγ production as well as 
increased degranulation (as measured by CD107a surface detection) upon p38 
blockade. Targeting the p38 pathway might therefore improve functionality in 
the highly differentiated cells in old melanoma patients and might therefore be 
beneficial for improving anti-tumour immune responses.  
It should be noted that growth arrest in senescence is thought to be a 
physiological mechanism to prevent malignancy and blockade of p38 might 
therefore promote tumour growth. Interestingly, a number of melanoma cell 
lines display aberrant intracellular signalling pathways and use p38 signalling to 
promote growth and migration (Estrada, Dong, and Ossowski 2009). P38 
inhibition in melanoma patients might therefore affect the tumour directly as well 
as T cell functions. 
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 Signals inducing a cytotoxic phenotype in skin cells 6.4.2
Skin resident T cells in healthy individuals were shown in previous chapters to 
express no perforin and only low levels of granzyme B. In the skin T cells of 
patients with melanoma an increase in granzyme B but not in perforin was 
found, suggesting insufficient cytotoxic maturation. This chapter therefore 
explored what signals might contribute to cytotoxic maturation of T cells in the 
skin and confirmed that IL-2, IL-15 and CD3/CD28 stimulation induced 
granzyme B and perforin expression in skin resident T cells in vitro. This is 
consistent with previous findings in the blood that showed acquisition of 
granzyme B and perforin and increased cytotoxic function in T cells cultured 
with IL-2, IL-15 and strong signalling through the TCR/CD3 complex and CD28 
receptor (Janas et al. 2005; Alves et al. 2003; Grossman et al. 2004; Azuma et 
al. 1992) 
The fact that perforin and granzyme B levels were low under steady state 
conditions in healthy skin suggest that these cells are not exposed to sufficient 
amounts of IL-2 or IL-15 to induce cytotoxic granule formation. Indeed, IL-15 
and IL-2 are not normally expressed in healthy skin and the majority of skin 
derived cells only upregulate these cytokines during inflammatory conditions, as 
has been found to be the case for IL-15 in keratinocytes and dermal fibroblasts 
(Han et al. 1999; Rappl et al. 2001; Bouchaud et al. 2013). Similarly, only 
mature but not immature dendritic cells in the skin, such as Langerhans cells, 
will express the CD28 ligands CD80 and CD86 and therefore activate effector T 
cells in a contact dependent manner (Peña-Cruz et al. 2010). 
High expression of IL-15 and IL-2 and presence of activated dendritic cells 
might therefore explain the occurrence of perforin and granzyme B in psoriasis 
lesions (Uyemura et al. 1993; Nestle et al. 1994; Yawalkar et al. 2001; 
Bouchaud et al. 2013). Conversely, T cells detected in melanoma patients might 
only present low levels of cytotoxic granule components due to a lack of these 
cytokines and dendritic cell maturation in the areas within and surrounding the 
tumour (El Marsafy et al. 2009). 
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 The role of PD-1 in controlling skin cells 6.4.3
Results presented in previous chapters showed that although PD-1 expression 
is low in circulating T cells, it is constitutively expressed on a large proportion of 
T cells the skin in healthy individuals as well as patients with melanoma. We 
therefore hypothesized that signalling of this inhibitory receptor might inhibit 
cytotoxic marker expression. In this chapter the inhibitory role of PD-1 in skin T 
cells was confirmed by showing increased granzyme B expression following 
PD-1 ligand blockade during stimulation. However perforin expression and 
proliferation (as measured by ki67 expression) were not affected by the 
treatment. 
This work shows for the first time that PD-1 signalling can control granzyme B 
expression upon activation in human skin cells and is consistent with previous 
findings showing that PD-1 signalling reduces expression of transcription factors 
involved in effector functions (such as Tbet and Eomes) and cytotoxicity in 
circulating CD8+ T cells (Nurieva et al. 2006). Although blockade of the PD-1 
signalling pathway is also often associated with increased proliferation 
(Freeman et al. 2000; Carter et al. 2002), other studies have shown changes in 
T cell function (such as cytokine production) in the absence of proliferation in 
certain animal models or at higher antigen doses (Kuipers et al. 2006; 
Latchman et al. 2001). PD-1 might therefore still regulate proliferation and 
perforin production in skin resident T cells under physiological conditions or 
under experimental conditions other than the one used during this work. 
PD-1 signalling is only effective during stimulation and ligation of PD-1 in 
absence of TCR signalling has no significant effect on T cell functions (Freeman 
et al. 2000). Therefore, PD-1 binding to its ligands is physiologically only 
relevant in the context of concomitant T cell activation. This is consistent with 
our finding that the PD-1 ligands PDL-1 and PDL-2 were only expressed at low 
levels in healthy skin (where T cell activation does presumably not occur), whilst 
being upregulated in melanoma lesions. This work did not discern whether PDL-
1 and PDL-2 were expressed by healthy or malignant cells. Previous studies 
have shown that melanoma cells can express PDL-1 to evade immune 
responses and that inflammatory conditions promote PDL-1 and/or PDL-2 in 
skin derived Langerhans cells and keratinocytes (Peña-Cruz et al. 2010; 
Freeman et al. 2000; Gadiot et al. 2011). Increased PD-1 ligand expression in 
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melanoma lesions may therefore indicate the presence and activation of 
immune cells or tumour immune evasion.  
It should be noted that although the increase in granzyme B expression in skin 
resident T cells after PD-1 ligand blockade was significant, it was not as 
pronounced as in the blood, suggesting that additional mechanisms prevent 
cytotoxic T cell maturation in these tissue resident cells. 
 Points of consideration 6.4.4
One point of consideration is that increased granzyme B and perforin 
expression in vitro do not necessarily translate into increased killing capacity, as 
even cells that do express high levels of cytotoxic granule components might 
show impaired cytolytic activity (Lee et al. 1999). However, identifying 
mechanisms that allow skin resident T cells to acquire cytotoxic granule 
components is a first step in understanding how skin resident T cells in 
melanoma patients can be induced to become effective at killing melanoma 
cells in vivo. 
Whilst cells in healthy skin express only low levels of cytotoxic granule 
components, we identified in this chapter positive and negative signals that 
might control their cytotoxic maturation. The low expression of cytotoxic granule 
components in skin resident T cells of melanoma patients might therefore be 
explained by an imbalance of these signals. 
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7 Overall Discussion 
The results presented in this thesis do not only contribute to our understanding 
of T cell differentiation in the blood and skin of patients with melanoma, but also 
to our appreciation of the phenotypic properties of T cells residing in healthy 
skin. 
 T cells in healthy skin 7.1
 An imbalance between skin and blood T cells 7.1.1
Recent studies have shown that skin resident T cells are phenotypically and 
transcriptionally distinct from cells in the blood and recognize different targets 
(Clark, Chong, Mirchandani, Brinster, et al. 2006; L. K. Mackay et al. 2013). 
However, human skin resident T cells remain poorly characterized to this day. 
This work confirmed that T cells in the skin are at an imbalance with T cells in 
the blood in humans, as both CD4+ and CD8+ T cells are phenotypically distinct 
in both organs. Further, surface markers that define T cell differentiation in the 
blood were not co-expressed in the same manner in skin resident T cells and 
could therefore not be used in the same manner to define skin resident T cell 
differentiation stages. This also suggests that some of these surface receptors 
may have different physiological roles and may be differentially regulated in the 
skin compared to the blood. The role of markers for differentiation, such as 
CD45RA, CD27, CD28, CD57 and KLRG1, should therefore be considered with 
care in the context of tissue resident T cells.  
It is often stated that tissue resident T cells are TEM-like because they lack 
lymph node homing receptors and are at the site of potential pathogen 
encounter, making them important immune sentinels (Jiang et al. 2012; Ariotti et 
al. 2014). However, the data presented in this thesis suggests that skin resident 
T cells are in fact profoundly distinct from circulating TEM. For example, 
circulating TEM readily displayed effector functions such as pre-formed cytotoxic 
granule components, whilst the majority of T cells derived from healthy skin did 
not, although they could be induced to do so in vitro. This, together with the 
observation that skin resident T cells express high levels of the costimulatory 
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receptor CD28 and the inhibitory receptor PD-1, suggests that T cell functions in 
the skin are heavily regulated. 
 The skin as a tolerogenic environment 7.1.2
The concept that the skin is an environment that favours immune telerance over 
activation during steady state conditions is supported by the detection of the 
inhibitory receptor PD-1 on resident T cells as well as the presence of inhibitory 
cell types in the skin. 
The role of PD-1 in peripheral tolerance has been highlighted in PD-1 knock out 
mice that developed spontaneous systemic autoimmunity (Nishimura et al. 
1999). T cells obtained from healthy skin expressed high levels of PD-1, 
suggesting that PD-1 may also be an important factor in skin tolerance. Indeed, 
we observed that PD-1 signalling during CD3 activation decreased acquisition 
of granzyme B in skin derived T cells in vitro. The role of PD-1 in controlling T 
cell functions in the skin has been further exemplified in a mouse model, where 
OVA-expressing keratinocytes upregulated PDL-1 during inflammation and 
were more likely to be killed and contribute to immunopathology when exposed 
to PD-1 deficient compared to wild-type OVA-specific T cells (Okiyama and 
Katz 2014). 
Inhibitory CD4+ FoxP3 Treg cells are also important in immune tolerance in the 
skin and other organs(Dudda et al. 2008) and FoxP3 Treg frequency was found 
to be increased in the skin compared to the blood in this and previous studies 
(Booth et al. 2010; Vukmanovic-Stejic et al. 2013; Sanchez Rodriguez et al. 
2014). Other immunomodulatory cell types in the skin may include immature 
dendritic cells which patrol healthy skin and have been shown to readily 
promote in vitro Treg formation and proliferation rather than effector T cell 
differentiation (Seneschal et al. 2012; Chu et al. 2012). 
The skin is an organ that is constantly exposed to environmental insults, most of 
which might be innocuous or rapidly contained by innate immune mechanisms. 
In order to maintain tissue integrity, it is therefore important to limit immune 
mediated tissue damage through the mechanisms listed above, including PD-1 
signalling. However, during infection or malignancy, mechanisms must exist to 
promote inflammation and induction of T cell effector functions. 
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 Induction of effector T cell responses in the skin 7.1.3
Whilst not expressing perforin and granzyme under steady state conditions, skin 
derived T cells were shown to acquire perforin and granzyme B when exposed 
to IL-2, IL-15 or CD3/CD28 stimulation in vitro. This suggests that skin resident 
T cells can acquire effector functions given the appropriate signals and is 
supported by published observations that confirm granzyme B and perforin 
expression in the skin during autoimmune conditions such as psoriasis and 
vitiligo (van den Wijngaard et al. 2000; Yawalkar et al. 2001). 
The cue for the conversion of resting skin resident T cells to potent effector cells 
might simply be TCR-ligation through antigen recognition on a target cell, but is 
likely to further require costimulatory signals in form of receptors or cytokines 
provided by either target or bystander cells. The importance of cell help for 
effector T cell licensing in the skin has been demonstrated in a recent murine 
graft-versus-host model, where T cell infiltration into the skin graft was not 
sufficient for rejection but required local Langerhans-mediated help for T cell 
mediated killing of the mismatched graft (Bennett et al. 2011). Other cell types 
might also be involved in promoting effector T cell functions in the skin, such as 
activated dermal dendritic cells or keratinocytes, when exposed to danger 
signals (El Marsafy et al. 2009; Igyarta et al. 2011; Kupper 1990). In absence of 
receptor-mediated stimulation, increased local levels of inflammatory cytokines 
might be sufficient to induce effector functions in resident T cells and therefore 
contribute to a tissue-wide state of “readiness” when skin integrity is breached 
(Ariotti et al. 2014). 
A balance of pro- and anti-inflammatory signals therefore seems to determine 
effector function acquisition of T cells in the skin (as visualised in Fig. 7-1). In 
healthy skin, this balance is tilted in favour of the negative signals, possibly by 
virtue of missing inflammatory signals under steady state conditions and high 
prevalence of suppressive Tregs and PD-1. This balance must however be 
shifted in favour of T cell effector maturation in order for CD8+ T cell mediated 
immune responses to occur during infection and malignancy. 
 214 
 
Fig. 7-1: Schematic diagram visualising the proposed model for cytotoxic T cell 
differentiation in the skin. 
In healthy skin, T cells do not express cytotoxic granule components. Positive signals, such as 
TCR stimulation, costimulation with CD28 and inflammatory cytokines such as IL-2 and IL-15 
can induce differentiation into a cytotoxic phenotype. Negative signals such as the inhibitory 
receptor PD-1 and Treg cells may inhibit acquisition of effector functions.  
  T cells in patients with melanoma 7.2
 Lack of effector T cells in the skin of patients with melanoma 7.2.1.1
T cells in the skin of patients with melanoma showed phenotypic differences in 
the skin compared to healthy controls, which might have been caused by 
increased infiltration and/or local modulation of the cells. Interestingly, no 
increase in cytotoxic granule components was observed in the tissue CD8+ T 
cells of the patients. This suggests that a lack of inflammatory signals or 
prevalence of inhibitory signals prevent T cells in the patients from acquiring 
potent effector functions in order to mediate tumour rejection. High expression 
of PDL-1 and PDL-2 on melanoma or melanoma infiltrating cells in the primary 
lesion, as well as high levels of PD-1 expression on melanoma skin T cells, 
suggest that the tumour has hijacked the tolerogenic properties of the skin in 
order to avoid effective T cell activation and killing. Additional inhibitory 
mechanisms might prevent the development of effector functions in the 
melanoma microenvironment: This is supported by reports of increased levels 
of local Tregs, of inhibitory cytokines such as TGFβ and IL-10 and absence or 
lack of maturation of antigen presenting cells (Stene et al. 1988; Toriyama et al. 
1993; Vermi et al. 2003; Jacobs et al. 2012; Díaz-Valdés et al. 2011). In 
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summary, the balance of signals in the skin of patients with melanoma seems to 
be in tilted favour of immune tolerance and therefore prevent acquisition of 
effector molecules in local T cells.  
 T cell differentiation in blood and skin of melanoma patients 7.2.1.2
End stage differentiated and senescent CD8+ TEMRA cells were increased in old 
patients with melanoma and certain functions in these cells could be boosted 
through blockade of p38 signalling during activation. However, the origin and 
role of these cells in melanoma could not be established. Instead, melanoma-
specific T cells recognizing Melan-A and NY-ESO-1 derived peptides had a 
TCM-like phenotype. Similarly, the majority of T cells accumulating in the skin of 
the patients expressed surface receptors consistent with a TCM phenotype. A 
number of these cells also expressed high levels of the inhibitory receptors PD-
1 and CTLA-4, suggesting that these cells were exhausted. 
End stage differentiation, even during senescence, is usually associated with 
high effector functions at the expense of proliferative capacity and generally 
occurs in cells after repeated intermittent stimulation, particularly through strong 
TCR signalling or can be induced by bystander exposure to high levels of IL-15 
(Griffiths et al. 2013; van Baarle et al. 2005; Arne N. Akbar and Henson 2011). 
Exhaustion on the other hand is associated with immune dysfunction, both at 
the level of proliferation and effector functions and is caused by persistent 
stimulation and maintained by inhibitory receptor signalling (Wherry et al. 2007; 
Nakamoto et al. 2009). As the phenotype of skin resident T cells in melanoma 
patients suggests that they belong to the latter, it makes sense to design 
melanoma treatments that diminish inhibitory signalling and simultaneously 
boost acquisition of effector functions.  
 Clinical relevance of this work 7.3
The data presented in this thesis suggests that T cells in the skin of melanoma 
patients fail to differentiate into potent effector cells, therefore potentially 
impairing melanoma cell killing. IL-2, IL-15 or CD3/CD28 ligation were shown to 
induce expression of cytotoxic granule components, whilst PD-1 signalling 
inhibited it, suggesting targets that could be exploited to improve immune 
function in the patients. Indeed, various studies have already examined the 
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efficacy of boosting anti-melanoma immune function through administration of 
IL-2 and IL-15 or blocking antibodies that target inhibitory receptors such as PD-
1: 
Based on promising animal models (Rosenberg et al. 1985), administration of 
IL-2 was one of the first immunotherapies tested as treatment for melanoma. In 
270 metastatic melanoma patients treated with high dose recombinant IL-2, 
16% were partial or complete responders of which 12% remained disease free 
during the follow up period. However, 6 of the patients treated died of treatment 
toxicity (Atkins et al. 1999). Interestingly, frequency of perforin and granzyme B 
expressing cells increased upon treatment with IL-2 in the circulation of patients 
(Leger-Ravet et al. 1994), but IL-2 treatment also induced Treg expansion, with 
patients that showed particular high Treg expansions having worse clinical 
outcome than the other participants (Sim et al. 2014). 
IL-15 has been shown to improve disease outcome in a melanoma mouse 
model where adoptively transferred transgenic melanoma specific CD8+ T cells 
were pre-treated with the cytokine (Klebanoff et al. 2004). IL-15 was also 
efficacious in boosting T cell function in a number of non-melanoma mouse and 
in vitro models (Pagliari et al. 2013). A recent trial in metastatic melanoma 
patients and renal cell carcinoma patients showed that administration of 
recombinant IL-15 was safe and induced lymphocyte redistribution and 
expansion in patients. However, no objective clinical responses were recorded 
after treatment, despite a decrease in tumour metastases sizes in some 
patients (Conlon et al. 2014). It should also be noted however that IL-15 may 
directly act as a growth factor to the malignant cells (He et al. 2004). 
Inhibition of PD-1 signalling in order to boost immune function in melanoma 
patients is the focus of numerous emerging clinical trials that use monoclonal 
blocking antibodies against PD-1 or its ligands. A recent trial showed an 
encouraging 28% complete or partial response rate for advance stage 
melanoma patients after treatment with anti-PD1 and the response lasted for 
over a year in more than half of the responders that were followed up (Topalian 
et al. 2012). In a different study, a 17% response rate was found in melanoma 
patients treated with anti-PDL-1 (Brahmer et al. 2012). 
Combination therapy targeting PD-1 together with other inhibitory receptors 
associated with immune exhaustion such as CLTA-4 and TIM-3 have been 
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reported to rescue anti-tumour T cell responses in mouse models and in vitro 
and might therefore become the next generation of therapeutic targets in 
humans (Curran et al., 2010, Fourcade et al., 2010).  
Anti-melanoma T cell responses are a multistep process that requires activation 
in the lymph node, effective migration into the tumour itself, overcoming 
inhibitory signals within the tumour microenvironment and finally effective killing. 
In this thesis we have shown that T cells in melanoma patients can be impaired 
through different mechanisms in the skin compared to the blood. All these 
factors should therefore be considered carefully when manipulating T cell 
functions in order to treat patients with melanoma effectively. 
 Technical aspects of using flow cytometry 7.4
Because the data presented in this thesis were acquired over a period of 
several years, great care was applied in order to ensure consistency and 
reliability of results obtained. The same series of experiments (such as the 
screening for T cell memory subset frequency in melanoma patient and healthy 
controls) used continuously the same protocol with antibodies matched for 
fluorochrome, clone and manufacturer. Further, the same flow cytometer was 
used for acquisition of similar experiments and all flow cytometry files were re-
analysed prior of the writing of this thesis to assure a consistent gating strategy. 
Pure water was run between FACS tubes during acquisition to avoid spill over 
between samples and dead cells and duplets were excluded during analysis to 
avoid unspecific staining. Where possible, at least 20 000 CD8+ or CD4+ T cells 
were acquired for phenotyping purposes and at least 100 0000 CD8+ T cells for 
enumeration of rare events such as melanoma specific T cells using MHC-
Dextramers, as recommended by Britten and colleagues (Britten et al. 2009). 
However, a certain degree of variation between experiments could not be 
prevented due to unavoidable factors such as the occasional re-calibration of 
the flow cytometer or potential batch variation in the antibodies used. Different 
experiments may have involved the use of different clones for certain markers 
of interest (e.g. CD27 and CD45RA), further accounting for potential variation in 
results obtained in experiments using different antibody panels. 
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 Future work 7.5
 Identifying the source and role of increased TEMRA in old melanoma 7.5.1
patients 
Obtaining clinical follow up data for the patients that participated in this work 
might reveal changes in disease outcome in relation to CMV status and T cell 
differentiation levels and might hint at the role of TEMRA expansions in the 
melanoma setting. Testing for T cells recognizing alternative melanoma 
associated antigens to the ones used previously (using tetramer or dextramer 
technology) might elucidate the origin of TEMRA. Tyrosinase or gp100 specific T 
cells for example have not been investigated in this work. An alternative method 
for identifying the antigen specificity of the TEMRA could be to stimulate these 
cells with melanoma antigen peptide libraries, and measure potential cytokine 
responses. However, the limitation of this technique is that it relies on the TEMRA 
cells being functional in this assay. 
 Understanding T cell differentiation in healthy skin 7.5.2
This work showed that surface markers commonly used in the blood to measure 
T cell differentiation might not be applicable in the skin. The extent of 
differentiation of skin resident T cells therefore remains to be elucidated. One 
key experiment that will help to address this question will be to measure the 
telomere length of the skin resident T cells and compare levels to blood derived 
T cells. Preliminary experiments have shown that debris from the collagenase-
digested skin interfered with telomere probe binding in Flow-FISH experiments. 
Future experiments will therefore require FACS sorting of the skin cell 
preparations or could use cells from suction blisters.  
 FasL expression on skin T cells 7.5.3
This work showed that T cells in the skin of healthy individuals and patients with 
melanoma express only low levels of cytotoxic granule components, suggesting 
that skin resident T cells are not readily cytotoxic. However, T cell mediated 
killing can also be mediated through the receptor FasL (CD95L) and therefore 
be cytotoxic granule independent (Kägi et al. 1994). Future experiments 
addressing T cell cytotoxic function in the skin should therefore measure FasL 
expression of skin resident T cells. 
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